Tetrahydropyranopyrazole derivatives for treatment of cancer and viral infections
By introducing oxygen atoms into tetrahydropyranopyrazole compounds, it improves its stability and antiviral effect in human liver microsomes, solving the limitation of cell growth inhibition of existing mdm2/p53 binding antagonists in the treatment of cancer. and the problem of ineffectiveness against multiple viral infections have achieved the effect of enhancing tumor cell killing and broad-spectrum antiviral.
Patent Information
- Application Number
- CN202380031338.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-27
- Filing Date
- 2023-01-27
- Publication Date
- 2024-11-12
AI Technical Summary
The existing mdm2/p53 binding antagonists have limited cell growth inhibition effects when treating cancer, and have insufficient killing effect on tumor cells, and lack of compounds that can increase the pro-apoptotic function of tumor inhibitors, making it difficult to cure cancer. At the same time, existing antiviral agents are ineffective against multiple viral infections and are difficult to cope with the threat of rapidly spreading lethal viruses such as SARS, MERS and Ebola viruses.
A tetrahydropyranopyrazole compound was developed to enhance its stability and cytochrome P450 inhibition in human liver microsomes by introducing oxygen atoms into the central ring system, thereby enhancing its killing and antiviral effects on tumor cells.
This compound is more stable in human liver microsomes, reduces cytochrome P450 inhibition, enhances tumor cell killing ability, and demonstrates broad-spectrum antiviral effects on multiple viruses, improving the potential for treating cancer and preventing viral infections.
Smart Images

Figure CN118946568A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to novel compounds, compositions and their medical uses. In particular, the present invention relates to certain tetrahydropyranopyrazoles which can be used to treat cancer and / or treat or prevent viral infections. Background of the Invention
[0003] The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an admission that the document is part of the state of the art or is common general knowledge.
[0004] In the past decade, many small molecules and peptides that activate p53 tumor suppressor function in a DNA damage-independent manner have been identified (see, e.g., CJ Brown et al., Nature reviews: Cancer, 9, 862 (2009)). Some of these compounds weaken the interaction of p53 with two important p53 negative regulators mdm2 and / or mdmx (also known as mdm4) (see Hoe, CS et al., Nat Rev Drug Discov. 13, 217 (2014)).
[0005] There are several chemically different classes of mdm2 / p53 binding antagonists, and among them nutlin-3 is the most readily available and is commonly used to protect p53 from degradation (see LTVassilev et al., Science. 303, 844 (2004); IRHardcastle et al., Bioorganic & medicinal chemistry letters, 15, 1515 (2005); K.Ding et al., Journal of medicinal chemistry, 49, 3432 (2006); and CJBrown et al., ACS chemical biology, 8, 506 (2013)). A derivative of nutlin-3, RG7112 (Roche), recently completed phase I clinical trials (see I.Ray-Coquard et al., The Lancet Oncology, 13, 1133 (2012)).
[0006] Despite their cytotoxic effects, MDM2 / p53 binding antagonists also have reversible cytostatic effects, which may limit their efficacy. In part, this cytostatic effect may be due to the strong induction of p21(WAF1 / CIP1) by these compounds.
[0007] In the past few years, a series of reports have demonstrated that when combined with other targeted small molecules such as the ATM kinase inhibitor KU-55933 and BRAF V600E When the inhibitor vemurafenib is administered in combination, the efficacy of nutlin-3 in tumor cell killing is increased (see KD Sullivan et al., Nature Chemical Biology, 8, 646 (2012); Z. Jie et al., Clinical cancer research: an official journal of the American Association for Cancer Research, 19, 4383 (2013); and M. Lu et al., Cancer Cell, 23, 618 (2013)).
[0008] Previous publications have utilized a series of phenotypic screens to find novel p53 activators. These screens were performed using a murine fibroblast cell line (T22 RGCΔFos-LacZ cells) and resulted in the identification of compounds that activated p53 in all TP53 wild-type cells tested as described for nutlin-3 (see S. Lain et al., Cancer Cell, 13, 454 (2008); GM Marshall et al., PLoS genetics, 7, e1002135 (2011); H. Yuan et al., Blood, 119, 1904 (2012); A. Menssen et al., Proc Natl Acad Sci USA, 109, E187 (2012)).
[0009] Targeted therapeutics such as mdm2 / p53 binding antagonists and BCR / ABL tyrosine kinase inhibitors can reduce cancer growth but rarely lead to complete eradication of malignant cells. Therefore, there is a need to identify compounds that can increase the pro-apoptotic function of tumor suppressors, which may increase the chances of achieving a cure for cancer patients.
[0010] Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Western / Eastern equine encephalitis (WEE / EEE) and Ebola virus, as well as pandemic influenza (e.g., H1N1), are all lethal and can be transmitted by travelers. The rapid spread of these diseases poses a major threat to public health worldwide, and broad-spectrum antiviral agents will be needed to prevent large-scale epidemic outbreaks and allow as much time as possible for the development of effective vaccines ("Broad-spectrum antiviralagents," Jun-Da Zhu, Wen Meng, Xiao-Jia Wang and Hwa-Chain, R. Wang, Frontiers in Microbiology, doi: 10.3389 / fmicb.2015.00517). In addition, inhibition of DHODH or de novo pyrimidine biosynthesis has been reported as an antiviral approach for Ebola virus, HIV, HCV, hCMV, influenza, etc. (Hoffmann et al., Proc. Natl. Acad. Sci. 2011; 108: 5777; Wang et al., J. Virol. 2011; 85: 6548; Hahn et al., Viruses 2020; 12: 1394) and rotavirus (Chen et al., Antiviral Research 2019; 167: 35).
[0011] WO2017 / 077280 discloses 4,5,6,7-tetrahydroindazole compounds for use in treating cancer and viral infections.
[0012] Ladds, MJGW et al., Nature Communications, 9, 1-14 (2018) describe tetrahydroindazole-based inhibitors of human dihydroorotate dehydrogenase (hDHODH) that increase p53 synthesis and enhance tumor cell killing by blocking p53 degradation.
[0013] Popova, G. et al., Journal of Medicinal Chemistry, 63(8), 3915-3934 (2020) described tetrahydroindazole-based hDHODH inhibitors and evaluated their activity and in vitro metabolic stability. Summary of the invention
[0014] The compounds described by Ladds et al. (2018) and Popova et al. (2020) are tetrahydroindazoles, which have metabolic susceptibility and certain cytochrome P450 (CYP) susceptibility. The inventors unexpectedly found that by introducing an oxygen atom in the central ring system, the resulting tetrahydropyranopyrazoles are more stable in human liver microsomes and human hepatocytes, while showing relatively lower inhibition of a range of CYPs in human liver microsomes.
[0015] Compound
[0016] In the first aspect of the present invention, there is provided a compound of formula I
[0017]
[0018] or a pharmaceutically acceptable salt thereof, wherein:
[0019] A 1 represents aryl or heteroaryl and is optionally substituted;
[0020] A 2 represents aryl or heteroaryl and is optionally substituted;
[0021] L 1 Represents -C(O)-, -C(O)N(R 2 )-、-C(O)O-、-S(O) j -or-S(O) k N(R 3 )-;
[0022] R 1 represents H or C optionally substituted by one or more halogens 1-3 alkyl;
[0023] R 2 and R 3 Each independently represents H or C optionally substituted by one or more halogens 1-3 alkyl;
[0024] Each j independently represents 0, 1, or 2; and
[0025] Each k independently represents 1 or 2,
[0026] This compound (including pharmaceutically acceptable salts) may be referred to herein as the compound of the first aspect of the invention.
[0027] According to a first aspect of the present invention, there is provided a compound of formula I
[0028]
[0029] or a pharmaceutically acceptable salt thereof, wherein:
[0030] A 1 represents optionally one or more independently selected from G 1 The aryl group is optionally substituted by one or more independently selected from G 2 A heteroaryl group substituted with a group;
[0031] A 2 represents optionally one or more independently selected from G 3 The aryl group is optionally substituted by one or more independently selected from G 4 A heteroaryl group substituted with a group;
[0032] L 1 Represents -C(O)-, -C(O)N(R 2 )-、-C(O)O-、-S(O) j -or-S(O) k N(R 3 )-;
[0033] R 1 represents H or C optionally substituted by one or more halogens 1-3 alkyl;
[0034] R 2 and R 3 Each independently represents H or C optionally substituted by one or more halogens 1-3 alkyl;
[0035] Each G 1 independently represent halogen, R a1 、-CN、-A a1 -C(Q a1 )R b1 , -A b1 -C(Q b1 )N(R c1 )R d1 , -A c1 -C(Q c1 )OR e1 , -A d1 -S(O) p R f1 , -A e1 -S(O) q N(R g1 )R h1 , -A f1 -S(O) p OR i1 、-N 3 、-N(R j1 )R k1、-N(H)CN、-NO 2 、-ONO 2 、-OR l1 or -SR m1 ;
[0036] Each Q a1 To Q c1 Independently represents =O, =S, =NR n1 OR = N (OR o1 );
[0037] Each A a1 To A f1 independently represent a single bond, -N(R p1 )-or-O-;
[0038] Each G 2 independently represent halogen, R a2 、-CN、-A a2 -C(Q a2 )R b2 -A b2 -C(Q b2 )N(R c2 )R d2 , -A c2 -C(Q c2 )OR e2 , -A d2 -S(O) p R f2 , -A e2 -S(O) q N(R g2 )R h2 , -A f2 -S(O) p OR i2 、-N 3 、-N(R j2 )R k2 、-N(H)CN、-NO 2 、-ONO 2 、-OR l2 or -SR m2 ;
[0039] Each Q a2 To Q c2 Independently represents =O, =S, =NR n2 OR = N (OR o2 );
[0040] Each A a2 To A f2 independently represent a single bond, -N(R p2 )-or-O-;
[0041] Each G 3 independently represent halogen, R a3 、-CN、-A a3 -C(Q a3 )R b3 , -A b3 -C(Q b3 )N(R c3 )R d3 , -A c3 -C(Q c3 )OR e3 , -A d3 -S(O) p R f3 , -A e3 -S(O) q N(R g3 )R h3 , -A f3 -S(O) p OR i3 、-N 3 、-N(R j3 )R k3 、-N(H)CN、-NO 2 、-ONO 2 、-OR l3 or -SR m3 ;
[0042] Each Q a3 To Q c3 Independently represents =O, =S, =NR n3 OR = N (OR o3 );
[0043] Each A a3 To A f3 independently represent a single bond, -N(R p3 )-or-O-;
[0044] Each G 4 independently represent halogen, R a4 、-CN、-A a4 -C(Q a4 )R b4 , -A b4 -C(Q b4 )N(R c4 )R d4 , -A c4 -C(Q c4 )OR e4 , -A d4 -S(O) p R f4 , -A e4 -S(O)q N(R g4 )R h4 , -A f4 -S(O) p OR i4 、-N 3 、-N(R j4 )R k4 、-N(H)CN、-NO 2 、-ONO 2 、-OR l4 or -SR m4 ;
[0045] Each Q a4 To Q c4 Independently represents =O, =S, =NR n4 OR = N (OR o4 );
[0046] Each A a4 To A f4 independently represent a single bond, -N(R p4 )-or-O-;
[0047] Each R a1 and R f1 Independently represents optionally one or more independently selected from G 5a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 5b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 5c The aryl group is optionally substituted by one or more independently selected from G 5d A heteroaryl group substituted with a group;
[0048] Each R p1 independently represents H or C optionally substituted by one or more halogens 1-6 alkyl;
[0049] Each R b1 , R c1 , R d1 , R e1 , R g1 , R h1 , R i1 , R j1 , R k1 , R l1 , R m1 , R n1 and R o1 independently represents H, optionally one or more independently selected from G 5a The group substituted C 1-6Alkyl, optionally with one or more independently selected from G 5b A heterocycloalkyl substituted with a group, optionally with one or more independently selected from G 5c The aryl group is optionally substituted by one or more independently selected from G 5d A heteroaryl group substituted with a group; or
[0050] Optionally, R c1 and R d1 , R g1 and R h1 and / or R j1 and R k1 Any of the following is joined together with the nitrogen atom to which it is attached to form a 3- to 6-membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected halogens, C 1-3 Alkyl and =O group substitution;
[0051] Each R a2 and R f2 Independently represents optionally one or more independently selected from G 6a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 6b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 6c The aryl group is optionally substituted by one or more independently selected from G 6d A heteroaryl group substituted with a group;
[0052] Each R p2 independently represents H or C optionally substituted by one or more F 1-6 alkyl;
[0053] Each R b2 , R c2 , R d2 , R e2 , R g2 , R h2 , R i2 , R j2 , R k2 , R l2 , R m2 , R n2 and R o2 independently represents H, optionally one or more independently selected from G 6a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 6b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 6cThe aryl group is optionally substituted by one or more independently selected from G 6d A heteroaryl group substituted with a group; or
[0054] Optionally, R c2 and R d2 , R g2 and R h2 and / or R j2 and R k2 Any of the following is joined together with the nitrogen atom to which it is attached to form a 3- to 6-membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected halogens, C 1-3 Alkyl and =O group substitution;
[0055] Each R a3 and R f3 Independently represents optionally one or more independently selected from G 7a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 7b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 7c The aryl group is optionally substituted by one or more independently selected from G 7d A heteroaryl group substituted with a group;
[0056] Each R p3 independently represents H or C optionally substituted by one or more F 1-6 alkyl;
[0057] Each R b3 , R c3 , R d3 , R e3 , R g3 , R h3 , R i3 , R j3 , R k3 , R l3 , R m3 , R n3 and R o3 independently represents H, optionally one or more independently selected from G 7a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 7b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 7c The aryl group is optionally substituted by one or more independently selected from G 7d A heteroaryl group substituted with a group; or
[0058] Optionally, R c3 and R d3 , R g3 and R h3 and / or R j3 and R k3 Any of the following is joined together with the nitrogen atom to which it is attached to form a 3- to 6-membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected halogens, C 1-3 Alkyl and =O group substitution;
[0059] Each R a4 and R f4 Independently represents optionally one or more independently selected from G 8a The group substituted C 1-6 Alkyl or optionally one or more independently selected from G 8b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 8c The aryl group is optionally substituted by one or more independently selected from G 8d A heteroaryl group substituted with a group;
[0060] Each R p4 independently represents H or C optionally substituted by one or more F 1-6 alkyl;
[0061] Each R b4 , R c4 , R d4 , R e4 , R g4 , R h4 , R i4 , R j4 , R k4 , R l4 , R m4 , R n4 and R o4 independently represents H, optionally one or more independently selected from G 8a The group substituted C 1-6 Alkyl or optionally one or more independently selected from G 8b A heterocycloalkyl group substituted with:
[0062] Optionally, R c4 and R d4 , R g4 and R h4 and / or R j4 and R k4Any of the following is joined together with the nitrogen atom to which it is attached to form a 3- to 6-membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected halogens, C 1-3 Alkyl and =O group substitution;
[0063] Each G 5a , G 5b , G 6a , G 6b , G 7a , G 7b , G 8a and G 8b independently represent halogen, -CN, -N(R b5 )R c5 、-OR d5 、-SR e5 or =O;
[0064] Each G 5c , G 5d , G 6c , G 6d , G 7c , G 7d , G 8c and G 8d independently represent halogen, R a5 、-CN、-N(R b5 )R c5 、-OR d5 、-SR e5 or =O;
[0065] Each R a5 independently represents C optionally substituted by one or more F 1-6 alkyl;
[0066] Each R b5 , R c5 , R d5 and R e5 independently represents H or C optionally substituted by one or more F 1-6 Alkyl or =O;
[0067] or R b5 and R c5 are joined together with the nitrogen atom to which they are attached to form a 3 to 6 membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected F, C 1-3 Alkyl and =O group substitution;
[0068] Each j independently represents 0, 1, or 2; and
[0069] Each k, p and q independently represents 1 or 2,
[0070] This compound (including pharmaceutically acceptable salts) may be referred to herein as the compound of the first aspect of the invention.
[0071] It will be understood by those skilled in the art that reference herein to a compound of a particular aspect of the invention will include reference to all embodiments and specific forms thereof, which can be combined to form further embodiments.
[0072] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0073] Pharmaceutically acceptable salts include acid addition salts and base addition salts. These salts can be formed by conventional methods, for example, by reacting the free acid or free base form of the compounds of the invention with one or more equivalents of a suitable acid or base, optionally in a solvent or in a medium in which the salt is insoluble, followed by removal of the solvent or the medium using standard techniques (e.g., in a vacuum, by freeze drying or by filtering). Salts can also be prepared by, for example, exchanging the counter ion of the compounds of the invention in salt form with another counter ion using a suitable ion exchange resin.
[0074] Specific acid addition salts which may be mentioned include carboxylates (e.g. formate, acetate, trifluoroacetate, propionate, isobutyrate, heptanoate, decanoate, caprate, octanoate, stearate, acrylate, hexanoate, propiolate, ascorbate, citrate, glucuronate, glutamate, glycolate, α-hydroxybutyrate, lactate, tartrate, phenylacetate, mandelate, phenylpropionate, phenylbutyrate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, dinitrobenzoate, o-acetoxybenzoate, salicylate, nicotinate, isonicotinate, cinnamate, salts (e.g., oxalates, malonates, succinates, suberates, sebacates, fumarates, malates, maleates, hydroxymaleates, hippurates, phthalates or terephthalates), halide salts (e.g., chloride, bromide or iodide salts), sulfonates (e.g., benzenesulfonates, methylbenzenesulfonates, bromobenzenesulfonates or chlorobenzenesulfonates, xylenesulfonates, methanesulfonates, ethanesulfonates, propanesulfonates, isethionates, 1- or 2-naphthalenesulfonates or 1,5-naphthalenedisulfonates) or sulfates, pyrosulfates, hydrogensulfates, sulfites, hydrogensulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates or nitrates, etc.
[0075] Specific base addition salts that may be mentioned include salts formed with alkali metals (e.g. Na salts and K salts), salts formed with alkaline earth metals (e.g. Mg salts and Ca salts), salts formed with organic bases (e.g. ethanolamine, diethanolamine, triethanolamine, tromethamine and lysine) and inorganic bases (e.g. ammonia and aluminum hydroxide). More specifically, base addition salts that may be mentioned include Mg salts, Ca salts, most particularly K salts and Na salts.
[0076] For the avoidance of doubt, the compound of the first aspect of the present invention can exist in solid form, so the scope of the present invention includes all amorphous, crystallized and partially crystalline forms thereof, and can also exist in oily form. When the compound of the first aspect of the present invention exists in crystallized and partially crystalline forms, these forms can include solvates, which are included in the scope of the present invention. The compound of the first aspect of the present invention can also exist in solution form.
[0077] The compounds of the first aspect of the present invention may contain double bonds and may therefore exist as E (entgegen) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the present invention.
[0078] The compounds of the first aspect of the present invention may also exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the present invention.
[0079] The compounds of the present invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and / or diastereoisomerism. Diastereomers may be separated using conventional techniques such as chromatography or fractional crystallization. Various stereoisomers (i.e., enantiomers) may be separated by separation of racemic or other mixtures of compounds using conventional techniques such as fractional crystallization or HPLC techniques. Alternatively, the desired optical isomers may be obtained by reacting appropriate optically active starting materials under conditions that do not cause racemization or epimerization (i.e., the 'chiral pool' method), reacting appropriate starting materials with 'chiral auxiliary agents', which may then be removed at an appropriate stage by derivatization (i.e., resolution, including dynamic resolution); for example, reacting with a homochiral acid, followed by separation of diastereomeric derivatives by conventional means such as chromatography, or by reacting with appropriate chiral reagents or chiral catalysts under conditions known to those skilled in the art. All stereoisomers and mixtures thereof are included within the scope of the present invention.
[0080] In particular, the compounds of the first aspect of the present invention may exhibit stereoisomerism at the carbon marked with an asterisk (*) in the following compounds of formula I, wherein the compounds of the first aspect of the present invention exist in R- and S-configurations at that carbon (which configuration can be determined by a person skilled in the art).
[0081]
[0082] As used herein, references to halogen and / or halogen groups will each independently refer to fluorine, chlorine, bromine, and iodine (eg, fluorine (F) and chlorine (Cl)).
[0083] Unless otherwise stated, C is defined in this document. 1-z Alkyl groups (where z is the upper limit of the range) may be straight-chain or, when there are a sufficient number (i.e. a minimum of two or three where appropriate) of carbon atoms, branched, and / or cyclic (thus forming a C 3-z Cycloalkyl groups). Such groups may also be partially cyclic when there are a sufficient number of carbon atoms (i.e. a minimum of four). Partially cyclic alkyl groups that may be mentioned include cyclopropylmethyl and cyclohexylethyl. Such groups may also be polycyclic (e.g. bicyclic or tricyclic) or spirocyclic when there are a sufficient number of carbon atoms. Such alkyl groups may also be saturated or, when there are a sufficient number of carbon atoms (i.e. a minimum of two), unsaturated (forming, for example, C 2-z Alkenyl or C 2-z alkynyl group).
[0084] As used herein, the term aryl includes reference to C 6-14 (For example, C 6-10 ) aromatic groups. These groups may be monocyclic or bicyclic and, when bicyclic, may be fully or partially aromatic. C 6-10 Aryl groups include phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indanyl and the like (eg phenyl, naphthyl, etc., such as phenyl). For the avoidance of doubt, the point of attachment of substituents on an aryl group may be via any carbon atom of the ring system.
[0085] As used herein, the term heteroaryl (or heteroaromatic) includes reference to 5 to 14 (e.g., 5 to 10) heteroaromatic groups containing one or more heteroatoms selected from oxygen, nitrogen and / or sulfur. Such heteroaryl groups may contain one, two or three rings, at least one of which is aromatic (e.g., a heteroaryl group may contain two rings, one of which is aromatic). Where appropriate, the substituents on the heteroaryl / heteroaromatic group may be located on any atom in the ring system including heteroatoms. The point of attachment of the heteroaryl / heteroaromatic group may be via any atom including (where appropriate) heteroatoms in the ring system. In particular, a bicyclic heteroaryl / heteroaromatic group may contain a benzene ring fused to one or more additional aromatic or non-aromatic heterocycles, in which case the point of attachment of the polycyclic heteroaryl / heteroaromatic group may be via any ring including a benzene ring or a heteroaryl / heteroaromatic or heterocycloalkyl ring. Examples of heteroaryl / heteroaromatic groups that may be mentioned include pyridyl, pyrrolyl, furyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, imidazopyrimidinyl, imidazothiazolyl, thienothiphenyl, pyrimidinyl, furopyridinyl, indolyl, azaindolyl, pyrazinyl, pyrazolopyrimidinyl, indazolyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzotriazolyl and purinyl. Oxides of heteroaryl / heteroaromatic groups are also included within the scope of the present invention (e.g., N-oxides). As described above, heteroaryl includes polycyclic (e.g., bicyclic) groups, in which one ring is aromatic (and the others may or may not be aromatic). Thus, other heteroaryl groups that may be mentioned include, for example, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, dihydrobenzo[d]isothiazolyl, 3,4-dihydrobenzo[1,4]oxazinyl, dihydrobenzothiophenyl, indolinyl, 5H,6H,7H-pyrrolo[1,2-b]pyrimidinyl, tetrahydro-1,2-benzisoxazolyl, 1,2,3,4-tetrahydroquinolinyl, thiochromanyl, and the like.
[0086] As used herein, the term heterocycloalkyl may refer to non-aromatic monocyclic and bicyclic heterocycloalkyl groups (which groups may be further bridged), wherein at least one (e.g., one to four) atoms in the ring system are not carbon (i.e., are heteroatoms), and wherein the total number of atoms in the ring system is between 3 and 12 (e.g., between 5 and 10, most preferably between 3 and 8, such as 5- or 6-membered heterocycloalkyl groups). In addition, such heterocycloalkyl groups may be saturated or unsaturated, containing one or more double bonds and / or triple bonds, forming, for example, C 2-z (For example, C 4-z )heterocycloalkenyl (where z is the upper limit of the range) or C 7-zHeterocycloalkynyl group. 2-z Heterocycloalkyl groups include 7-azabicyclo-[2.2.1]heptyl, 6-azabicyclo[3.1.1]heptyl, 6-azabicyclo[3.2.1]-octanyl, 8-azabicyclo[3.2.1]octanyl, aziridinyl, azetidinyl, 2,3-dihydroisothiazolyl, dihydropyranyl, dihydropyridinyl, dihydropyrrolyl (including 2,5-dihydropyrrolyl), dioxolanyl (including 1,3-dioxolanyl), dioxane (including 1,3-dioxane and 1,4-dioxane), dithianyl (including 1,4-dithianyl), dithiolanyl (including 1,3-dithiolanyl), ), imidazolidinyl, imidazolinyl, isothiazolidinyl, morpholinyl, 7-oxabicyclo[2.2.1]heptanyl, 6-oxabicyclo[3.2.1]octanyl, oxetanyl, oxiranyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrrolidonyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, sulfolane, 3-sulfolene, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl (e.g., 1,2,3,4-tetrahydropyridinyl and 1,2,3,6-tetrahydropyridinyl), thietanyl, thiirane, thiolanyl, tetrahydrothiopyranyl, thiomorpholinyl, trithianyl (including 1,3,5-trithianyl), tropanyl, and the like. Substituents on heterocycloalkyl groups may be located on any atom in the ring system, including heteroatoms, as appropriate. In addition, in the case where the substituent is another cyclic compound, the cyclic compound may be connected through a single atom on the heterocycloalkyl group to form a so-called "spiro" compound. The point of attachment of the heterocycloalkyl group may be via any atom in the ring system, including (where appropriate) additional heteroatoms (e.g., nitrogen atoms), or atoms on any fused carbocyclic ring that may be present as part of the ring system. The heterocycloalkyl group may also be in N- or S-oxidized form.
[0087] At each occurrence mentioned herein, specific heterocycloalkyl groups that may be mentioned include 3 to 8 membered heterocycloalkyl groups (eg 4 to 6 membered heterocycloalkyl groups).
[0088] For the avoidance of doubt, as used herein, references to heteroatoms will take their normal meaning as understood by those skilled in the art. Specific heteroatoms that may be mentioned include phosphorus, selenium, tellurium, silicon, boron, oxygen, nitrogen and sulfur (e.g. oxygen, nitrogen and sulfur).
[0089] For the avoidance of doubt, reference to a polycyclic (e.g. bicyclic) group (e.g. when used in the context of a heterocycloalkyl group) will refer to a ring system in which more than two breaks are required to convert the ring into a straight chain, wherein the minimum number of such breaks corresponds to the number of rings defined (e.g. the term bicyclic may mean that a minimum of two breaks are required to convert the ring into a straight chain). For the avoidance of doubt, the term bicyclic (e.g. when used in the context of a heterocycloalkyl group) may refer to a group in which the second ring of the bicyclic ring system is formed between two adjacent atoms of the first ring, and may also refer to a group in which two non-adjacent atoms are linked by an alkylene or heteroalkylene chain (where appropriate), the latter group being referred to as bridged.
[0090] For the avoidance of doubt, when an aryl or heteroaryl group is substituted via a double bond such as =0, it is understood that the aryl or heteroaryl group is partially aromatic, i.e. the aryl or heteroaryl group consists of at least two rings, at least one of which is not aromatic.
[0091] The present invention also includes isotopically labeled compounds of the present invention, which are identical to those described herein, but one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number that is usually present in nature (or the most abundant one in nature). All isotopes of any particular atom or element as described herein are included within the scope of the compounds of the present invention. Therefore, the compounds of the present invention also include deuterated compounds, i.e., where one or more hydrogen atoms are replaced by the hydrogen isotope deuterium.
[0092] For the avoidance of doubt, where the identities of two or more substituents in a compound of the invention may be the same, the actual identities of the corresponding substituents are not in any way interdependent. 3 In the case of groups, those R 3 The groups may be the same or different. Similarly, when more than one R a1 and each independently represents one or more G 1a C 1-6 When alkyl, each G 1a The identities are not dependent on each other in any way.
[0093] For the avoidance of doubt, when the term “A a1 To A f1 ", those skilled in the art will understand that it is inclusively meant to mean A a1 , A b1 , A c1 , A d1 , A e1 and A f1The same reasoning will apply to other such terms used herein unless otherwise stated.
[0094] Those skilled in the art will appreciate that the compounds of the present invention that are the subject of the present invention include those compounds that are stable. That is, the compounds of the present invention include those compounds that are sufficiently stable to withstand, for example, isolation from a reaction mixture to a useful degree of purity.
[0095] All embodiments and specific features of the invention mentioned herein may be adopted independently or in combination with any other embodiments and / or specific features mentioned herein (thus describing more specific embodiments and specific features as disclosed herein) without departing from the disclosure of the present invention.
[0096] As used herein, the term "optionally substituted" means that the referenced group may be substituted with one or more additional groups.
[0097] In a specific embodiment of the first aspect of the invention, A 1 represents optionally one or more (eg one, two or three, eg one or two) independently selected from G 1 Phenyl substituted with a group, or optionally substituted with one or more (eg, one, two or three, such as one or two) independently selected from G 2 A heteroaryl group substituted with a group.
[0098] In a more specific embodiment, A 1 represents optionally one or more (eg one, two or three, eg one or two) independently selected from G 2 A heteroaryl group substituted with a group.
[0099] In still more specific embodiments, A 1 represents optionally one or more (eg one or two) groups (ie G 2 A monocyclic or bicyclic heteroaryl group substituted with 2 The groups are independently selected from halogen, R a2 、-C(O)OR e2 、-OR l2 and-SR m2 .
[0100] In still more specific embodiments, A 1 represents optionally one or more (eg one or two) groups (ie G 2 A monocyclic or bicyclic heteroaryl group substituted with 2 The groups are independently selected from halogen (eg F), C optionally substituted with one or more fluorine 1-3 Alkyl (e.g. -CF 3)、-C(O)OH、-C(O)OC 1-3 Alkyl, -OH, -OC 1-3 Alkyl, -SH and -SC 1-3 Alkyl (e.g. F, C 1-2 Alkyl, -OH and -SCH 3 ).
[0101] In still more specific embodiments, A 1 represents optionally one or more (eg one or two) groups (ie G 2 A monocyclic or bicyclic heteroaryl group substituted with 2 The groups are independently selected from halogen (eg, F), C 1-3 Alkyl, -CF 3 、-C(O)OH、-C(O)OC 1-3 Alkyl, -OH, -OC 1-3 Alkyl, -SH and -SC 1-3 Alkyl (e.g. F, C 1-2 Alkyl, -OH and -SCH 3 ).
[0102] In still more specific embodiments, A 1 represents optionally one or more (eg one or two) groups (ie G 2 A monocyclic or bicyclic heteroaryl group substituted with 2 The groups are independently selected from halogen (eg, F), C 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, -OH, -OC 1-3 Alkyl, -SH and -SC 1-3 Alkyl (e.g. F, C 1-2 Alkyl, -OH and -SCH 3 ).
[0103] For example, A 1 may represent optionally one or two independently selected from halogen, R a2 、-C(O)OR e2 、-OR l2 and-SR m2 The group (ie G 2 Group) (e.g. one or two independently selected from halogen (e.g. F), C 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, -OH, -OC 1-3 Alkyl, -SH and -SC 1-3 Alkyl groups, for example one or two independently selected from F, C 1-2 Alkyl, -OH and -SCH3 The group (ie G 2 For the avoidance of doubt, these bicyclic heteroaryl (e.g. 9-membered bicyclic heteroaryl, such as tetrahydro-1,2-benzisoxazolyl, such as tetrahydro-1,2-benzisoxazol-3-yl) groups may be unsubstituted.
[0104] In addition, A 1 may represent optionally one or two independently selected from halogen, R a2 、-C(O)OR e2 、-OR l2 and-SR m2 The group (ie G 2 Group) (e.g. one or two independently selected from halogen (e.g. F), C 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, -OH, -OC 1-3 Alkyl, -SH and -SC 1-3 Alkyl groups, for example one or two selected from F, C 1-3 Alkyl, -C(O)OH and -C(O)OC 1-3 An alkyl group, such as a -C(O)OC 1-3 For the avoidance of doubt, these monocyclic heteroaryl (e.g. 6-membered monocyclic heteroaryl, e.g. pyridyl, e.g. pyridin-2-yl) groups may be unsubstituted.
[0105] In a specific embodiment, represents A 1 The monocyclic or bicyclic heteroaryl group may be a 5- or 6-membered monocyclic heteroaryl group or a 9-membered bicyclic heteroaryl group. Specifically, the monocyclic or bicyclic heteroaryl group may be selected from pyridyl (e.g., pyridin-2-yl and pyridin-3-yl), pyrazinyl (e.g., pyrazin-2-yl), benzofuranyl (e.g., benzofuran-3-yl), thiazolyl (e.g., thiazol-4-yl), thienyl (e.g., thien-2-yl), isoxazolyl (e.g., isoxazol-3-yl), 4,5,6,7-tetrahydrobenzo[c]isoxazolyl (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl) (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl-3-yl), 1,3-benzoxazolyl (e.g., 1,3-benzoxazolyl-2-yl), and 1,2-benzisoxazolyl (e.g., 1,2-benzisoxazol-3-yl).
[0106] In an alternative embodiment, represents A 1The monocyclic or bicyclic heteroaryl group may be a 5- or 6-membered monocyclic heteroaryl group or a 9-membered bicyclic heteroaryl group. Specifically, the monocyclic or bicyclic heteroaryl group can be selected from tetrahydro-2,1-benzisoxazolyl (e.g., tetrahydro-2,1-benzisoxazol-3-yl), benzoxazolyl (e.g., 1,3-benzisoxazol-3-yl or 1,2-benzisoxazol-3-yl), pyrazinyl, indazolyl, quinolinyl, 5H,6H,7H,8H-imidazo[1,5-a]pyridin-3-yl, 5H,6H,7H,8H-imidazo[1,5-a]pyridin-1-yl, imidazo[1,5-a]pyridin-3-yl, pyridyl (e.g., pyridin-2-yl), thiazolyl (e.g., thiazol-4-yl), isoxazolyl (e.g., isoxazol-3-yl) and tetrahydro-1,2-benzisoxazolyl (e.g., tetrahydro-1,2-benzisoxazol-3-yl). More specifically, the monocyclic or bicyclic heteroaryl group can be selected from pyridyl (e.g., pyridin-2-yl), thiazolyl (e.g., thiazol-4-yl), isoxazolyl (e.g., isoxazol-3-yl), and tetrahydro-1,2-benzisoxazolyl (e.g., tetrahydro-1,2-benzisoxazol-3-yl). In some embodiments, A 1 It is 5H,6H,7H,8H-imidazo[1,5-a]pyridin-3-yl or 5H,6H,7H,8H-imidazo[1,5-a]pyridin-1-yl.
[0107] In a specific embodiment of the first aspect of the invention, A 2 represents optionally one or more (preferably one, two or three, such as one or two) independently selected from G 3 Phenyl substituted with a group, or optionally substituted with one or more (preferably one, two or three, such as one or two) independently selected from G 4 A 5- or 6-membered heteroaryl group substituted with
[0108] In a more specific embodiment of the first aspect of the invention, A 2 represents optionally one or more (preferably one, two or three, such as one or two) independently selected from G 3 The aryl group is substituted with a group.
[0109] In a more specific embodiment of the first aspect of the invention, A 2 represents optionally one or more (preferably one, two or three, such as one or two) independently selected from G 3 A phenyl group substituted with a group.
[0110] In a more specific embodiment, A 2 represents optionally one or more (e.g. one or two) independently selected from halogen, R a3 AND-OR l3 The group (ie G3 A phenyl group substituted with a phenyl group.
[0111] In other embodiments, G 3 represents a group selected from halogen, -A c3 -C(Q c3 )OR e3 (e.g. -C(O)OR e3 , for example, where R e3 Represents C 1-3 Alkyl), R a3 AND-OR l3 The group.
[0112] In other embodiments, G 3 represents a group selected from halogen, -A a3 -C(Q a3 )R b3 (e.g. -C(O)heteroaryl, e.g. -C(O)-morpholinyl, e.g. -C(O)-morpholin-4-yl) or -A c3 -C(Q c3 )OR e3 (e.g. -C(O)OR e3 , for example, where R e3 Represents C 1-3 Alkyl), R a3 AND-OR l3 The group.
[0113] In an alternative embodiment, G 3 represents a group selected from halogen, -R a3 AND-OR l3 The group.
[0114] More specifically, A 2 may represent optionally one or more (eg one or two) independently selected from halogen (eg F), -C(O)OC 1-3 Alkyl (e.g. -C(O)OCH 2 CH 3 ) and C 1-4 Alkyl (e.g. -CH 3 and -C(CH 3 ) 3 ) group (i.e. G 3 For example, A 2 may represent optionally one or two independently selected from F, -CH 3 、-C(O)OCH 2 CH 3 and -C(CH 3 ) 3 The group (ie G 3substituted with one or two F groups, for example.
[0115] Or, A 2 may represent optionally one or more (eg one or two) independently selected from halogen (eg F), -C(O)-morpholinyl (eg -C(O)-morpholin-4-yl), -C(O)OC 1-3 Alkyl (e.g. -C(O)OCH 2 CH 3 ) and C 1-4 Alkyl (e.g. -CH 3 and -C(CH 3 ) 3 ) group (i.e. G 3 A phenyl group substituted with a phenyl group.
[0116] In a more specific embodiment, A 2 At least position 2 (ie, the point of attachment relative to the required tetrahydroindazole, as depicted in Formula I, where one skilled in the art will understand that the point of attachment is referred to as position 1) is unsubstituted.
[0117] Thus, in certain embodiments, the 2 The group can be described as:
[0118]
[0119] Among them G 3 As defined herein (i.e. as defined in any embodiment of the first aspect of the invention, or any combination thereof, for example wherein G 3 represents independently selected from halogen, R a3 AND-OR l3 A group, for example, selected from F, -CH 3 and -C(CH 3 ) 3 t represents 0 to 5 (eg 0 to 2), and the bond split by the wavy line represents the point of attachment to the necessary tetrahydroindazole group.
[0120] More specifically, A 2 It may be a phenyl group substituted with one or two substituents present at the 3-position, 4-position, 5-position and / or 6-position. 2 Phenyl may be substituted only in the 6-position (thus being unsubstituted in the 2-, 3-, 4- and 5-positions), substituted only in the 4- and 6-positions or substituted only in the 3- and 4-positions.
[0121] In other embodiments, A 2 At least the 2-position is optionally substituted with halogen (eg chlorine or fluorine).
[0122] In a specific embodiment of the first aspect of the invention, L 1 stands for -C(O)N(R 2 )-、-C(O)O-、-S(O) 2 N(R 3 )-, -C(O)- or -S(O) 2 -(e.g. -C(O)- or -S(O) 2 In a more specific embodiment, L 1 Represents -C(O)-.
[0123] In a specific embodiment of the first aspect of the invention, R 1 represents H or C optionally substituted by one or more F 1-3 Alkyl (e.g. C 1 Alkyl) (e.g. H or -CH 3 ). More specifically, R 1 Can represent H.
[0124] In a specific embodiment of the first aspect of the invention, R 2 and R 3 Each independently represents H or C optionally substituted by one or more F 1-3 In a more specific embodiment, R 2 represents H. In a more specific embodiment, R 3 represents H. Therefore, in a still more specific embodiment, R 2 and R 3 Each represents H.
[0125] In a specific embodiment of the first aspect of the invention:
[0126] Each G 1 Independently represents -CN, -A a1 -C(Q a1 )R b1 , -A b1 -C(Q b1 )N(R c1 )R d1 , -A c1 -C(Q c1 )OR e1 , -A d1 -S(O) p R f1 , -A e1 -S(O) q N(R g1 )R h1 , -A f1 -S(O) p OR i1 、-N 3、-N(R j1 )R k1 、-N(H)CN、-NO 2 、-ONO 2 , halogen, R a1 、-OR l1 or -SR m1 (e.g. halogen, R a1 、-C(O)OR e1 、-OR l1 and-SR m1 );
[0127] Each Q a1 To Q c1 Independently represents =O, =S, =NR n1 OR = N (OR o1 )(e.g. =O); and / or (e.g. and)
[0128] Each A a1 To A f1 independently represent a single bond, -N(R p1 )-or-O-.
[0129] In a specific embodiment of the first aspect of the invention:
[0130] Each G 2 Independently represents -CN, -A a2 -C(Q a2 )R b2 -A b2 -C(Q b2 )N(R c2 )R d2 , -A c2 -C(Q c2 )OR e2 , -A d2 -S(O) p R f2 , -A e2 -S(O) q N(R g2 )R h2 , -A f2 -S(O) p OR i2 、-N 3 、-N(R j2 )R k2 、-N(H)CN、-NO 2 、-ONO 2 , halogen, R a2 、-OR l2 or -SR m2 (e.g. halogen, R a2 、-C(O)ORe2 、-OR l2 or -SR m2 );
[0131] Each Q a2 To Q c2 Independently represents =O, =S, =NR n2 OR = N (OR o2 )(e.g. =O); and / or (e.g. and)
[0132] Each A a2 To A f2 independently represent a single bond, -N(R p2 )-or-O-.
[0133] In a specific embodiment, each G 2 independently represent halogen, R a2 、-C(O)OR e2 、-OR l2 and-SR m2 In a more specific embodiment, each G 2 independently represent halogen (e.g. F), C 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, -OH, -OC 1-3 Alkyl, -SH and -SC 1-3 Alkyl (e.g. F, C 1-2 Alkyl, -OH and -SCH 3 ).
[0134] In a specific embodiment of the first aspect of the invention:
[0135] Each G 3 Independently represents -CN, -A a3 -C(Q a3 )R b3 , -A b3 -C(Q b3 )N(R c3 )R d3 , -A c3 -C(Q c3 )OR e3 , -A d3 -S(O) p R f3 , -A e3 -S(O) q N(R g3 )R h3 , -A f3 -S(O) p OR i3 、-N 3 、-N(Rj3 )R k3 、-N(H)CN、-NO 2 、-ONO 2 , halogen, R a3 、-OR l3 or -SR m3 (e.g. halogen, R a3 、-OR l3 or -SR m3 );
[0136] Each Q a3 To Q c3 Independently represents =O, =S, =NR n3 OR = N (OR o3 )(e.g. =O); and / or
[0137] Each A a3 To A f3 independently represent a single bond, -N(R p3 )-or-O-.
[0138] In a more specific embodiment, each G 3 independently represent halogen, R a3 OR l3 .
[0139] In still more specific embodiments, each G 3 independently represents halogen (such as F) or C 1-4 Alkyl, such as F, -CH 3 or -C(CH 3 ) 3 .
[0140] In still more specific embodiments, each G 3 independently represents F or -CH 3 , for example F.
[0141] In a specific embodiment of the first aspect of the invention:
[0142] Each G 4 Independently represents -CN, -A a4 -C(Q a4 )R b4 , -A b4 -C(Q b4 )N(R c4 )R d4 , -A c4 -C(Q c4 )OR e4 , -A d4 -S(O) p R f4 , -Ae4 -S(O) q N(R g4 )R h4 , -A f4 -S(O) p OR i4 、-N 3 、-N(R j4 )R k4 、-N(H)CN、-NO 2 、-ONO 2 , halogen, R a4 、-OR l4 or -SR m4 (e.g. halogen, R a4 、-OR l4 or -SR m4 );
[0143] Each Q a4 To Q c4 Independently represents =O, =S, =NR n4 OR = N (OR o4 )(e.g. =O); and / or (e.g. and)
[0144] Each A a4 To A f4 independently represent a single bond, -N(R p4 )-or-O-.
[0145] In a particular embodiment, p represents 2 and / or (for example and) q represents 2.
[0146] In some embodiments, A 1 represents optionally one or more independently selected from G 2 A 9-membered bicyclic heteroaryl substituted with a group (e.g., 5H,6H,7H,8H-imidazo[1,5-a]pyridin-3-yl or 5H,6H,7H,8H-imidazo[1,5-a]pyridin-1-yl); 2 represents optionally one or more independently selected from G 3 A phenyl group substituted with 2 is optionally substituted at least 2 positions with halogen (eg chlorine or fluorine); R 1 represents H; and L 1 Represents -C(O)-.
[0147] In some embodiments, A 1is a 9-membered bicyclic heteroaryl (e.g., 5H, 6H, 7H, 8H-imidazo [1, 5-a] pyridin-3-yl, 5H, 6H, 7H, 8H-imidazo [1, 5-a] pyridin-1-yl, 4H, 5H, 6H, 7H-1, 2-benzisoxazol-3-yl, 4H, 5H, 6H, 7H-2, 1-benzisoxazol-3-yl or 4H, 5H, 6H, 7H-indazol-3-yl); a 6-membered heteroaryl (e.g., pyridinyl) or a 5-membered heteroaryl (e.g., pyrazolyl or imidazolyl), wherein the 5-membered or 6-membered heteroaryl is optionally replaced by one or more independently selected from G 2 A 2 is optionally one or more independently selected from G 3 Phenyl substituted with a group; R 1 is H; and / or L 1 It is -C(O)-.
[0148] In some embodiments, each G 2 Can independently represent R a2 (For example, C 1-2 alkyl); and / or each G 3 independently represent halogen, R a3 , -A b3 -C(Q b3 )N(R c3 )R d3 , -A c3 -C(Q c3 )OR e3 , -A d3 -S(O) p R f3 、-OR l3 ; optionally wherein:
[0149] Halogen is fluorine or chlorine, R a3 Yes CH 3 or CF 3 , A b3 , A c3 and A d3 It is a single bond, Q b3 and Q c3 is = O, p is 2,
[0150] R c3 and R d3 Yes CH 3 or are joined together with the nitrogen atom to which they are attached to form a 5- or 6-membered ring, which optionally contains one further heteroatom (e.g. oxygen),
[0151] R e3 It is C 1-3 Alkyl, R f3 Yes CH 3,
[0152] R l3 Yes CH 3 CF 3 、N(CH 3 ) 2 Substituted C 2 Alkyl, OH, OCH 3 or N(C=O)CH 3 , and / or C(=O)N(CH 3 ) 2 Substituted C 1 alkyl.
[0153] In a particular embodiment of the first aspect of the invention, the compound of formula I is not:
[0154]
[0155] Specific compounds of the first aspect of the invention that may be mentioned include the compounds of the Examples provided herein, and pharmaceutically acceptable salts thereof.
[0156] Specific compounds of the first aspect of the invention which may be mentioned include:
[0157] N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0158] (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0159] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0160] N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0161] (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0162] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0163] N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0164] (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0165] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0166] N-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0167] N-((4S)-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0168] N-((4R)-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0169] N-1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0170] N-((4S)-1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0171] N-((4R)-1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0172] N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0173] (S)-N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0174] (R)-N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0175] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0176] (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0177] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0178] (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0179] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0180] (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0181] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0182] (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0183] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0184] (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0185] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0186] (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0187] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0188] (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0189] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0190] (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0191] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0192] (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0193] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0194] (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0195] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0196] (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0197] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0198] (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0199] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0200] (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0201] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0202] (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0203] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0204] (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0205] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0206] (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0207] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0208] (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0209] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0210] (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0211] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0212] (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0213] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0214] (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0215] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0216] (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0217] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0218] (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0219] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0220] (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0221] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0222] (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0223] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0224] (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0225] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0226] (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0227] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0228] (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0229] (S)-5-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-1-methyl-1H-imidazole-4-carboxamide;
[0230] (R)-5-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-1-methyl-1H-imidazole-4-carboxamide;
[0231] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0232] (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0233] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0234] (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0235] (S)-4-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-methyl-1H-pyrazole-3-carboxamide;
[0236] (R)-4-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-methyl-1H-pyrazole-3-carboxamide;
[0237] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0238] (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0239] (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0240] (R)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0241] (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0242] (R)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0243] (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0244] (R)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0245] (S)-N-(1-(3-(methylsulfonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0246] (R)-N-(1-(3-(methylsulfonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0247] (S)-N-(1-(2-chloro-3-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0248] (R)-N-(1-(2-chloro-3-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0249] (S)-N-(1-(2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0250] (R)-N-(1-(2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0251] (S)-N-(1-(o-tolyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0252] (R)-N-(1-(o-tolyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0253] (S)-N-(1-(2-chloro-5-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0254] (R)-N-(1-(2-chloro-5-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0255] (S)-N-(1-(2-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0256] (R)-N-(1-(2-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0257] (S)-N-(1-(2-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0258] (R)-N-(1-(2-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0259] (S)-N-(1-(3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0260] (R)-N-(1-(3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0261] (S)-N-(1-(3-(trifluoromethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0262] (R)-N-(1-(3-(trifluoromethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0263] (S)-N-(1-(2-fluoro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0264] (R)-N-(1-(2-fluoro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0265] (S)-N-(1-(2,6-difluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0266] (R)-N-(1-(2,6-difluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0267] (S)-N-(1-(2-chloro-6-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0268] (R)-N-(1-(2-chloro-6-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0269] (S)-N-(1-(2-methoxy-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0270] (R)-N-(1-(2-methoxy-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0271] (S)-N-(1-(2-chloro-3-hydroxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0272] (R)-N-(1-(2-chloro-3-hydroxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0273] (S)-N-(1-(2-chloro-3-(2-(dimethylamino)ethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0274] (R)-N-(1-(2-chloro-3-(2-(dimethylamino)ethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0275] (S)-N-(1-(2-chloro-3-(2-(dimethylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0276] (R)-N-(1-(2-chloro-3-(2-(dimethylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0277] (S)-N-(1-(2-chloro-3-(2-(methylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0278] (R)-N-(1-(2-chloro-3-(2-(methylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0279] (S)-N-(1-(3-(2-acetylaminoethoxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0280] (R)-N-(1-(3-(2-acetylaminoethoxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0281] (S)-N-(1-(2-chloro-3-(2-methoxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0282] (R)-N-(1-(2-chloro-3-(2-methoxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0283] (S)-N-(1-(2-chloro-3-(2-hydroxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0284] (R)-N-(1-(2-chloro-3-(2-hydroxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0285] (S)-2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoic acid isopropyl ester;
[0286] (R)-2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoic acid isopropyl ester;
[0287] (S)-N-(1-(2-chloro-3-(dimethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0288] (R)-N-(1-(2-chloro-3-(dimethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0289] (S)-N-(1-(2-chloro-3-(pyrrolidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0290] (R)-N-(1-(2-chloro-3-(pyrrolidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0291] (S)-N-(1-(2-chloro-3-(piperidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0292] (R)-N-(1-(2-chloro-3-(piperidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0293] (S)-N-(1-(2-chloro-3-(morpholine-4-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0294] (R)-N-(1-(2-chloro-3-(morpholine-4-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0295] (S)-N-(1-(2-chloro-3-(diethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0296] (R)-N-(1-(2-chloro-3-(diethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0297] and pharmaceutically acceptable salts thereof.
[0298] As described herein, the compounds of the first aspect of the present invention may exist in the form of stereoisomers. Specifically, the compounds of the first aspect of the present invention may exist in the form of stereoisomers at the positions marked with asterisks in Formula I as described above, and it will be understood by those skilled in the art that the compounds of the first aspect of the present invention may exist in the R- or S- configuration at this position.
[0299] For the avoidance of doubt, it will be understood by those skilled in the art that when the carbon marked with an asterisk in the above Formula I herein is the only stereocenter in a compound of Formula I, the compound of Formula I may exist as two enantiomeric forms having different configurations at that stereocenter, which enantiomers may be referred to as R- and S-enantiomers (indicating the configuration at that position, as understood by those skilled in the art).
[0300] In particular, the compounds of the first aspect of the invention may be present as a mixture of stereoisomers (e.g., a mixture of approximately equal amounts), i.e., a mixture of each possible stereoisomer. In particular, when the compounds of the invention are present as R- and S-enantiomers (i.e., the R- and S-configurations at the carbons marked with asterisks in the compounds of formula I as described above), the compounds of the first aspect of the invention may be a mixture of those enantiomers, in particular a mixture of approximately equal amounts (e.g., a racemic mixture).
[0301] In other embodiments, the compounds of the first aspect of the invention may exist in the R- or S-configuration of the labeled carbon (e.g., R- or S-enantiomers), in which case the compound may be present in the substantial absence of compounds of alternative configurations (e.g., a purity relative to the alternative configuration greater than 60%, such as greater than 70%, greater than 80% or greater than 90% (e.g., greater than 99%, such as greater than or equal to 99.9%)).
[0302] For example, where the compound of the first aspect of the invention exists as an R- or S-enantiomer as described above, as will be appreciated by those skilled in the art, the compound may have an enantiomeric excess (ee) of greater than 60%, such as greater than 70%, greater than 80% or greater than 90% (e.g. greater than 99%, such as greater than or equal to 99.9%).
[0303] In particular, the compounds of the first aspect of the invention may exist as the S-enantiomer as described above.
[0304] Therefore, in a specific embodiment of the first aspect of the present invention, the compound of formula I is a compound of formula Ia
[0305]
[0306] Among them A 1 , A 2 , L 1 and R 1 As defined in the first aspect of the present invention (including all embodiments and combinations of embodiments thereof).
[0307] In particular, the compound of formula Ia is provided in the form of a compound of formula I or a pharmaceutically acceptable salt thereof substantially free of alternative configurations, such as a compound of formula Ib or a pharmaceutically acceptable salt thereof:
[0308]
[0309] Among them A 1 , A 2 , L 1 and R 1 As defined in the first aspect of the present invention (including all embodiments and combinations of embodiments thereof).
[0310] Specifically, the compound of formula Ia or its pharmaceutically acceptable salt can be provided in a purity of greater than 60%, such as greater than 70%, greater than 80% or greater than 90% (e.g., greater than 99%, such as greater than or equal to 99.9%) relative to the compound of formula Ib or its pharmaceutically acceptable salt (e.g., when present in a purity of greater than 90%, the compound of formula Ia or its pharmaceutically acceptable salt will account for greater than 90% of the combined amount of compounds of formula Ia and Ib and their pharmaceutically acceptable salts).
[0311] In alternative embodiments, references to the S-enantiomer or compound of formula Ia may be replaced with references to the R-enantiomer or compound of formula Ib, and vice versa.
[0312] For example, the compounds of the first aspect of the invention may be provided as compounds of formula Ib or pharmaceutically acceptable salts thereof with a purity greater than 60%, for example greater than 70%, greater than 80% or greater than 90% (for example greater than 99%, for example greater than or equal to 99.9%) relative to compounds Ia or pharmaceutically acceptable salts thereof.
[0313] Other compounds of the first aspect of the invention that may be mentioned include:
[0314] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0315] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0316] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0317] N-((4S)-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0318] N-((4S)-1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0319] (S)-N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0320] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0321] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0322] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0323] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0324] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0325] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0326] (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0327] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0328] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0329] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0330] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0331] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0332] (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0333] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0334] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0335] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0336] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0337] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0338] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0339] (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0340] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0341] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide;
[0342] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0343] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0344] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0345] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide;
[0346] (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0347] (S)-5-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-1-methyl-1H-imidazole-4-carboxamide;
[0348] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0349] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide;
[0350] (S)-4-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-methyl-1H-pyrazole-3-carboxamide;
[0351] (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0352] (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;
[0353] (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide;
[0354] (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide;
[0355] (S)-N-(1-(3-(methylsulfonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0356] (S)-N-(1-(2-chloro-3-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0357] (S)-N-(1-(2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0358] (S)-N-(1-(o-tolyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0359] (S)-N-(1-(2-chloro-5-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0360] (S)-N-(1-(2-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0361] (S)-N-(1-(2-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0362] (S)-N-(1-(3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0363] (S)-N-(1-(3-(trifluoromethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0364] (S)-N-(1-(2-fluoro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0365] (S)-N-(1-(2,6-difluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0366] (S)-N-(1-(2-chloro-6-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0367] (S)-N-(1-(2-methoxy-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0368] (S)-N-(1-(2-chloro-3-hydroxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0369] (S)-N-(1-(2-chloro-3-(2-(dimethylamino)ethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0370] (S)-N-(1-(2-chloro-3-(2-(dimethylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0371] (S)-N-(1-(2-chloro-3-(2-(methylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0372] (S)-N-(1-(3-(2-acetylaminoethoxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0373] (S)-N-(1-(2-chloro-3-(2-methoxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0374] (S)-N-(1-(2-chloro-3-(2-hydroxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0375] (S)-2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoic acid isopropyl ester;
[0376] (S)-N-(1-(2-chloro-3-(dimethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0377] (S)-N-(1-(2-chloro-3-(pyrrolidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0378] (S)-N-(1-(2-chloro-3-(piperidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0379] (S)-N-(1-(2-chloro-3-(morpholine-4-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0380] (S)-N-(1-(2-chloro-3-(diethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide;
[0381] and pharmaceutically acceptable salts thereof.
[0382] Treatments and medical uses
[0383] As described herein, the compounds of the first aspect of the invention have therapeutic activity.
[0384] Therefore, in a second aspect of the present invention, there is provided a compound as defined in the first aspect of the present invention (including all embodiments and combinations of embodiments thereof), or a pharmaceutically acceptable salt thereof, for use in medicine (which may also be referred to as use as a medicament).
[0385] In an alternative second aspect of the present invention, there is provided a method for treating a disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in the first aspect of the present invention (including all embodiments and combinations thereof) or a pharmaceutically acceptable salt thereof.
[0386] In another alternative second aspect of the present invention, there is provided a compound as defined in the first aspect of the present invention (including all embodiments and combinations of embodiments thereof), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treating a disease.
[0387] The compounds of the present invention can be used to treat cancer and / or viral infection. Therefore, in the third aspect of the present invention, there is provided a compound or a pharmaceutically acceptable salt thereof as defined in the first aspect of the present invention (including all embodiments and combinations thereof), which is used to treat cancer and / or treat or prevent viral infection.
[0388] In an alternative third aspect of the present invention, a method for treating cancer and / or treating or preventing viral infection is provided, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound as defined in the first aspect of the present invention (including all embodiments and combinations of their embodiments) or a pharmaceutically acceptable salt thereof.
[0389] In another alternative third aspect of the present invention, there is provided a compound as defined in the first aspect of the present invention (including all embodiments and combinations of embodiments thereof) or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for treating cancer and / or treating or preventing viral infection.
[0390] It will be understood by those skilled in the art that the treatment of a particular condition (or similarly, the treatment of the condition) is referred to in its normal meaning in the medical field. In particular, these terms may refer to achieving a reduction in the severity of one or more clinical symptoms associated with the condition. For example, in the case of cancer, the term may refer to achieving a reduction in the amount of cancer cells present (e.g., in the case of cancers that form solid tumors, indicated by a reduction in tumor volume). Similarly, in the case of viral infection, the term may refer to achieving a reduction in viral load (i.e., the number of viral units present in a given amount of plasma in the relevant patient, e.g., the number of viral units per milliliter of plasma).
[0391] Those skilled in the art will appreciate that reference to the prevention of a particular condition (and similarly, the prevention of the condition) takes its normal meaning in the medical art and includes reference to the prophylaxis of the condition (and vice versa). In particular, the term may refer to achieving a reduction in the likelihood that a patient (or healthy subject) will develop a condition (e.g., at least a 10% reduction, such as at least a 20%, 30% or 40% reduction, such as at least a 50% reduction).
[0392] As used herein, reference to a patient refers to a living subject being treated, including a mammalian (eg, human) patient. Thus, in certain embodiments of all aspects of the invention, the treatment is in a mammal (eg, a human).
[0393] As used herein, the term therapeutically effective amount refers to the amount of a compound that confers a therapeutic effect on the patient being treated. The effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject gives an indication of the effect and / or feels the effect).
[0394] Although the compounds of the first aspect of the invention may themselves have pharmacological activity, certain pharmaceutically acceptable (e.g., "protected") derivatives of the compounds of the invention may exist or be prepared which may not have such activity but may be administered parenterally or orally and subsequently metabolized in vivo to form the compounds of the invention. Thus, such compounds (which may have some pharmacological activity, provided that such activity is significantly lower than the activity of the active compounds to which they are metabolized) may be described as "prodrugs" of the compounds of the invention.
[0395] As used herein, reference to a prodrug will include compounds that, after enteral or parenteral administration (e.g., oral or parenteral administration), form a compound of the invention in an experimentally detectable amount within a predetermined time. All prodrugs of the compounds of the first aspect of the invention are included within the scope of the invention.
[0396] Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see:
[0397] a) Design of Prodrugs, edited by H.Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol.42, p.309-396, edited by K.Widder et al., (Academic Press, 1985);
[0398] b) A Textbook ofDrug Design and Development, edited by Krogsgaard-Larsen and H.Bundgaard, Chapter 5 "Design and Application of Prodrugs", edited by H.Bundgaard p.113-191 (1991);
[0399] c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
[0400] d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); and N. Kakeya, et al., Chem Pharm Bull, 32, 692 (1984).
[0401] As non-limiting examples, hydroxyl or carboxylic acid groups may be protected as esters, while amines may be protected as carbamates.
[0402] For the avoidance of doubt, the compounds of the first aspect of the present invention are useful because they are pharmacologically active and / or are metabolized in vivo after oral or parenteral administration to form pharmacologically active compounds. Specifically, as described herein, the compounds of the first aspect of the present invention can be used to treat cancer, which term will be readily understood by those skilled in the art.
[0403] In a particular embodiment of all aspects of the invention, references to treating cancer and / or treating or preventing viral infections will specifically refer to treating cancer.
[0404] In an alternative embodiment of all aspects of the invention, references to treating cancer and / or treating or preventing viral infections will specifically refer to treating or preventing (more specifically treating) viral infections.
[0405] In certain embodiments of all aspects of the invention, the cancer is a cancer selected from:
[0406] soft tissue cancers, such as sarcomas, myxomas, rhabdomyomas, fibromas, lipomas, and teratomas;
[0407] Lung cancer, such as bronchogenic carcinoma, alveolar or bronchiolar carcinoma, bronchial adenoma, sarcoma, lymphoma, enchondromatous hamartoma, mesothelioma;
[0408] Gastrointestinal cancer, such as esophageal cancer, stomach cancer, pancreatic cancer, small intestine cancer, large intestine cancer (such as colon cancer);
[0409] Urogenital tract cancers, such as kidney, bladder and urethra cancers, prostate cancer, testicular cancer;
[0410] Liver cancer, such as hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;
[0411] Bone cancers, such as osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor;
[0412] Cancer of the head and / or nervous system, such as cancer of the skull, meninges, brain, or spinal cord;
[0413] Gynecological cancers, such as uterine cancer, cervical cancer, ovarian cancer, vulvar cancer, vaginal cancer, and fallopian tube cancer;
[0414] Hematologic cancers, such as cancers of the blood and bone marrow (e.g., leukemias such as acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia), Hodgkin's disease, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia, Burkitt's lymphoma, multiple myeloma, Richter's syndrome, and T-cell lymphoma;
[0415] Skin cancers, such as malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipomas, hemangiomas, dermatofibromas, keloids; neurofibromatosis and adrenal cancer; and
[0416] Neuroblastoma.
[0417] As used herein, reference to cancer cells and the like will include reference to cells afflicted with any one of the aforementioned conditions.
[0418] More specific cancers that may be mentioned include cancers corresponding to the cell lines used in the examples provided herein. For example, specific cancers that may be mentioned include:
[0419] Colon cancer;
[0420] Skin cancer (e.g., as defined herein, such as malignant melanoma);
[0421] Lymphoma;
[0422] Leukemia (such as chronic myeloid leukemia); and
[0423] Sarcomas (such as those described herein).
[0424] In more specific embodiments, the cancer is selected from skin cancer (e.g., malignant melanoma) and hematological cancer (e.g., chronic myeloid leukemia). For example, the cancer can be a skin cancer as known to those skilled in the art, such as a skin cancer described herein.
[0425] More specifically, the cancer may be chronic myeloid leukemia (CML) or malignant melanoma. Most specifically, the cancer may be malignant melanoma.
[0426] In specific embodiments of all aspects of the invention, reference to a viral infection will refer to an infection caused by one or more viruses. Viruses can cause human diseases such as AIDS, Ebola hemorrhagic fever, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Western / Eastern equine encephalitis (WEE / EEE), dengue fever, Zika fever, influenza, hepatitis, West Nile fever, polio and measles.
[0427] The virus can be an RNA virus, such as a single-stranded RNA (ssRNA) or double-stranded RNA (dsRNA) virus, wherein the ssRNA virus can be a positive or negative sense ssRNA virus. For the purposes of the present invention, unless otherwise specified, an RNA virus is a virus belonging to Group III, IV, V or VI of the Baltimore classification system. Such viruses include, but are not limited to, the following:
[0428] Double-stranded (ds) RNA viruses (Group III), including rotaviruses and picobirnaviruses.
[0429] Positive-sense ssRNA viruses (Group IV) include coronavirus, bymovirus, comovirus, nepovirus, nodavirus, picornavirus, potyvirus, sobemovirus, luteovirus, carmovirus, dianthovirus, flavivirus, pestivirus, tomato dwarf virus, hepatitis C virus, alphavirus, carlavirus, furovirus, hordeivirus, potexvirus, rubivirus, tobravirus, tricornavirus, tymovirus, and hepatitis E virus.
[0430] Negative-sense ssRNA viruses (Group V), including Ebola virus, Marburg virus, Measles virus, Mumps virus, Nipah virus, Hendra virus, RSV, NOV, Rabies virus, Nyavirus, Lassa virus, Hantavirus, Crimean-Congohemorrhagic fever, influenza virus, and hepatitis D virus.
[0431] Retroviruses (Group VI), including lentiviruses such as HIV-1 and HIV-2.
[0432] It will be appreciated by those skilled in the art that treatment with the compounds of the first aspect of the invention may further include additional (i.e., additional / other) treatments for the same condition (i.e., in combination therewith). Those additional treatments may be known treatments, e.g., may represent the standard of care treatment for that particular condition.
[0433] For example, when used to treat cancer, treatment with the compounds of the invention can be combined with other means for treating cancer known to those skilled in the art, such as treatment with one or more other therapeutic agents useful for treating cancer (including chemotherapeutic drugs and treatment with cell-based therapies such as immunotherapy) and / or treatment with one or more physical methods for treating cancer (e.g., treatment by surgery and / or radiation therapy).
[0434] Thus, treatment with a compound of the first aspect of the invention may further include such treatment against (ie in combination with) another (ie additional / other) cancer of cancer (ie for use in treating a cancer as described herein, such as malignant melanoma).
[0435] In particular, treatment with the compounds of the invention may be carried out in combination (e.g. in a patient who is also receiving treatment with one or more (e.g. one) additional compounds (i.e. therapeutic agents)) with one or more (e.g. one) additional compounds (i.e. therapeutic agents):
[0436] (i) capable of reducing the level of nucleoside and / or nucleotide in cells (e.g. cancer cells); and / or
[0437] (ii) is a p53 activator (e.g., an MDM2 inhibitor),
[0438] Both are described below.
[0439] Similarly, when used to treat or prevent viral infection, treatment or prevention using the compounds of the invention may be combined with one or more other therapeutic agents known to those skilled in the art to be useful for treating or preventing viral infection (e.g., antiviral compounds or vaccines).
[0440] Pharmaceutical composition
[0441] As described herein, the compounds of the present invention can be used as medicaments. Such compounds can be administered alone or can be administered via known pharmaceutical compositions / formulations.
[0442] In the fourth aspect of the present invention, a pharmaceutical composition is provided, which comprises the compound of the present invention (first aspect) and optionally one or more pharmaceutically acceptable adjuvants, diluents and / or carriers.
[0443] Those skilled in the art will appreciate that references herein to compounds of the first aspect of the invention for specific uses (and similarly, to uses and methods of use associated with the compounds of the invention) may apply mutatis mutandis to pharmaceutical compositions comprising the compounds of the invention as described herein.
[0444] In the fifth aspect of the present invention, a pharmaceutical composition is provided, comprising a compound as defined in the first aspect of the present invention and optionally one or more pharmaceutically acceptable adjuvants, diluents and / or carriers, for use in treating cancer and / or treating or preventing viral infection (as defined in the first aspect of the present invention).
[0445] It will be appreciated by those skilled in the art that the compounds of the present invention may act systemically and / or locally (ie, at a specific site).
[0446] It will be understood by those skilled in the art that the compounds and compositions described in all aspects of the present invention will generally be administered orally, intravenously, subcutaneously, buccally, rectally, transdermally, nasally, tracheally, bronchially, sublingually, intranasally, topically, by any other parenteral route, or via inhalation in a pharmaceutically acceptable dosage form. Pharmaceutical compositions as described herein will include compositions in the form of tablets, capsules, or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like. Alternatively, particularly when these compounds of the present invention act locally, the pharmaceutical compositions may be formulated for topical administration.
[0447] Therefore, in specific embodiments of all relevant aspects of the invention, the pharmaceutical preparation is provided in a pharmaceutically acceptable dosage form, which includes tablets or capsules, liquid forms for oral or injection administration, suppositories, creams, gels, foams, inhalants (e.g., for intranasal application), or forms suitable for topical administration. For the avoidance of doubt, in such embodiments, the compounds of the invention may be present in solid (e.g., solid dispersion), liquid (e.g., solution) or other forms (e.g., in micellar form).
[0448] For example, in the preparation of a pharmaceutical preparation for oral administration, the compound can be mixed with a solid powdered ingredient such as lactose, sucrose, sorbitol, mannitol, starch, pullulan, a cellulose derivative, gelatin or another suitable ingredient, as well as with a disintegrant and a lubricant such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol wax. The mixture can then be processed into granules or compressed into tablets.
[0449] Soft gelatin capsules can be prepared with capsules containing one or more active compounds (e.g., compounds of the invention, and optionally additional therapeutic agents) and, for example, vegetable oils, fats, or other suitable vehicles for soft gelatin capsules. Similarly, hard gelatin capsules can contain a combination of the compound and solid powdered ingredients such as lactose, sucrose, sorbitol, mannitol, potato starch, corn starch, pullulan, cellulose derivatives, or gelatin.
[0450] Dosage units for rectal administration can be prepared: (i) in the form of suppositories containing the compound mixed with a neutral fat base; (ii) in the form of gelatin rectal capsules containing a mixture of the active substance with vegetable oil, paraffin oil or other suitable vehicles for gelatin rectal capsules; (iii) in the form of ready-to-use microenemas; or (iv) in the form of dry microenema preparations to be reconstituted in a suitable solvent immediately before administration.
[0451] Liquid preparations for oral administration can be made into syrup or suspension (such as solution or suspension) form, it contains the compound, and the remainder of the preparation is composed of a mixture of sugar or sugar alcohol and ethanol, water, glycerol, propylene glycol and polyethylene glycol. If necessary, such liquid preparations can contain coloring agents, flavoring agents, saccharin and carboxymethyl cellulose or other thickening agents. Liquid preparations for oral administration can also be made into a dry powder form reconstructed with a suitable solvent before use.
[0452] Solutions for parenteral administration can be prepared as solutions of the compound in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing components and / or buffering components and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as dry preparations that are reconstituted with a suitable solvent temporarily before use.
[0453] In certain embodiments of the fourth and fifth aspects of the invention, the pharmaceutical composition does not comprise liposomes.
[0454] It will be appreciated by those skilled in the art that the compounds of the present invention can be administered with different dosages (for example, in the form of compositions as described in the fourth and fifth aspects of the present invention), and suitable dosages are easily determined by those skilled in the art. Oral, pulmonary and topical dosages (and subcutaneous dosages, but these dosages may be relatively low) can be in the range of about 0.01mg / kg body weight / day (mg / kg / day) to about 200mg / kg / day, preferably about 0.01 to about 10mg / kg / day and more preferably about 0.1 to about 5.0mg / kg / day. For example, when orally administered, treating with such compounds and compositions can include administering compositions containing generally about 0.01mg to about 2000mg, for example, about 0.1mg to about 500mg or 1mg to about 100mg of active ingredient. When mixed intravenously, the most preferred dosage range during constant rate infusion is about 0.001 to about 10mg / kg / hour. Advantageously, treatment may comprise administration of such compounds and compositions in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily (with reference to the doses described herein).
[0455] In any event, a person skilled in the art (e.g., a physician) will be able to determine the actual dosage most suitable for an individual patient, which may vary with the route of administration, the type and severity of the condition to be treated, and the species, age, weight, sex, renal function, liver function, and response of the specific patient to be treated. The above dosages are examples of average situations; there may, of course, be individual situations where a higher or lower dosage range is desired, and these are within the scope of the present invention.
[0456] As described above, it will be appreciated by those skilled in the art that treatment with the compounds of the present invention may further include additional (i.e., additional / other) treatments for the same condition (i.e., in combination with them). In particular, treatment with the compounds of the present invention may be combined with other means for treating cancer (e.g., treatment with one or more other therapeutic agents that can be used to treat cancer) or other means for treating or preventing viral infections.
[0457] In certain embodiments of the fourth and fifth aspects of the invention, the pharmaceutical composition may further comprise one or more additional (ie other) therapeutic agents.
[0458] In more specific embodiments, the one or more additional therapeutic agents is an agent used to treat cancer (eg, an additional agent used to treat a cancer as described herein (eg, malignant melanoma)).
[0459] In other embodiments, the one or more additional therapeutic agents is an agent used to treat or prevent a viral infection, such as a viral infection described herein.
[0460] It will be appreciated by those skilled in the art that combinations of therapeutic agents may also be described as a combination product and / or provided in a kit-of-parts format.
[0461] In a sixth aspect of the present invention, there is provided a combination product comprising:
[0462] (A) a compound as defined in the first aspect of the present invention; and
[0463] (B) one or more additional therapeutic agents,
[0464] Components (A) and (B) are each formulated as a mixture, optionally with one or more pharmaceutically acceptable adjuvants, diluents or carriers.
[0465] In a seventh aspect of the present invention, a kit is provided, comprising:
[0466] (a) a compound as defined in the first aspect of the invention, or a pharmaceutical composition as defined in the fourth or fifth aspect of the invention; and
[0467] (b) one or more additional therapeutic agents, optionally in admixture with one or more pharmaceutically acceptable adjuvants, diluents or carriers,
[0468] The components (a) and (b) are each provided in a form suitable for administration in combination with the other component.
[0469] In certain embodiments of the sixth and seventh aspects of the invention, the additional therapeutic agent is a therapeutic agent for treating cancer (eg, an additional agent for treating a cancer as described herein (eg, malignant melanoma)).
[0470] In certain embodiments of the sixth and seventh aspects of the invention, the additional therapeutic agent is an agent for the treatment of malignant melanoma.
[0471] In certain embodiments of the sixth and seventh aspects of the invention, the additional therapeutic agent is an agent:
[0472] (i) is capable of reducing the level of nucleosides and / or nucleotides in a cell (e.g. a cancer cell, such as a cell forming part of a cancer as described herein); and / or
[0473] (ii) is a p53 activator (eg, an MDM2 inhibitor).
[0474] For the avoidance of doubt, a compound (i.e., a therapeutic agent)
[0475] (i) is capable of reducing the level of nucleosides and / or nucleotides in a cell (e.g. a cancer cell, such as a cell forming part of a cancer as described herein); and / or
[0476] (ii) is a p53 activator (e.g., an MDM2 inhibitor),
[0477] Those skilled in the art will readily identify, and particularly include, those therapeutic agents that are commercially available (eg, agents with marketing authorization in one or more regions, such as Europe or the United States).
[0478] It will be understood by those skilled in the art that reference to a therapeutic agent capable of reducing the level of nucleosides and / or nucleotides in a cell (e.g., a cancer cell, such as a cell forming part of a cancer as described herein) may refer to a compound capable of reducing the level of such nucleosides and / or nucleotides (e.g., the level of uridine and / or uridine phosphates (e.g., monophosphates, diphosphates and triphosphates)) in such a cell by at least 10% (e.g., at least 20%, at least 30% or at least 40%, such as at least 50%, at least 60%, at least 70% or at least 80%, such as at least 90%) when compared to the level of such nucleosides and / or nucleotides in such a cell prior to treatment with the relevant compound.
[0479] It will also be appreciated by those skilled in the art that reference to a therapeutic agent capable of reducing the level of nucleosides and / or nucleotides in a cell (e.g., a cancer cell, such as a cell forming part of a cancer as described herein) may include reference to a compound that acts by inhibiting the uptake of such nucleosides and / or nucleotides by such a cell. For example, such a therapeutic agent may include a uridine uptake inhibitor (e.g., the therapeutic agent nilotinib or dipyridamole), as known to those skilled in the art.
[0480] Specific therapeutic agents capable of reducing intracellular nucleoside and / or nucleotide levels include nilotinib, dipyridamole, imatinib, gefitinib, ibrutinib, varlitinib, volitinib, and vemurafenib (e.g., nilotinib and imatinib).
[0481] For example, therapeutic agents capable of reducing intracellular nucleoside and / or nucleotide levels include nilotinib, dipyridamole, imatinib, ibrutinib, and vemurafenib.
[0482] More specific therapeutic agents capable of reducing intracellular nucleoside and / or nucleotide levels include nilotinib, ibrutinib, and dipyridamole.
[0483] More specific therapeutic agents capable of reducing intracellular nucleoside and / or nucleotide levels include imatinib.
[0484] More specific therapeutic agents capable of reducing intracellular nucleoside and / or nucleotide levels include vemurafenib.
[0485] For example, therapeutic agents capable of reducing intracellular nucleoside and / or nucleotide levels include ASLAN001 (valitinib), ibrutinib, rapamycin, vemurafenib, gefitinib, antimycin A, BI-2536, VX-680, roscovitine, olomoucine, imatinib (STI-571), AG1879, AG1517, AG1478, AG825, AG18, AG490, vinblastine, etoposide, genistein, U0126, Raf-1 inhibitor 1, H89, KN93, staurosporine, ZM336372, and indirubin-3'-monoxime.
[0486] In particular, therapeutic agents capable of reducing intracellular nucleoside and / or nucleotide levels include ASLAN001 (vacitinib).
[0487] In particular, therapeutic agents capable of reducing intracellular nucleoside and / or nucleotide levels include ibrutinib.
[0488] Other compounds that can reduce the level of nucleosides and / or nucleotides in cells include BIBW2992, AG013736, PF-02341066 / PF-2341066, BMS-354825, 5-aza-2'-deoxycytidine, LY317615, CP-358774 / OSI-774, RAD001 / SDZ-RAD / Certican, GW572016 / GW2016, AMN-107, GW786034 / Armala, AP24534, BAY73-4506, INCB018424, Bay 43-9006 / Nexaxar, Sutent / SU-11248, Torisel / CCI-779, tasocitinib / CP-690550, GSK1120212, ZD6474, PLX4032 / RG7204 / RO5185426, SAHA / Zolinza / MK-0683, AT-877 / HA-1077, and quizartinib.
[0489] It will be understood by those skilled in the art that reference to a p53 activator may refer to a therapeutic agent that is capable of: increasing p53 synthesis and / or stability (e.g. by increasing thermostability or by inhibiting degradation); and / or increasing transcription factor function within a cell (e.g. a cancer cell, such as a cell forming part of a cancer as described herein).
[0490] In particular, it may refer to increasing p53 synthesis and / or stability such that the level of p53 within such a cell is at least increased by at least 10% (e.g. at least 20%, at least 30% or at least 40%, such as at least 50%, at least 60%, at least 70% or at least 80%, such as at least 90% or at least 100%) when compared to the level of p53 in a cell (e.g. a cancer cell, such as a cell forming part of a cancer as described herein) prior to treatment with the relevant compound. Furthermore, it may refer to an increase in p53 transcription factor function in such a cell by at least 10% (e.g. at least 20%, at least 30% or at least 40%, such as at least 50%, at least 60%, at least 70% or at least 80%, such as at least 90% or at least 100%) when compared to the level of p53 in a cell (e.g. a cancer cell, such as a cell forming part of a cancer as described herein) prior to treatment with the relevant compound.
[0491] Those skilled in the art will further appreciate that reference to p53 activators may include reference to therapeutic agents that act by inhibiting MDM2 (eg, the therapeutic agent nutlin-3).
[0492] It will be understood by those skilled in the art that reference to a therapeutic agent that acts by inhibiting MDM2 may refer to a compound that is capable of inhibiting MDM2 activity in a cell (e.g., a cancer cell, such as a cell forming part of a cancer as described herein) by at least 10% (e.g., at least 20%, at least 30% or at least 40%, such as at least 50%, at least 60%, at least 70% or at least 80%, such as at least 90%) when compared to the level of MDM2 activity in such a cell prior to treatment with the relevant compound.
[0493] Specific therapeutic agents that can activate p53 (e.g., by inhibiting MDM2) include nutlin-3, RO5045337, idasanutlin, AMG-232, DS3032b, serdemetan, ALRN-6924, SAR-405838, CGM-097, RO-5503781, RO-6839921, and HDM-201.
[0494] More specific therapeutic agents capable of activating p53 (eg, by inhibiting MDM2) include nutlin-3.
[0495] Other therapeutic agents that can activate p53 (eg, by increasing p53 levels) include PS-341 / MS-341, Ara-C, doxorubicin, 5-FU, Camptosar, and mithramycin A.
[0496] In alternative embodiments of the sixth and seventh aspects of the invention, the additional therapeutic agent is a therapeutic agent for treating or preventing a viral infection (eg, a viral infection as described herein).
[0497] Preparation of compounds / compositions
[0498] The pharmaceutical compositions / formulations, combination products and kits described herein may be prepared according to standard and / or accepted pharmaceutical practice.
[0499] Thus, in another aspect of the present invention, there is provided a process for the preparation of a pharmaceutical composition / formulation as defined above, said process comprising combining a compound of the present invention as defined above with one or more pharmaceutically acceptable adjuvants, diluents or carriers.
[0500] In other aspects of the invention, there is provided a method for preparing a combination product or kit of parts as defined above, the method comprising combining a compound of the invention as defined above or a pharmaceutically acceptable salt thereof with other therapeutic agents useful for treating cancer and / or treating or preventing viral infections and at least one pharmaceutically acceptable adjuvant, diluent or carrier.
[0501] As used herein, reference to combining shall mean that the two components are suitable for administration in conjunction with each other.
[0502] Therefore, with respect to the method for preparing a kit of parts as defined above, by "combining" two components with each other, we consider that the two components of the kit of parts may be:
[0503] (i) provided as separate preparations (ie independently of each other) which are subsequently used together in combination therapy with each other; or
[0504] (ii) The separate components are packaged and presented together as a "combination pack" for use in conjunction with each other in a combination therapy.
[0505] The compounds of the invention as defined herein may be prepared according to techniques well known to those skilled in the art, for example as described in the Examples provided hereinafter.
[0506] In an eighth aspect of the present invention, there is provided a method for preparing a compound of formula I or a pharmaceutically acceptable salt thereof as defined in the first aspect of the present invention, the method comprising:
[0507] (i) making the compound of formula II
[0508]
[0509] Where R 1 and A 2As defined in the first aspect of the present invention, and a compound of formula III
[0510] LG 1 -L 1 -A 1 (III)
[0511] Among them A 1 and L 1 As defined in the first aspect of the present invention and LG 1 represents a suitable leaving group, in the presence of a suitable solvent and optionally in the presence of a suitable base and / or a suitable catalyst, under conditions known to those skilled in the art (for example, when LG 1 When it represents -OH, the reaction can be carried out in the presence of reagents known to those skilled in the art to be suitable for carrying out peptide coupling reactions, for example in the presence of HOBt and EDC.HCl or alternatively HATU or HBTU, and optionally in the presence of a suitable base such as Et 3 in the presence of N);
[0512] (ii) When L 1 stands for -C(O)N(R 2 )-, where R 2 When H represents, the compound of formula II and the compound of formula IV
[0513] A 1 -N=C=O(IV)
[0514] Among them A 1 As defined in the first aspect of the present invention, in the presence of a suitable solvent and optionally in the presence of a suitable base and / or a suitable catalyst, under conditions known to those skilled in the art; or
[0515] (iii) making the compound of formula (V)
[0516]
[0517] Where R 1 , A 1 and L 1 As defined in the first aspect of the present invention, and a compound of formula VI
[0518] LG 2 -A 2 (VI)
[0519] Among them A 2 As defined in the first aspect of the present invention and LG 2represents a suitable leaving group, in the presence of a suitable solvent and optionally in the presence of a suitable base and / or a suitable catalyst, under conditions known to those skilled in the art (e.g., under Buchwald-Hartwig conditions known to those skilled in the art, for example, wherein LG 2 represents a suitable leaving group such as a halogen and over a suitable catalyst such as a suitable Pd catalyst (e.g. Pd 2 (dba) 3 ) and a suitable base, or under Chan-Lam conditions known to those skilled in the art, such as where LG 2 represents a suitable leaving group such as -B(OH) 2 and in the presence of a suitable catalyst such as a suitable Cu catalyst (e.g. Cu(OAc) 2 ) and a suitable base).
[0520] The compounds of formula II, III, IV, V and VI are commercially available, known in the literature or can be obtained from available starting materials using appropriate reagents and reaction conditions by analogous methods of the methods described herein or by conventional synthesis procedures according to standard techniques. In this regard, those skilled in the art can refer in particular to "Comprehensive Organic Synthesis", BMTrost and I.Fleming, Pergamon Press, 1991. Other references that can be used include "Heterocyclic Chemistry", JA Joule, K. Mills and GF Smith, 3rd edition, Chapman & Hall published; "Comprehensive Heterocyclic Chemistry II", AR Katritzky, CWRees and EFV Scriven, Pergamon Press, 1996; and "Science of Synthesis", Vol. 9-17 (Hetarenes and Related Ring Systems), Georg Thieme Verlag, 2006.
[0521] For example, the compound of formula II can be prepared by:
[0522]
[0523] Where R 1 and A 2 As defined herein for compounds of Formula I (and Formula Ia), with a suitable chiral amide (e.g. (S S)-2-methyl-2-propanesulfenamide) under conditions known to those skilled in the art (e.g., in the presence of a suitable catalyst (e.g., Ti(OEt) 4 ) and a suitable reducing agent (e.g., lithium L-tri-sec-butylborohydride (L-selectride)), and in the presence of a suitable solvent), followed by cleavage of the amide (i.e., providing the free amine of the compound of formula II) under conditions known to those skilled in the art.
[0524] In addition, the compound of formula VII can be prepared by the following reaction:
[0525]
[0526] Where R 1 As defined herein for the compound of formula VII, and the compound of formula IX
[0527]
[0528] Among them A 2 The reaction is carried out under conditions known to those skilled in the art as defined herein for compounds of formula I (and formula Ia).
[0529] Optionally, where R 1 The compound of formula VII representing H can be prepared by the following reaction: a compound of formula X
[0530]
[0531] with a compound of formula IX as defined herein under conditions known to those skilled in the art.
[0532] It will be appreciated by those skilled in the art that compounds of formula III are commercially available, known in the literature or can be prepared by methods analogous to the synthesis of compounds of formula I, but wherein A 2 represents H or a suitable protecting group known to those skilled in the art, wherein in the latter case the preparation will require removal of the protecting group under conditions known to those skilled in the art to afford a compound of formula III.
[0533] Compounds of formula VII, VIII, IX and X are commercially available, known in the literature or can be obtained by methods analogous to those described herein or by conventional synthetic procedures according to standard techniques, from available starting materials using appropriate reagents and reaction conditions.
[0534] It will be appreciated by those skilled in the art that the compounds of formula Ia and Ib as defined herein and their pharmaceutically acceptable salts may be prepared by a similar method to the synthesis of the compounds of formula I and their pharmaceutically acceptable salts described in the eighth aspect of the present invention. Specifically, such a method may be carried out according to the eighth aspect of the present invention, wherein the compounds of formula II and formula V are replaced by the following compounds:
[0535]
[0536] For example, compounds of formula II wherein the stereochemistry shown is reversed (i.e. providing the opposite enantiomer) may be prepared by reacting a compound of formula VII as defined herein with a suitable chiral amide (e.g. (S S )-2-methyl-2-propanesulfenamide) under conditions known to those skilled in the art (e.g., in the presence of a suitable catalyst (e.g., Ti(OEt) 4 ) and a suitable reducing agent (e.g. NaBH 4 ) and in the presence of a suitable solvent), followed by cleavage of the amide (ie, providing the free amine of the compound corresponding to the compound of formula II) under conditions known to those skilled in the art.
[0537] As defined above, A 1 , A 2 , L 1 and R 1 Substituents on the group can be modified once or many times after or during the method for preparing the compound of formula Ia (and similarly, compound of formula Ib) by methods well known to those skilled in the art as described above. Examples of these methods include substitution, reduction, oxidation, dehydrogenation, alkylation, dealkylation, acylation, hydrolysis, esterification, etherification, halogenation and nitration. The precursor group can be changed into another type of group or a group defined in formula I at any time during the reaction sequence. Those skilled in the art can also refer to " Comprehensive Organic Functional Group Transformations ", AR Katritzky, O. Meth-Cohn and C W Rees, Pergamon Press, 1995 and / or " Comprehensive Organic Transformations ", RC Larock, Wiley-VCH, 1999.
[0538] Such compounds can be isolated from their reaction mixtures and, if desired, purified using conventional techniques known to those skilled in the art. Thus, the methods for preparing the compounds of the invention as described herein can include the separation and optional purification of the compounds of the invention (e.g., the separation and optional purification of compounds of Formula I) as a final step.
[0539] It will be appreciated by those skilled in the art that in the methods described above and below, the functional groups of the intermediate compounds may need to be protected by protecting groups. The protection and deprotection of the functional groups may be carried out before or after the reactions in the above schemes.
[0540] The protecting group can be applied and removed according to the technology known to those skilled in the art and as described below. For example, the protected compound / intermediate chemical conversion described herein can be made into unprotected compound using standard deprotection techniques. The involved chemical types will determine the needs and type of the protecting group, and the order to complete the synthesis. The use of protecting groups is fully described in " Protective Groups in Organic Synthesis ", the 3rd edition, TW Greene & P.GMWutz, Wiley-Interscience (1999).
[0541] Compounds as described herein (particularly, compounds as defined in the first aspect of the invention) may have the following advantages: they may be more effective, less toxic, longer acting, more potent, produce fewer side effects, be more easily absorbed, and / or have better pharmacokinetic characteristics (e.g., higher oral bioavailability and / or lower clearance), and / or have other useful pharmacological, physical or chemical properties, whether for the above indications or otherwise, compared to compounds known in the prior art. In particular, such compounds may have the following advantages: they are more effective and / or exhibit favorable properties in vivo.
[0542] Without wishing to be bound by theory, it is believed that the compounds described herein are potent inhibitors of DHODH, which results in activity as inhibitors of de novo pyrimidine nucleotide synthesis. Cancer cells are known to have greater susceptibility to modulation of nucleotide levels due to their defective cell cycle checkpoints. This allows for potent and selective inhibition of cancer cell growth and promotion of cancer cell death. In addition, the compounds described herein are combined with therapeutic agents that can reduce the level of nucleotides and nucleosides (e.g., pyrimidine nucleotides and nucleosides) in cells (e.g., by inhibiting uptake or preventing intracellular retention; for example, the therapeutic agent nilotinib) and are believed to provide an effective and synergistic combination therapy.
[0543] Surprisingly, despite their activity in reducing nucleotide and nucleoside levels in such cells, the compounds described herein have also been found to increase p53 synthesis (p53 is a known tumor suppressor). In addition, it has been found that combining the compounds described herein with other p53 activators (e.g., MDM2 inhibitors, such as nutlin-3) also provides an effective and synergistic combination therapy.
[0544] Again without wishing to be bound by theory, it is believed that the synergistic effects observed between the DHODH inhibitors described herein and p53 degradation inhibitors such as nutlin-3 are caused by the ability of the DHODH inhibitors to increase p53 synthesis. This increase in p53 synthesis and the inhibition of p53 degradation by nutlin-3 (MDM2 inhibitor) results in a more potent increase in p53 levels, which serves to induce p53 pro-apoptotic functions.
[0545] Furthermore, the compounds described herein are believed to be potent inhibitors of viral replication, making them particularly useful in treating or preventing viral infections. BRIEF DESCRIPTION OF THE DRAWINGS
[0546] Figure 1 Simplified depictions of the de novo synthesis (blue) and salvage (black) pathways of pyrimidine nucleotides are shown.
[0547] Figure 2 Results obtained from Biological Example 2 are shown, wherein compounds of Synthetic Examples 6, 9, 11 and 13 reduced MOLM13 cell growth and / or viability, and this effect was largely prevented by the addition of excess uridine. Example
[0548] Unless otherwise stated, chemicals and reagents were obtained from commercial suppliers and used as received. All reactions involving moisture-sensitive reagents were performed in oven- or flame-dried glassware under a positive pressure of nitrogen.
[0549] Thin layer chromatography was performed using aluminum plates coated with silica gel (using the fluorescent indicator UV254). The developed plates were air-dried and then exposed to UV light or by KMnO 4Dip staining was used for analysis. Flash column chromatography was performed using silica gel (60-120 μm). Low resolution (LR) electrospray mass spectrometry (LC-MS) analysis was obtained by electrospray ionization (ESI) on a Shimadzu LCMS (SQD)-2010EV or Agilent LCMS (SQD)-1200 series LC / G6125B-MS. Nuclear magnetic resonance (NMR) spectra were recorded at 400 MHz for protons (1H NMR) and 100 MHz for carbon (13C NMR) and fluorine (19F NMR) on a Varian / Bruker spectrometer; chemical shifts were reported in units of ppm (δ) relative to the residual protons in the deuterated solvent peak. Coupling constants (J) were reported in Hz and to the nearest 0.1 Hz. The following abbreviations were used; s, singlet; d, doublet; dd, doublet of doublet; t, triplet; m, multiplet; q, quartet; and br, broad peak. Signal assignments were proposed based on observed values. HPLC analysis was obtained on a Shimadzu HPLC 2010CHT HPLC consisting of a LC 20ADprominence pump, a DGU-20A3 prominence degasser, a SPD-M20Aprominence DAD detector, and a SIL-HTC autosampler. Separation was achieved using a Waters X-Select CSH C18 (4.6x150) mm; 5u column.
[0550] Analytical RPLC-MS was performed using HPLC-MS Shimadzu HPLC 2010CHT coupled to Shimadzu LCMS (SQD)-2010EV under the following conditions: column: Waters X-Select C18 CSH (3.0*50) mm 2.5μ; mobile phase: ACN / water gradient (0.05% HCOOH); flow rate, 1.2 mL / min; detection, UV (214, 254, 280 nm) and MS (ESI, positive & negative polarity) or Agilent LCMS (SQD)-1200 series LC / G6125B-MS mass spectrometer equipped with electrospray ionization (ESI+). The HPLC-MS methods are as follows: Method 1 - Waters X-Select C18 CSH (3.0*50) mm 2.5μ, 4 min gradient mobile phase ACN / [5 mM NH 4 HCO 3 / H 2 O]; Method 2 - Column: Waters X-Select C18 CSH (3.0*50) mm 2.5μ; Mobile phase, ACN / water gradient (0.05% HCOOH), using positive and negative electrospray ionization.
[0551] Preparative RP-LC was performed using a Shimadzu preparative HPLC system consisting of a CBM-20A system controller, an LC-8A binary gradient pump, an SPD-M20A photodiode array detector, an Xselect PrepC185mm OBD TM FRC-10A fraction collector with 30x250 mm, 5 μm column, using ACN / H 2 O (0.05% HCOOH) gradient, flow rate 30mL / min, UV (220 or 254nm) detection. Prep C185mm OBD TM 30x250mm, 5μm column, on GILSON 333 / 334 Prep-Scale system, flow rate 30mL / min, detection at 254nm, using ACN / H 2 O (0.05% HCOOH) gradient system.
[0552] Preparative and analytical chiral HPLC were performed using a variety of columns and conditions.
[0553] UPLC analysis method
[0554]
[0555] Example compounds
[0556] The invention is illustrated by the following example compounds.
[0557] In the event of a discrepancy between the nomenclature and the compound structure depicted in the Figures, the latter shall prevail (unless contradicted by any experimental details that may be given and / or unless clear from the context).
[0558] The following compounds were prepared in the manner described below.
[0559] Example 1: N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0560]
[0561] Step-1: Synthesis of 4-((dimethylamino)methylene)-2H-pyran-3,5(4H,6H)-dione (INT-1.1): A solution of tetrahydropyran-3,5-dione (5.00 g, 43.85 mmol) in toluene (50 mL) was added to DMF-DMA (10.45 g, 87.71 mmol) and heated at 90° C. for 6 h. After completion of the reaction (monitored by TLC), the solvent was evaporated in vacuo, and the residue was triturated with n-pentane to give INT-1.2 (5.1 g, crude) as an off-white solid; 1H NMR (400 MHz, DMSO-d6): δ 8.08 (s, 1H), 4.02 (s, 4H), 3.45 (s, 3H), 3.16 (s, 3H).
[0562] Step-2: Synthesis of 1-(2-fluorophenyl)-1,7-dihydropyrano[3,4-c]pyrazole-4(5H)-one (INT-1.2): A solution of INT-1.1 (4.10 g, 24.23 mmol), 1-(2-fluorophenyl)hydrazine (3.94 g, 24.23 mmol) in AcOH (3.6 mL, 63.0 mmol) and ethanol (40 mL) were refluxed for 16 h. After completion (monitored by TLC), the reaction mixture was diluted with water and extracted with DCM (3X100 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The resulting crude solid was purified by silica gel (100-200 mesh) column chromatography eluting with 5-10% methanol in DCM to afford INT-1.2 (2.85 g, 50.7%) as a white solid; LCMS (ESI) m / z = 233.1 [M+H] +.
[0563] Step-3: Synthesis of 1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-amine (INT-1.3): To a solution of INT-1.2 (2.00 g, 8.61 mmol) in 2-propanol (50 mL) was added ammonium acetate (6.63 g, 86.13 mmol) and molecular sieves After vigorous stirring, carefully add NaBH 3 CN (2.70 g, 43.06 mmol). The reaction was heated to 70 ° C for 48 hours. After completion (monitored by TLC), the reaction mixture was filtered and concentrated in vacuo. The residue was purified by silica gel (100-200 mesh) column chromatography and eluted with 5-10% methanol in DCM to give INT-1.3 (1.40 g, 70%) as a white solid; LCMS (ESI) m / z=234.2 [M+H] +.
[0564] Step-4: Synthesis of N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-1): A solution of INT-1.3 (0.200 g, 0.861 mmol) in DCM (5 mL) was cooled to 0°C. 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic acid (0.157 g, 0.947 mmol) and triethylamine (0.3 mL, 2.584 mmol) were added. The resulting mixture was stirred for 5 min, and then T was added. 3 P (50% ethyl acetate, 0.4 mL, 1.29 mmol). The reaction mixture was stirred at room temperature for 16 h. After completion (monitored by TLC), the reaction mixture was diluted with water and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo to give the crude title compound. The crude solid material was purified by column chromatography on silica gel (100-200 mesh) eluting with 5-10% MeOH in DCM to give pure Ex-1; LCMS (ESI) m / z=381.9 [M+H]+.
[0565] Ex-1 was separated and purified by chiral HPLC to obtain Ex-2 (22 mg, 8.5%) and Ex-3 (22 mg, 7.8%), which were off-white solids (DAICEL CHIRALPAK-IG (250x30 mm, 5μ) / mobile phase: A. n-hexane + 0.1% DEA; B. DCM: MEOH (50:50) isocratic 50% B / flow rate: 30 mL min -1 )t R (Peak 1) 9.1, t R (Peak 2) 10.4.
[0566] Example 2: (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (peak 1)
[0567]
[0568] LCMS (ESI) m / z=381.9[M+H]+; HPLC: 98.7% (t R=5.920min); 1H NMR (400MHz, DMSO-d6): δ7.71(s,1H),7.62-7.43(m,5H),7.42-7.32(m,1H),5.10-4.99(m,1H),4.77-4.51(m,2H),3.99(br t,J=5.9Hz,2H),3.85(d,J=3.9Hz,2H),2.99(brt,J=6.6Hz,2H),1.90-1.83(m,2H),1.80-1.72(m,2H).
[0569] Example 3: (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (peak 2)
[0570]
[0571] LCMS (ESI) m / z=381.9[M+H]+; HPLC: 99.8% (t R =5.926min); 1H NMR (400MHz, DMSO-d6): δ7.71(s,1H),7.61-7.44(m,5H),7.41-7.34(m,1H),5.17-4.98(m,1H),4.75-4.5 3(m,2H),4.01-3.98(m,2H),3.86-3.82(m,2H),3.01-2.98(m,2H),1.89-1.81(m,2H),1.81-1.72(m,2H).
[0572] Example 4: N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide
[0573]
[0574] Step-1: Synthesis of N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide (Ex-4): To a solution of INT-1.3 (0.100 g, 0.430 mmol) in DCM (5 mL) at 0°C were added 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxylic acid (0.768 g, 0.473 mmol) and triethylamine (0.3 mL, 1.29 mmol). The mixture was stirred for 5 min and then T was added.3 P (50% ethyl acetate). The reaction was stirred at room temperature for 16 hours. Upon completion (monitored by TLC), the reaction mixture was diluted with water and extracted with ethyl acetate (3x30 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo to give a solid residue. The crude title compound was purified by column chromatography on silica gel (100-200 mesh) eluting with 5-10% MeOH in DCM to give pure Ex-4; LCMS (ESI) m / z=381.8 [M+H]+.
[0575] Ex-4 was separated and purified by chiral HPLC to obtain Ex-5 (17 mg, 7.8%) and Ex-6 (18 mg, 8.5%) as off-white solids (DAICEL CHIRALPAK-IG (250x30 mm, 5μ) / mobile phase: A. n-hexane + 0.1% DEA; B. DCM: MEOH (50:50) isocratic 50% B / flow rate: 30 mL min-1)t R (Peak 1) 8.9, t R (Peak 2) 11.5.
[0576] Example 5: (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide (peak 1)
[0577]
[0578] LCMS (ESI) m / z=381.8[M+H]+; HPLC: 98.9% (t R =7.011min); 1H NMR (400MHz, CDCl 3 ): δ7.75(s,1H),7.61(d,J=8.8Hz,1H),7.51(t,J=7.1Hz,1H),7.47-7.36 (m,1H),7.30-7.28(m,1H),7.25-7.21(m,1H),6.75(s,1H),5.22-5.20(m ,1H),4.80-4.63(m,2H),4.55-4.35(m,2H),4.09-4.05(m,1H),3.92-3.8 8(m,1H),2.81(brt,J=6.4Hz,2H),2.04-1.94(m,2H),1.85-1.79(m,2H).
[0579] Example 6: (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide (peak 2)
[0580]
[0581] LCMS (ESI) m / z=380.8[M+H]+; HPLC: 97.7% (t R =7.023min); 1H NMR (400MHz, CDCl 3 ): δ7.76-7.72(m,1H),7.61(d,J=8.3Hz,1H),7.55-7.48(m,1H),7.45-7.37(m,1H),7.33-7.27(m,1H),7.23-7.20(m,1H ),6.75(s,1H),5.29-5.08(m,1H),4.69-4.65(m,2H),4.52-4.49(m,2H),4.09-4.05(m,1H),3.92-3.88(m,1H),2.82(br t,J=6.1Hz,2H),2.05-1.95(m,2H),1.91-1.75(m,2H).
[0582] Example 7: N-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0583]
[0584] Step-1: Synthesis of (2-chloro-6-fluoro-3-methoxyphenyl)hydrazine hydrochloride (INT-7.1): To a stirred solution of 2-chloro-6-fluoro-3-methoxyaniline (4,00 g, 22.8 mmol) in concentrated HCl (20 mL) was added NaNO at 0 °C. 2 (1.91 g, 27.33 mmol). The reaction was stirred at 0 °C for 1 h. After 1 h, SnCl in concentrated HCl (20 mL) was added dropwise at 0 °C. 2 (12.84 g, 56.95 mmol). The resulting reaction mixture was stirred at room temperature for 16 h. After completion (monitored by TLC), the formed precipitate was filtered off and dried in vacuo to give compound INT-7-1 (6.03 g, crude product) as a white solid. LCMS (ESI) m / z=190.9 [M+H]+.
[0585] Step-2: Synthesis of 1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,7-dihydropyrano[3,4-c]pyrazole-4(5H)-one (INT 7.2): A solution of INT-1.1 (5.00 g, 29.55 mmol) and INT-7.1 (5.60 g, 29.55 mmol) in 4M HCl in dioxane (10 mL, 29.55 mmol) was heated at 100 ° C for 16 h. After completion (monitored by TLC), the reaction mixture was diluted with water and extracted with DCM (3X100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo. The resulting crude material was purified by silica gel column chromatography, eluted with 5-10% MeOH in DCM to give INT-7.2 (2.5 g, 57%) as a white solid. LCMS (ESI) m / z = 296.9 [M+H] +.
[0586] Step-3: Synthesis of (S,Z)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,7-dihydropyrano[3,4-c]pyrazol-4(5H)-ylidene)-2-methylpropane-2-sulfenamide (INT-7.3): To a solution of ketone INT-7.2 (3.5 g, 11.8 mmol) and (S)-2-methylpropane-2-sulfenamide (0.77 g, 34.54 mmol) in THF (10 mL) was added Ti(OiPr) at room temperature. 4 The reaction mixture was heated to 100 ° C for 4 h. After completion (monitored by TLC), the reaction mixture was diluted with water and extracted with DCM (3X100 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The crude material was purified by silica gel column chromatography and eluted with 5-10% MeOH in DCM to give compound 6 (2.3 g, 18%) as a white solid. LCMS (ESI) m / z=400.1[M+H]+.
[0587] Step-4: Synthesis of (S)-N-((S)-1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-2-methylpropane-2-sulfinamide (INT-7.4): To a solution of INT-7.3 (2.3 g, 0.775 mmol) in anhydrous THF (5 mL) at 0°C was added L-tri-sec-butyl lithium borohydride (1M THF solution, 1.55 mL, 1.55 mmol). The reaction mixture was stirred at room temperature for 3 h, and after completion (monitored by TLC), the reaction mixture was washed with saturated NH 4Cl aqueous solution was quenched and extracted with DCM (3 × 100 mL). The combined organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to give INT-7.4 (2.5 g, crude product) as a pale white solid. The material was used directly in the next step without further purification.
[0588] Step-5: Synthesis of (S)-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-4-amine hydrochloride (INT-7.5): A solution of INT-7.4 (0.110 g, 0.284 mmol) in DCM (2 mL) at 0 ° C was added to a solution of 4M HCl in dioxane (5 mL). The reaction mixture was stirred at room temperature for 4 h. After completion (monitored by TLC), the volatiles were removed in vacuo to give an oily residue, which was triturated with ether to give INT-7.5 (0.100 g, crude) as an off-white solid; LCMS (ESI) m / z=283.90[M+H]+.
[0589] Step-6: Synthesis of N-((4R)- and N-((4S)-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-8 and Ex-9): To a solution of INT-7.5 (0.250 g, 0.823 mmol) and 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic acid (0.137 g, 0.823 mmol) in DMF (5 mL) at 0°C was added DIPEA (0.437 mL, 2.469 mmol), and then HATU (0.470 g, 1.234 mmol) was added. The resulting reaction mixture was stirred at room temperature for 16 h. After completion (monitored by TLC), the reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (3X100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo to give the crude material. The crude compound was purified by silica gel column chromatography, eluting with 5-10% MeOH in DCM. The column purified compound (mixture of Ex-8 and Ex-9) was separated and purified by chiral HPLC to give Ex-8 (0.010 g, 3%) and Ex-9 (0.050 g, 15%) as off-white solids.
[0590] Example 8: N-((4R)-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (peak 1)
[0591]
[0592] LCMS (ESI) m / z=446.0[M+H]+; HPLC: 99.1% (t R =5.483min);1H NMR (400MHz, DMSO-d6): δ7.73(d,J=3.5Hz,1H),7.59-7.36(m,4H),5.14-4.98(m,1H),4.64-4.36(m, 2H), 4.00 (t, J = 5.9Hz, 2H), 3.92 (s, 3H), 3.85-3.82 (m, 2H), 3.00 (t, J = 6.5Hz, 2H), 1.90-1.70 (m, 4H).
[0593] Example 9: N-((4S)-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (peak 2)
[0594]
[0595] LCMS (ESI) m / z=446.05[M+H]+; HPLC: 99.8% (t R =5.481min);1H NMR (400MHz, DMSO-d6): δ7.73(d,J=3.5Hz,1H),7.56(d,J=2.7Hz,1H),7.53-7.35(m,3H),5.19-4.95(m,1H),4.6 4-4.29(m,2H),4.00(t,J=5.9Hz,2H),3.92(s,3H),3.85-3.82(m,2H),3.00(t,J=6.5Hz,2H),1.98-1.66(m,4H).
[0596] In addition, the following compounds were prepared similarly to the above method:
[0597] Example 10: N-((4R)-1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Peak 1)
[0598]
[0599] LCMS (ESI) m / z=416.0[M+H]+; HPLC: 99.1% (t R=5.326min);1H NMR (400MHz, DMSO-d6): δ7.74(d,J=3.1Hz,1H),7.69-7.35(m,5H),5.22-4.90(m,1H),4.62-4.34(m,2H) ,4.00(t,J=5.9Hz,2H),3.85-3.83(m,2H),3.00(t,J=6.4Hz,2H),1.95-1.69(m,3H),1.20-1.13(m,1H).
[0600] Example 11: N-((4S)-1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (peak 2)
[0601]
[0602] LCMS (ESI) m / z=416.0[M+H]+; HPLC: 99.8% (t R =5.319min);1H NMR(400MHz,DMSO-d6)δ7.01(s,1H),6.84-6.77(m,1H),6.73-6.64(m,2H),6.60-6.53(m,1H),4.36(brs,1H),3.89- 3.58(m,2H),3.26(t,J=5.9Hz,2H),3.22-3.06(m,2H),2.31(t,J=6.4Hz,2H),1.24-1.01(m,4H),0.55-0.37(m,1H).
[0603] Example 12: (S)-N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Peak 1)
[0604]
[0605] LCMS (ESI) m / z=416.0[M+H]+; HPLC: 99.1% (t R=5.326min);1H NMR (400MHz, DMSO-d6): δ7.74(d,J=3.1Hz,1H),7.69-7.35(m,5H),5.22-4.90(m,1H),4.62-4.34(m,2H) ,4.00(t,J=5.9Hz,2H),3.85-3.83(m,2H),3.00(t,J=6.4Hz,2H),1.95-1.69(m,3H),1.20-1.13(m,1H).
[0606] Example 13: (S)-N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Peak 2)
[0607]
[0608] LCMS (ESI) m / z=416.0[M+H]+; HPLC: 99.8% (t R =5.319min);1H NMR(400MHz,DMSO-d6)δ7.01(s,1H),6.84-6.77(m,1H),6.73-6.64(m,2H),6.60-6.53(m,1H),4.36(brs,1H),3.89- 3.58(m,2H),3.26(t,J=5.9Hz,2H),3.22-3.06(m,2H),2.31(t,J=6.4Hz,2H),1.24-1.01(m,4H),0.55-0.37(m,1H).
[0609] Example 14: (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0610]
[0611] Step-1: Synthesis of hydrazine (INT-14.1): To a stirred solution of 2-chloro-3-methylaniline (5.0 g, 35.5 mmol) in concentrated HCl (25 mL) was added sodium nitrite (8.53 g, 124.0 mmol) at 0°C. The reaction was stirred at 0°C for 1 h. After 1 h, stannous chloride dihydrate (31.9 g, 141.0 mmol) dissolved in hydrochloric acid (25 mL) was added dropwise at 0°C. The reaction was stirred at room temperature and the progress of the reaction was monitored by TLC. After 16 h, the precipitate was filtered, washed with ether and n-pentane, and dried in vacuo to give pure compound INT-1.1 (5.2 g, 94%) as a white solid. LCMS (ESI) m / z=157.06[M+H] + .
[0612] Step-2: Synthesis of 1-(2-chloro-3-methylphenyl)-1,7-dihydropyrano[3,4-c]pyrazol-4(5H)-one (INT14.2): To a stirred solution of INT-14.1 (5.0 g, 31.9 mmol) in acetic acid (15 mL) was added INT-1.1 (3.78 g, 22.3 mmol) at room temperature. The reaction mixture was heated at 100 °C for 16 h. After completion, the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting crude material was purified by silica gel column chromatography using a gradient of 50-60% EtOAc in hexane to give INT-1.3 (2.52 g, 30%) as a yellow solid. LCMS (ESI) m / z=263.12 [M+H] + .
[0613] Step-3: Synthesis of (S,Z)-N-(1-(2-chloro-3-methylphenyl)-1,7-dihydropyrano[3,4-c]pyrazol-4(5H)-ylidene)-2-methylpropane-2-sulfenamide (INT-14.3): 2 Titanium tetraisopropoxide (13.9 mL, 45.7 mmol) and (S)-2-methylpropane-2-sulfenamide (2.77 g, 22.8 mmol) were added to a stirred solution of INT-14.2 (2.0 g, 7.61 mmol) in THF (20 mL) under atmosphere. The reaction was stirred at 80 ° C for 7 h. After completion, the reaction was cooled to room temperature and quenched with brine. The solid precipitate was filtered through a celite bed and washed with EtOAc. The collected filtrate was extracted with EtOAc, dried over sodium sulfate, and concentrated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography using a gradient of 50-60% EtOAc in hexane to give INT-1.4 (1.8 gm, 65%) as a yellow solid. LCMS (ESI) m / z=366.27 [M+H]+ .
[0614] Step-4: Synthesis of (S)-N-((S)-1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-2-methylpropane-2-sulfenamide (INT-14.4): Heat the mixture at -78°C in N 2 To a stirred solution of INT-14.3 (1.8 g, 4.92 mmol) in THF (18 mL) was added L-tri-sec-butylborohydride lithium (1M THF solution) (6.55 g, 34.4 mmol) under atmosphere. The reaction was stirred at room temperature for 4 h. After completion, the reaction mixture was quenched with a saturated saline solution and extracted with EtOAc. The combined organic layers were dried over sodium sulfate, concentrated in vacuo and purified by flash column chromatography using a 60-70% EtOAc in hexane gradient to give INT-1.5 (1.8 g, 99%) as a yellow solid. LCMS (ESI) m / z=368.28 [M+H] + .
[0615] Step-5: Synthesis of (S)-1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-4-amine hydrochloride (INT-14.5): To a stirred solution of INT-14.4 (1.8 g, 4.89 mmol) in DCM (36 mL) at 0°C was added a 4M HCl solution in 1,4-dioxane (21 mL). The reaction mixture was stirred at room temperature for 4 h. After completion of the reaction, the solvent was evaporated to give a crude product. The crude product was dissolved in DCM and reprecipitated with n-pentane to give INT-14.5 (1.25 g, 97%) as an off-white solid. LCMS (ESI) m / z=264.29[M+H] + .
[0616] Step-6: Synthesis of (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-14): To a stirred solution of 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic acid (0.075 g, 0.46 mmol) and INT-14.6 (0.12 g, 0.46 mmol) in anhydrous DMF (1.2 mL) at 0°C was added HATU (0.21 g, 0.55 mmol) and DIPEA (0.10 mL, 0.55 mmol). The reaction was then stirred at room temperature for 16 h. After completion, the reaction mass was poured into ice water and extracted with EtOAc. The collected organic layer was washed with brine, dried over sodium sulfate and evaporated in vacuo to obtain the crude compound. The crude product was purified by silica gel column chromatography using a 2-10% MeOH in DCM solution gradient to obtain an enantiomeric mixture of Ex-14 [74:26] (120 mg) as an off-white solid compound. Ex-14 was further separated and purified by chiral HPLC to obtain pure Ex-14 (70 mg, 36.8%) as a white solid [column name: CHIRALCEL-OJH (4.6*250) mm, 5u; mobile phase: CO 2 / MeOH solution containing 0.1% AH (80:20); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 3.19 min. (74%), t R (Peak-2)3.59min.(26%)]. LCMS(ESI)m / z=412.28[M+H] + ; Chiral HPLC (peak-1): 99.8% (t R =3.18min); UPLC (method E): 96.6% (t R 9.27min); 1H NMR (400MHz, DMSO-d6): δ7.66(s,1H),7.56(s,1H),7.53(dd,J=6.8Hz,J=2.4Hz,1H),7.42-7.39(m,3H),5.07-5.03(m,1H),4.53(dd,J=14.8Hz,J =11.6Hz,2H),3.99(t,J=6.0Hz,2H),3.83(td,J=11.6Hz,J=4.0Hz,2H),2 .99(t,J=6.4Hz,2H),2.43(s,3H),1.86-1.84(m,2H),1.79-1.76(m,2H).
[0617] Example 15: (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide
[0618]
[0619] To a stirred solution of 5-ethyl-1-methyl-1H-imidazole-4-carboxylic acid (0.25 g, 1.59 mmol) and INT-14.5 (0.35 g, 1.33 mmol) in anhydrous DMF (3.5 mL) at 0 ° C. HATU (0.61 g, 1.59 mmol) and DIPEA (0.694 mL, 3.98 mmol) were added. The reaction was then stirred at room temperature for 16 h. After completion, the reaction mass was poured into ice water and extracted with EtOAc. The collected organic layer was washed with brine, dried over sodium sulfate and evaporated in vacuo to obtain a crude compound. The crude product was purified by silica gel column chromatography using a 2-10% MeOH solution gradient in DCM to obtain an enantiomeric mixture of Ex-01 [28:78] (250 mg) as an off-white solid compound. Ex-15 was further separated and purified by chiral HPLC to obtain pure Ex-15 (30 mg, 5.6%) as a white solid [column name: Chiralpak-IG (4.6X250) mm, 5um, mobile phase: IPA / ACN containing 0.1% TEA = 70:30 (v / v), flow rate: 1.0 ml / min, temperature: 25°C, flow mode: isocratic, t R (Peak-1) 4.82min.(28%), t R (Peak-2)5.78min.(78%)]. LCMS(ESI)m / z=400.11[M+H] + ; Chiral HPLC (peak-2): 99.5% (t R 5.76min); UPLC (method B): 99.9% (t R 8.18min); 1H NMR (400MHz, DMSO-d6): δ7.67(s,1H),7.56(s,1H),7.55-7.52(m,1H),7.48(d,J=8.4Hz,1H),7.42-7.37(m,2H),5.07-5.03(m,1H),4.53 (dd, J = 14.8Hz, J = 11.2Hz, 2H), 3.83 (qd, J = 11.6Hz, J = 3.6Hz, 2H), 3.60 (s, 3H), 2.98 (q, J = 7.6Hz, 2H), 3.43 (s, 3H), 1.22 (t, J = 7.6Hz, 3H).
[0620] Example 16: (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide
[0621]
[0622] To a stirred solution of 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxylic acid (0.38 g, 2.28 mmol) and INT-14.5 (0.4 g, 1.52 mmol) in anhydrous DMF (4.0 mL) at 0 ° C. HATU (0.87 g, 2.28 mmol) and DIPEA (0.80 mL, 2.28 mmol) were added. The reaction was then stirred at room temperature for 16 h. After completion, the reaction mass was poured into ice water and extracted with EtOAc. The collected organic layer was washed with brine, dried over sodium sulfate and evaporated in vacuo to give a crude compound. The crude product was purified by silica gel column chromatography using a gradient of 2-10% MeOH in DCM to give an enantiomeric mixture of Ex-16 [12:88] (160 mg) as an off-white solid compound. Ex-16 was further separated and purified by chiral HPLC to obtain pure Ex-16 (80 mg, 12.8%) as a white solid [column name: CHIRALPAK IA (4.6*250) mm, 5u; mobile phase: CO2 / IPA containing 0.2% TEA:ACN (50:50) = (60:40) (v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.93min.(12%), t R (Peak-2)3.69min.(88%)]. LCMS(ESI)m / z=412.09[M+H] + ; Chiral HPLC (peak-2): 99.8% (t R 3.77min); UPLC (method A): 99.5% (t R11.08min); 1H NMR (400MHz, DMSO-d6): δ7.89(d,J=8.4Hz,1H),7.67(s,1H),7.54(dd,J=7.6 Hz,J=1.6Hz,1H),7.42-7.36(m,2H),6.76(s,1H),5.09-5.05(m,1H),4.52(dd ,J=14.8Hz,J=14.4Hz,2H),4.44-4.33(m,2H),3.85(td,J=11.6Hz,J=4.0Hz,2 H), 2.76 (t, J = 6.4Hz, 2H), 2.43 (s, 3H), 1.93-1.87 (m, 2H), 1.76-1.70 (m, 2H).
[0623] Example 17: (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
[0624]
[0625] HATU (0.76 g, 1.99 mmol) and DIPEA (0.70 mL, 3.98 mmol) were added to a stirred solution of 4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid (0.33 g, 1.99 mmol) and INT-14.5 (0.35 g, 1.33 mmol) in anhydrous DMF (3.5 mL) at 0 ° C. The reaction was then stirred at room temperature for 16 h. After completion, the reaction mass was poured into ice water and extracted with EtOAc. The collected organic layer was washed with brine, dried over sodium sulfate and evaporated in vacuo to obtain a crude compound. The crude product was purified by silica gel column chromatography using a gradient of 2-10% MeOH in DCM to obtain an enantiomeric mixture of Ex-17 [24:76] (250 mg) as an off-white solid compound. Ex-17 was further separated and purified by chiral HPLC to obtain pure Ex-17 (66 mg, 12.1%) as a white solid [column name: Chiralpak-IA (4.6*250) mm, 5u; mobile phase: CO2 / IPA containing 0.2% TEA = (60:40) (v / v); flow rate: 3 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.79 min. (24%), t R (Peak-2) 3.67 min. (76%)]. LCMS (ESI) m / z = 412.19 [M+H] +; Chiral HPLC (peak-2): 99.3% (t R 3.90min); UPLC (method B): 97.2% (t R 7.32min); 1H NMR (400MHz, DMSO-d6): δ12.82(br,s,1H),7.67(s,1H),7.59(br,s,1H),7.53 (dd,J=7.6Hz,J=1.6Hz,1H),7.40(t,J=7.6Hz,1H),7.36(dd,J=7.6Hz,J=1.6Hz ,1H),5.10-5.06(m,1H),4.49(dd,J=14.8Hz,J=14.4Hz,2H),3.83(d,J=4.0Hz, 2H), 2.69-2.66 (m, 2H), 2.59 (t, J = 6.0Hz, 2H), 2.43 (s, 3H), 1.74-1.64 (m, 4H).
[0626] Example 18: (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide
[0627]
[0628] To a stirred solution of 4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxylic acid (0.38 g, 2.28 mmol) and INT-14.5 (0.40 g, 1.52 mmol) in anhydrous DMF (4.0 mL) was added HATU (0.87 g, 2.28 mmol) and DIPEA (0.80 mL, 4.55 mmol) at 0 °C. The reaction was then stirred at room temperature for 16 h. After completion, the reaction mass was poured into ice water and extracted with EtOAc, and the collected organic layer was washed with brine, dried over sodium sulfate and evaporated in vacuo to give the crude compound. The crude product was purified by silica gel column chromatography using a gradient of 2-10% MeOH in DCM to give an enantiomeric mixture of Ex-18 [75:25] (350 mg) as an off-white solid compound. Ex-18 was further separated and purified by chiral HPLC to obtain pure Ex-18 (110 mg, 17.5%) as a white solid [column name: CHIRALCEL OJ-H (4.6*250) mm, 5u; mobile phase: CO 2 / MEOH containing 0.2% TEA = (60:40) (v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R(Peak-1) 2.08min. (75%), t R (Peak-2)3.32min.(25%)]. LCMS(ESI)m / z=413.16[M+H] + ; Chiral HPLC (peak-1): 99.9% (t R 1.94min); UPLC (method A): 99.4% (t R 11.41min); 1H NMR (400MHz, DMSO-d6): δ8.75(d,J=7.6Hz,1H),7.67(s,1H),7.53(dd,J=7.6Hz,J=0.8Hz,1 H),7.41(t,J=8.0Hz,1H),7.33(dd,J=7.6Hz,J=1.2Hz,1H),5.14-5.10(m,1H),4.51(dd,J=1 4.8Hz, J=6.0Hz, 2H), 3.88 (dd, J=11.6Hz, J=4.0Hz, 1H), 3.81 (dd, J=11.6Hz, J=4.8Hz, 1H), 2 .72(t,J=6.0Hz,2H),2.63-2.55(m,2H),2.43(s,3H),1.82-1.76(m,2H),1.72-1.66(m,2H).
[0629] Example 19: (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide
[0630]
[0631] To a stirred solution of 4-ethyl-5-methyl-1H-pyrazole-3-carboxylic acid (0.35 g, 2.28 mmol) and INT-14.5 (0.40 g, 1.52 mmol) in anhydrous DMF (4.0 mL) at 0 ° C. HATU (0.87 g, 2.28 mmol) and DIPEA (0.8 mL, 4.58 mmol) were added. The reaction was then stirred at room temperature for 16 h. After completion, the reaction mass was poured into ice water and extracted with EtOAc. The collected organic layer was washed with brine, dried over sodium sulfate and evaporated in vacuo to obtain a crude compound. The crude product was purified by silica gel column chromatography using a gradient of 2-10% MeOH in DCM to obtain an enantiomeric mixture of Ex-19 [18:82] (300 mg) as an off-white solid compound. Ex-19 was further separated and purified by chiral HPLC to obtain pure Ex-19 (75 mg, 12.4%) as a white solid [column name: Chiralpak-IA (4.6*250) mm, 5u; mobile phase: CO2 / IPA containing 0.2% TEA = (60:40) (v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.11min.(18%), t R (Peak-2) 2.56 min. (82%)]. LCMS (ESI) m / z = 400.21 [M+H] + ; Chiral HPLC (peak-2): 99.1% (t R 2.60min); UPLC (method A): 99.5% (t R 7.79min); 1HNMR (400MHz, DMSO-d6): δ12.7(s,1H),7.67(s,1H),7.57(d,J=8.0Hz,1H),7.54(dd,J=7.2Hz,J=1.6Hz,1H),7.42-7.36(m,2H),5.10-5.06 (m,1H),4.52(dd,J=14.8Hz,J=10.0Hz,2H),3.85(dd,J=16.0Hz,J=12.4Hz, 2H), 2.65 (q, J = 7.2Hz, 2H), 2.43 (s, 3H), 2.17 (s, 3H), 1.07 (t, J = 7.6Hz, 3H).
[0632] Example 20: (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide
[0633]
[0634] HATU (0.72 g, 1.14 mmol) and DIPEA (0.41 mL, 2.28 mmol) were added to a stirred solution of 4,5-dimethylpicolinic acid (0.17 g, 1.14 mmol) and INT-14.5 (0.2 g, 0.76 mmol) in anhydrous DMF (2.0 mL) at 0 ° C. The reaction was then stirred at room temperature for 16 h. After completion, the reaction mass was poured into ice water and extracted with EtOAc. The collected organic layer was washed with brine, dried over sodium sulfate and evaporated in vacuo to obtain a crude compound. The crude product was purified by silica gel column chromatography using a gradient of 2-10% MeOH in DCM to obtain an enantiomeric mixture of Ex-20 [78:22] (200 mg) as an off-white solid compound. Ex-20 was further separated and purified by chiral HPLC to obtain pure Ex-20 (70 mg, 23.2%) as a white solid [column name: Lux-Amylose-1 (4.6*250) mm, 5u; mobile phase: CO 2 / IPA containing 0.2% TEA = (60:40) (v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.91min. (78%), t R (Peak-2)3.60min.(22%)]. LCMS(ESI)m / z=397.04[M+H] + ; Chiral HPLC (peak-1): 99.3% (t R 2.90min); UPLC (method A): 99.9% (t R 6.67min); 1H NMR (400MHz, DMSO-d6): δ8.41(d,J=8.4Hz,1H),8.34(s,1H),7.90(s,1H),7 .70(s,1H),7.53(dd,J=6.8Hz,J=2.8Hz,1H),7.43-7.37(m,2H),5.14-5.11 (m,1H),4.55(dd,J=14.8Hz,J=12.4Hz,2H),3.93(dd,J=11.6Hz,J=4.0Hz,1 H), 3.85 (dd, J=7.6Hz, J=4.0Hz, 1H), 2.43 (s, 3H), 2.35 (s, 3H), 2.29 (s, 3H).
[0635] Example 21: (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0636]
[0637] Step-1: Synthesis of (2-chloro-3-methoxyphenyl)hydrazine hydrochloride (INT-21.1): According to the experimental procedure of INT-14.1, the reaction was carried out on a 5.0 g scale to obtain INT-21.1 (4.8 g, 87%) as a white solid. LCMS (ESI) m / z = 173.01 [M+H] + .
[0638] Step-2: Synthesis of 1-(2-chloro-3-methoxyphenyl)-1,7-dihydropyrano[3,4-c]pyrazol-4(5H)-one (INT21.2): According to the experimental procedure of INT-14.2, the reaction was carried out on a 2.5 g scale to obtain INT-21.2 (0.75 g, 18%) as a yellow solid. LCMS (ESI) m / z=279.23 [M+H] + .
[0639] Step-3: Synthesis of (S,E)-N-(1-(2-chloro-3-methoxyphenyl)-1,7-dihydropyrano[3,4-c]pyrazole-4(5H)-ylidene)-2-methylpropane-2-sulfenamide (INT-21.3): According to the experimental procedure of INT-14.3, the reaction was carried out on a 2.0 g scale to obtain INT-213 (1.70 gm, 62%) as a yellow solid. LCMS (ESI) m / z=382.29 [M+H] + .
[0640] Step-4: Synthesis of (S)-N-((S)-1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-2-methylpropane-2-sulfenamide (INT-21.4): According to the experimental procedure of INT-14.4, the reaction was carried out on a scale of 1.7 g to obtain INT-21.4 (1.4 g, 82%) as a yellow solid. LCMS (ESI) m / z=384.27 [M+H] + .
[0641] Step-5: Synthesis of (S)-1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-4-amine hydrochloride (INT-21.5): According to the experimental procedure of INT-14.5, the reaction was carried out on a 2.0 g scale to obtain INT-2.5 (1.4 g, 96%) as an off-white solid. LCMS (ESI) m / z=280.09 [M+H] + .
[0642] Step-6: Synthesis of (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-21): According to the experimental procedure of Ex-14, the reaction was carried out with 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic acid on a scale of 0.15 g to obtain an enantiomeric mixture of Ex-21 [82:18] (120 mg) as an off-white solid compound. Ex-21 was further separated and purified by chiral HPLC to obtain pure Ex-21 (25 mg, 11%) as a white solid [column name: Lux_Amylose_1 (4.6*250) mm, 5u; mobile phase: CO 2 / IPA (60:40) containing 0.1% AH; flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 5.64min.(82%), t R (Peak-2)7.63min.(18%)]. LCMS(ESI)m / z=428.23[M+H] + ; Chiral HPLC (peak-1): 99.9% (t R 5.64min); UPLC (method A): 99.4% (t R 9.50min); 1H NMR (400MHz, DMSO-d6): δ7.66(s,1H),7.56(s,1H),7.46(t,J=8.4Hz,1H),7.41 (d,J=8.4Hz,1H),7.32(d,J=8.0Hz,1H),7.12(d,J=8.0Hz,1H),5.07-5.03(m,1 H),4.53(dd,J=14.8Hz,J=11.2Hz,2H),3.99(t,J=5.6Hz,2H),3.93(s,3H),3.8 3(t,J=3.2Hz,2H), 2.99(t,J=6.4Hz,2H), 1.86-1.84(m,2H), 1.78-1.77(m,2H).
[0643] Example 22: (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide
[0644]
[0645] According to the experimental procedure of Ex-15, the reaction was carried out on a scale of 0.25 g to obtain an enantiomeric mixture of Ex-22 [83:17] (140 mg) as an off-white solid compound. Ex-22 was further separated and purified by chiral HPLC to obtain pure Ex-22 (60 mg, 16.1%) as a white solid [column name: Lux Amylose-1 (4.6*250) mm, 5u; mobile phase: CO 2 / IPA containing 0.2% AH=(60:40)(v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 3.39min.(83%), t R (Peak-2) 4.19 min. (17%)]. LCMS (ESI) m / z = 416.22 [M+H] + ; Chiral HPLC (peak-1): 99.8% (t R 3.38min); UPLC (method A): 99.9% (t R 13.67min); 1H NMR (400MHz, DMSO-d6): δ7.67(s,1H),7.56(s,1H),7.50-7.48(m,1H),7.45(d,J=8.0Hz,1H),7.32(d,J=8.0Hz,1H),7.12(dd,J=7.6Hz,J=0.8Hz,1H ),5.07-5.03(m,1H),4.55(dd,J=14.8Hz,J=10.4Hz,2H),3.92(s,3H),3.8 7-3.79(m,2H),3.60(s,3H),2.97(q,J=7.6Hz,2H),1.12(t,J=7.6Hz,3H).
[0646] Example 23: (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide
[0647]
[0648] According to the experimental procedure of Ex-16, the reaction was carried out on a scale of 0.20 g to obtain an enantiomeric mixture of Ex-23 [77:23] (135 mg) as an off-white solid compound. Ex-23 was further separated and purified by chiral HPLC to obtain pure Ex-23 (27 mg, 8.83%) as a white solid [column name: Chiralcel OJ-H (4.6*250) mm, 5u; mobile phase: CO 2 / IPA containing 0.2% TEA = (80:20) (v / v); flow rate: 3 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak 1) 4.07 min. (77%), t R (Peak 2)5.02min.(23%)]. LCMS(ESI)m / z=428.38[M+H] + ; Chiral HPLC (peak-1): 99.5% (t R 4.10min); UPLC (method A): 95.3% (t R 10.78min); 1HNMR (400MHz, DMSO-d6): δ7.90 (d, J=8.0Hz, 1H), 7.67 (s, 1H), 7.46 (t, J= 8.0Hz,1H),7.32(dd,J=8.4Hz,J=0.8Hz,1H),7.11(dd,J=6.8Hz,J=1.2Hz,1H),6.76(s ,1H),5.08-5.04(m,1H),4.53(dd,J=14.8Hz,J=10.4Hz,2H),4.48-4.32(m,2H),3.93( s,3H),3.89-3.81(m,2H),2.76(t,J=6.4Hz,2H),2.07-1.87(m,2H),1.76-1.70(m,2H).
[0649] Example 24: (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
[0650]
[0651] According to the experimental procedure of Ex-17, the reaction was carried out on a scale of 0.30 g to obtain an enantiomeric mixture of Ex-24 [74:26] (230 mg) as an off-white solid compound. Ex-24 was further separated and purified by chiral HPLC to obtain pure Ex-24 (113 mg, 24.6%) as a white solid [column name: Chiralcel OJH (4.6*250) mm, 5u; mobile phase: CO 2 / MeOH containing 0.2% TEA = (70:30) (v / v); flow rate: 3 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.25min. (74%), t R (Peak-2)2.93min.(26%)]. LCMS(ESI)m / z=428.23[M+H] + ; Chiral HPLC (peak-1): 99.3% (t R 2.26min); UPLC (method A): 99.0% (t R 11.08min); 1HNMR (400MHz, DMSO-d6): δ12.77(s,1H),7.67(s,1H),7.57(br,s,1H ),7.46(t,J=8.4Hz,1H),7.32(dd,J=8.8Hz,J=1.2Hz,1H),7.11(dd,J=8.0Hz,J=1 .2Hz,1H),5.10-5.06(m,1H),4.52(dd,J=14.8Hz,J=10.0Hz,2H),3.92(s,3H),3. 83(d,J=4.0Hz,2H),2.69-2.66(m,2H),2.58(t,J=5.6Hz,2H),1.72-1.66(m,4H).
[0652] Example 25: (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide
[0653]
[0654] According to the experimental procedure of Ex-18, the reaction was carried out on a scale of 0.30 g to obtain an enantiomeric mixture of Ex-25 [25:75] (300 mg) as an off-white solid compound. Ex-25 was further separated and purified by chiral HPLC to obtain pure Ex-25 (138 mg, 30.0%) as a white solid [column name: Chiralcel OJH (4.6*250) mm, 5u; mobile phase: CO 2 / MeOH containing 0.2% TEA = (70:30) (v / v); flow rate: 3 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 3.18min. (25%), t R (Peak-2) 4.16 min. (75%)]. LCMS (ESI) m / z = 429.17 [M+H] + ; Chiral HPLC (peak-2): 99.4% (t R 4.18min); UPLC (method D): 99.9% (t R 7.51min); 1HNMR (400MHz, DMSO-d6): δ8.77(d,J=7.6Hz,1H),7.67(s,1H),7.47(t,J=8.8Hz,1H ),7.32(dd,J=8.8Hz,J=1.2Hz,1H),7.07(dd,J=8.0Hz,J=1.2Hz,1H),5.13-5.09(m,1H),4.52(d d,J=14.8Hz,J=20.8Hz,2H),3.93(s,3H),3.90(dd,J=11.6Hz,J=4.4Hz,1H),3.80(dd,J=11.6Hz ,J=4.8Hz,1H),2.72(t,J=6.0Hz,2H),2.61-2.55(m,2H),1.83-1.77(m,2H),1.72-1.68(m,2H).
[0655] Example 26: (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide
[0656]
[0657] According to the experimental procedure of Ex-19, the reaction was carried out on a scale of 0.40 g to obtain an enantiomeric mixture of Ex-26 [81:19] (150 mg) as an off-white solid compound. Ex-26 was further separated and purified by chiral HPLC to obtain pure Ex-26 (60 mg, 10.1%) as a white solid [column name: Chiralcel OJH (4.6*250) mm, 5u; mobile phase: CO 2 / IPA containing 0.2% TEA = (70:30) (v / v); flow rate: 3 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.12min.(81%), t R (Peak-2)3.07min.(19%)]. LCMS(ESI)m / z=416.19[M+H] + ; Chiral HPLC (peak-1): 99.5% (t R 2.12min); UPLC (method A): 99.9% (t R 11.20min); 1H NMR (400MHz, DMSO-d6): δ12.76(s,1H),7.67(s,1H),7.58(d,J=8.0Hz,1H),7. 46(t,J=8.0Hz,1H),7.32(dd,J=8.4Hz,J=0.8Hz,1H),7.12(dd,J=8.0Hz,J=1. 6Hz,1H),5.10-5.06(m,1H),4.53(dd,J=14.8Hz,J=24.4Hz,2H),3.93(s,3H), 3.85(d,J=4.0Hz,2H),2.68-2.62(m,2H),2.18(s,3H),1.07(t,J=7.2Hz,3H).
[0658] Example 27: (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide
[0659]
[0660] According to the experimental procedure of Ex-20, the reaction was carried out on a scale of 0.20 g to obtain an enantiomeric mixture of Ex-27 [79:21] (210 mg) as an off-white solid compound. Ex-27 was further separated and purified by chiral HPLC to obtain pure Ex-27 (90 mg, 30.5%) as a white solid [column name: Lux-Amylose-1 (4.6*250) mm, 5u; mobile phase: CO 2 / IPA containing 0.2% TEA = (60:40) (v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 3.35min. (79%), t R (Peak-2) 4.30 min. (21%)]. LCMS (ESI) m / z = 413.23 [M+H] + ; Chiral HPLC (peak-1): 99.1% (t R 3.36min); UPLC (method A): 99.8% (t R 11.30min); 1HNMR (400MHz, DMSO-d6): δ8.41(d,J=8.0Hz,1H),8.34(s,1H),7.90(s,1H),7.70(s,1H),7.47(t,J=8.4Hz,1H),7.33(dd,J=8.4Hz,J=1.2Hz ,1H),7.12(dd,J=8.0Hz,J=1.6Hz,1H),5.14-5.10(m,1H),4.55(dd,J=14.8H z,J=12.0Hz,2H),3.95(s,3H),3.93-3.83(m,2H),2.34(s,3H),2.28(s,3H).
[0661] Example 28: (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide
[0662]
[0663] According to the experimental procedure of Ex-15, the reaction was carried out on a scale of 0.20 g to obtain an enantiomeric mixture of Ex-28 [22:78] (150 mg) as an off-white solid compound. Ex-28 was further separated and purified by chiral HPLC to obtain pure Ex-28 (50 mg, 17.1%) as a white solid [column name: Chiralpak IG (4.6*250) mm, 5u; mobile phase: CO 2 / ACN / IPA containing 0.2% TEA=(60:40) (v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 3.85min. (22%), t R (Peak-2)5.69min.(78%)]. LCMS(ESI)m / z=434.33[M+H] + ; Chiral HPLC (peak-2): 96.4% (t R 5.58min); UPLC (method A): 99.5% (t R 10.51min); 1H NMR(DMSO-d6)δ7.74(d,J=3.6Hz,1H),7.56(d,J=2.4Hz,1H),7.54-7.47(m,2H),7.42-7.38(m,1H),5.08-5.04(m,1H),4.55(dd,J=14. 8Hz, J=2.8Hz, 1H), 4.45 (d, J=14.8Hz, 1H), 3.92 (s, 3H), 3.89-3.80 (m, 2H), 3.60 (s, 3H), 2.97 (q, J=7.6Hz, 2H), 1.22 (t, J=7.6Hz, 3H).
[0664] Example 29: (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide
[0665]
[0666] According to the experimental procedure of Ex-16, the reaction was carried out on a scale of 0.20 g to obtain an enantiomeric mixture of Ex-29 [22:78] (150 mg) as an off-white solid compound. Ex-29 was further separated and purified by chiral HPLC to obtain pure Ex-29 (50 mg, 16.7%) as a white solid [column name: CHIRALPAK-IA (4.6*250) mm, 5u; mobile phase: CO 2 / 100% MeOH (50:50); flow rate: 4.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.01min.(22%), t R (Peak-2)2.57min.(78%)]. LCMS(ESI)m / z=446.26[M+H] + ; Chiral HPLC (peak-2): 99.8% (t R 2.62min); UPLC (method C): 97.8% (t R 6.92min); 1H NMR (400MHz, DMSO-d6): δ7.95 (dd, J=8.4Hz, J=8.4Hz, 1H), 7.74 (d, J=2.8Hz, 1H), 7.50 ( td,J=9.2Hz,J=2.8,1H),7.40(dd,J=4.8Hz,J=4.8Hz,1H),6.76(d,J=1.6Hz,1H),5.09-5 .05(m,1H),4.54(d,J=14.8Hz,1H),4.46(d,J=19.6Hz,1H),4.42-4.34(m,2H),3.92(s, 3H), 3.86 (d, J = 4.4Hz, 2H), 2.76 (t, J = 6.4Hz, 2H), 1.93-1.87 (m, 2H), 1.76-1.70 (m, 2H).
[0667] Example 30: (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
[0668]
[0669] According to the experimental procedure of Ex-17, the reaction was carried out on a scale of 0.15 g to obtain an enantiomeric mixture of Ex-30 [22:78] (170 mg) as an off-white solid compound. Ex-30 was further separated and purified by chiral HPLC to obtain pure Ex-30 (60 mg, 26.7%) as a white solid [column name: CHIRALPAK-IG (4.6*250) mm, 5u; mobile phase: CO 2 / MeOH containing 0.2% TEA (50:50); flow rate: 3 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 4.39 min. (22%), t R (Peak-2) 6.38 min. (78%)]. LCMS (ESI) m / z = 446.19 [M+H] + ; Chiral HPLC (peak-2): 99.8% (t R 6.38min); UPLC (method B): 98.4% (t R 10.44min); 1H NMR (400MHz, DMSO-d6): δ12.77(s,1H),7.72(d,J=2.8Hz,1H),7.60(dd,J=8.0Hz,J=8.4Hz,1H),7.50(t,J=8.8Hz,1H),7.42-7.38(m ,1H),5.10-5.08(m,1H),4.49(dd,J=14.8Hz,J=18.4Hz,2H),3.92(s,3H),3.84(s,2H),2.60(s,2H),2.59(s,2H),1.72-1.66(m,4H).
[0670] Example 31: (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide
[0671]
[0672] According to the experimental procedure of Ex-18, the reaction was carried out on a scale of 0.15 g to obtain an enantiomeric mixture of Ex-31 [75:25] (190 mg) as an off-white solid compound. Ex-31 was further separated and purified by chiral HPLC to obtain pure Ex-31 (57 mg, 25.3%) as a white solid [column name: CHIRALCEL-OJH (4.6*250) mm, 5u; mobile phase: CO2 / MeOH containing 0.1% AH (60:40); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 1.95min.(75%), t R (Peak-2) 2.39 min. (25%)]. LCMS (ESI) m / z = 447.17 [M+H] + ; Chiral HPLC (peak-1): 99.9% (t R 1.95min); UPLC (method C): 96.7% (t R 12.72min); 1HNMR(DMSO-d6)δ8.89-8.84(m,1H),7.74(s,1H),7.50(t,J=9.2Hz,1H),7.42-7.38(m,1H),5.14-5.10(m,1H),4.49(dd,J=14.8Hz ,J=12.8Hz,2H),3.92(s,3H),3.89-3.86(m,1H),3.82-3.78(m,1H),2. 72(t,J=5.6Hz,2H),2.57(s,2H),1.83-1.77(m,2H),1.72-1.66(m,2H).
[0673] Example 32: (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide
[0674]
[0675] According to the experimental procedure of Ex-19, the reaction was carried out on a scale of 0.15 g to obtain an enantiomeric mixture of Ex-32 [75:15] (220 mg) as an off-white solid compound. Ex-32 was further separated and purified by chiral HPLC to obtain pure Ex-32 (75 mg, 34.3%) as a white solid [column name: CHIRALCEL-OJH (4.6*250) mm, 5u; mobile phase: CO 2 / MeOH containing 0.2% isopropylamine (80:20); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.17 min. (75%), t R (Peak-2) 2.72 min. (15%)]. LCMS (ESI) m / z = 434.24 [M+H] + ; Chiral HPLC (peak-1): 99.9% (t R 2.18min); UPLC (method C): 99.3% (t R 9.29min); 1H NMR (400MHz, DMSO-d6): δ12.7(s,1H),7.74(d,J=2.4Hz,1H),7.65(width,s,1H),7.50(t,J=9.2Hz,1H),7.42-7.38(m,1H),5.09-5.08(m ,1H),4.50(dd,J=14.8Hz,J=19.2Hz,2H),3.92(s,3H),3.85(d,J=3.6Hz,2H),2.66-2.65(m,2H),2.17(s,3H),1.08(t,J=8.8Hz,3H).
[0676] Example 33: (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide
[0677]
[0678] According to the experimental procedure of Ex-20, the reaction was carried out on a scale of 0.50 g to obtain an enantiomeric mixture of Ex-33 [18:82] (210 mg) as an off-white solid compound. Ex-33 was further separated and purified by chiral HPLC to obtain pure Ex-33 (44 mg, 6.08%) as a white solid [column name: CHIRALPAK-IG (4.6*250) mm, 5u; mobile phase: CO 2 / MeOH containing 0.2% AH (50:50); flow rate: 4.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 4.51min. (18%), t R (Peak-2) 5.83 min. (82%)]. LCMS (ESI) m / z = 431.24 [M+H] + ; Chiral HPLC (peak-2): 99.8% (tR 5.83min); UPLC (method C): 98.7% (t R 8.61min); 1H NMR (400MHz, DMSO-d6): δ8.44(dd, J=8.4Hz, J=8.8Hz, 1H), 8.35(s, 1H), 7.90( s,1H),7.76(d,J=2.0Hz,1H),7.50(td,J=2.8Hz,J=9.2Hz,1H),7.40(dd,J=4. 8Hz, J=4.8Hz, 1H), 5.14-5.12 (m, 1H), 4.60 (dd, J=15.2Hz, J=12.8Hz, 1H), 4.4 8(d,J=14.8Hz,1H),3.98(s,3H),3.89-3.85(m,2H),2.35(s,3H),2.29(s,3H).
[0679] Example 34: (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0680]
[0681] Step-1: Synthesis of (2-chloro-6-methylphenyl)hydrazine hydrochloride (INT-34.1): According to the experimental procedure of INT-14.1, the reaction was carried out on a 2.0 g scale to obtain INT-4.1 (1.9 g, 85%) as a white solid. LCMS (ESI) m / z = 157.06 [M+H] + .
[0682] Step-2: Synthesis of 1-(2-chloro-6-methylphenyl)-1,7-dihydropyrano[3,4-c]pyrazol-4(5H)-one (INT34.2): According to the experimental procedure of INT-14.2, the reaction was carried out on a 2.0 g scale to obtain INT-4.2 (1.0 g, 29%) as a yellow solid. LCMS (ESI) m / z=263.06 [M+H] + .
[0683] Step-3: Synthesis of (S,Z)-N-(1-(2-chloro-6-methylphenyl)-1,7-dihydropyrano[3,4-c]pyrazole-4(5H)-ylidene)-2-methylpropane-2-sulfenamide (INT-34.3): According to the experimental procedure of INT-14.3, the reaction was carried out on a 2.0 g scale to obtain INT-4.3 (1.7 gm, 61%) as a yellow solid. LCMS (ESI) m / z=365.09 [M+H]+ .
[0684] Step-4: Synthesis of (S)-N-((S)-1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-2-methylpropane-2-sulfenamide (INT-34.4): According to the experimental procedure of INT-14.4, the reaction was carried out on a scale of 1.7 g to obtain INT-34.4 (1.6 g, 93%) as a yellow solid. LCMS (ESI) m / z=368.14 [M+H] + .
[0685] Step-5: Synthesis of (S)-1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-4-amine hydrochloride (INT-34.5): According to the experimental procedure of INT-14.5, the reaction was carried out on a scale of 1.6 g to obtain INT-34.5 (1.30 g, 99%) as an off-white solid. LCMS (ESI) m / z=265.14 [M+H] + .
[0686] Step-6: Synthesis of ((S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-34): Following the experimental procedure of Ex-14, the reaction was carried out with 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic acid on a scale of 0.10 g to give a mixture of enantiomers of Ex-34 [30 :69] (110 mg), which is an off-white solid compound. Ex-34 was further separated and purified by chiral HPLC to obtain pure Ex-34 (20 mg, 12.8%), which is a white solid [column name: Chiralpak-IG (4.6X250) mm, 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100% (v / v); flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic, t R (Peak-1) 21.6min.(30%), t R (Peak-2) 25.7 min. (69%)]. Ex-34 was isolated and characterized as a mixture of atropisomers. LCMS (ESI) m / z = 412.23 [M+H] + ; Chiral HPLC (peak-1): 80.7% (t R 22.12min), (peak-2): 19.2% (t R 28.27min); UPLC (method D): (peak-1) 18.4% (tR 13.08min), (peak-2) 79.3% (t R 13.42min); two rotamer peaks were observed in 1H NMR. 1H NMR (400MHz, DMSO-d6): δ7.89 (br, s, 1H), 7.68 (d, J = 4.0 Hz, 1H), 7.56 (s, 1H), 7.56-7.45 (m, 2H), 7.40 (d, J = 6.4 Hz, 1H), 5.08-5.05 (m, 1H), 4.49-4.37 (m, 2H), 4.00 (t, J = 5.6 Hz, 2H), 3.84-3.77 (m, 2H), 2.99 (t, J = 6.4 Hz, 2H), 2.02 (s, 2.4H), 1.98 (s, 0.6H), 1.79-1.78 (m, 2H), 1.77-1.75 (m, 2H).
[0687] Example 35: (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide
[0688]
[0689] According to the experimental procedure of Ex-15, the reaction was carried out on a scale of 0.40 g to obtain an isomeric mixture of Ex-35 [6:9:8:37:36] (400 mg) as an off-white solid compound. Ex-35 was further separated and purified by chiral HPLC to obtain pure Ex-35 (135 mg, 22.2%) as a white solid [column name: Chiralpak-IG (4.6X250) mm, 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100%; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic, t R (Peak-1) 8.22min.(6%), t R (Peak-2) 9.48min.(9%), t R (Peak-3) 11.01min.(8%), t R (Peak-4) 13.36min.(37%), t R (Peak-5) 16.8 min. (36%)]. Ex-35 was isolated and characterized as a mixture of atropisomers. LCMS (ESI) m / z = 400.18 [M+H] + ; Chiral HPLC (peak-4): 52.1% (t R 13.38min), (peak-5): 47.5% (t R16.8min); UPLC (method C): (peak-1) 46.9% (t R 9.44min), (peak-2) 52.3% (t R 9.59min); two rotamer peaks were observed in 1H NMR. 1H NMR (400MHz, DMSO-d6): δ7.70 (d, J = 4.0 Hz, 1H), 7.56 (d, J = 1.6 Hz, 1H), 7.55-7.45 (m, 3H), 7.41 (d, J = 7.2 Hz, 1H), 5.08-5.05 (m, 1H), 4.55-4.37 (m, 2H), 3.86-3.78 (m, 2H), 3.60 (s, 3H), 2.98 (q, J = 7.6 Hz, 2H), 2.01 (s, 1.5H), 1.98 (s, 1.5H), 1.12 (t, J = 7.2 Hz, 3H).
[0690] Example 36: (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide
[0691]
[0692] According to the experimental procedure of Ex-16, the reaction was carried out on a scale of 0.40 g to obtain an enantiomeric mixture of Ex-36 [18:82] (350 mg) as an off-white solid compound. Ex-36 was further separated and purified by chiral HPLC to obtain pure Ex-36 (55 mg, 8.8%) as a white solid [column name: Chiralpak-IA (4.6X250) mm, 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100%; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic, t R (Peak-1&2) 6.10min.(18%), t R (Peak-3&4) 7.50 min. (82%)]. Ex-36 was isolated and characterized as a mixture of atropisomers. LCMS (ESI) m / z = 412.19 [M+H] + ; Chiral HPLC (peak-3): 52.0% (t R 7.60min), (peak-4): 47.0% (t R 7.64min); UPLC (method G): (peak-1) 47.1% (t R 9.34min), (peak-2) 52.8% (t R9.49min); two rotamer peaks were observed in 1H NMR. 1H NMR (400MHz, DMSO-d6): 8.03 (d, J = 8.4 Hz, 0.5H), 7.89 (d, J = 8.4 Hz, 0.5H), 7.69 (d, J = 5.2 Hz, 1H), 7.53-7.50 (m, 1H), 7.47 (dd, J = 8.8 Hz, J = 1.2 Hz, 1H), 7.40 (d, J = 7.2 Hz, 1H),6.76(s,1H),5.09-5.07(m,1H),4.49-4.35(m,4H),3.86-3.83(m,2H),2.76(t, J=6.4Hz,2H),2.02(s,1.5H),1.98(s,1.5H),1.93-1.87(m,2H),1.76-1.70(m,2H).
[0693] Example 37: (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
[0694]
[0695] According to the experimental procedure of Ex-17, the reaction was carried out on a scale of 0.40 g to obtain an enantiomeric mixture of Ex-37 [6:9:6:35:41] (250 mg) as an off-white solid compound. Ex-37 was further separated and purified by chiral HPLC to obtain pure Ex-37 (40 mg, 6.4%) as a white solid [column name: Chiralpak IG (4.6*250) mm, 5u; mobile phase: CO 2 / IPA containing 0.2% TEA = (60:40) (v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 4.34min.(6%), t R (Peak-2) 5.27min.(9%), t R (Peak-3) 5.88min.(6%), t R (Peak-4) 6.54 min. (35%), t R (Peak-5) 7.46 min. (41%)]. Ex-37 was isolated and characterized as a mixture of atropisomers. LCMS (ESI) m / z = 412.19 [M+H] + ; Chiral HPLC (peak-4): 54.0% (t R6.65min), (peak-5): 46.0% (t R 7.61min); UPLC (method G): (peak-1) 53.6% (t R 11.77min), (peak-2) 44.6% (t R 11.88min); two rotamer peaks were observed in 1H NMR. 1H NMR (400MHz, DMSO-d6): δ12.76 (s, 1H), 7.68 (d, J = 4.8 Hz, 1H), 7.66-7.49 (m, 2H), 7.46 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 7.2 Hz, 1H), 5.10-5.08 (m, 1H), 4.48-4.37 (m, 2H), 3.87-3.81 (m, 2H), 2.69 (s, 2H), 2.59 (t, J = 5.6 Hz, 2H), 2.02 (s, 1.5H), 1.98 (s, 1.5H), 1.71-1.68 (m, 4H).
[0696] Example 38: (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide
[0697]
[0698] According to the experimental procedure of Ex-18, the reaction was carried out on a scale of 0.40 g to obtain an enantiomeric mixture of Ex-38 [12:10:33:45] (350 mg) as an off-white solid compound. Ex-38 was further separated and purified by chiral HPLC to obtain pure Ex-38 (100 mg, 16.0%) as a white solid [column name: Chiralpak IG (4.6 x 250 mm), 5μ; mobile phase: CO 2 / IPA containing 0.2% AH=(65:35) (v / v); flow rate: 3.0 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi; t R (Peak-1) 4.83min.(12%), t R (Peak-2) 6.46min.(10%), t R (Peak-3) 8.08min.(33%), t R (Peak-4) 9.90 min. (45%)]. Ex-38 was isolated and characterized as a mixture of atropisomers. LCMS (ESI) m / z = 413.18 [M+H] +; Chiral HPLC (peak-3): 44.0% (t R 8.34min), (peak-4): 55.0% (t R 10.36min); UPLC (method G): (peak-1) 42.9% (t R 11.20min), (peak-2) 56.6% (t R 11.34min); two rotamer peaks were observed in 1H NMR. 1H NMR (400MHz, DMSO-d6): δ8.86 (d, J = 19.2 Hz, 0.5H), 8.79 (d, J = 7.6 Hz, 0.5H), 7.69 (s, 1H), 7.53-7.37 (m, 3H), 5.15-5.11 (m, 1H), 4.42 (td, J = 14.8 Hz, J = 6.8 Hz, 2H), 3.97-3.77 (m, 2H), 2.72 (t, J = 6.0 Hz, 2H), 2.57 (s, 2H), 2.02 (s, 1.5H), 1.97 (s, 1.5H), 1.81-1.79 (m, 2H), 1.71-1.68 (m, 2H).
[0699] Example 39: (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide
[0700]
[0701] According to the experimental procedure of Ex-19, the reaction was carried out on a scale of 0.40 g to obtain an enantiomeric mixture of Ex-25 [7:7:49:46] (350 mg) as an off-white solid compound. Ex-25 was further separated and purified by chiral HPLC to obtain pure Ex-25 (45 mg, 7.4%) as a white solid [column name: Chiralpak-IG (4.6X250) mm, 5um; mobile phase: MeOH / CAN containing 0.1% ammonium hydroxide = 50:50; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic, t R (Peak-1) 3.05min.(7%), t R (Peak-2) 3.3min.(7%), t R (Peak-3) 4.38min.(49%), t R (Peak-4) 5.02 min. (46%)]. Ex-39 was isolated and characterized as a mixture of atropisomers. LCMS (ESI) m / z = 400.18 [M+H] +; Chiral HPLC (peak-3): 51.0% (t R 4.38min), (peak-4): 45.0% (t R 5.02min); UPLC (method L): (peak-1) 54.8% (t R 12.39min), (peak-2) 44.7% (t R 1H NMR (400MHz, DMSO-d6): δ12.7 (br, s, 1H), 7.70 (d, J = 4.0 Hz, 1H), 7.60 (br, s, 1H), 7.53-7.51 (m, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 7.2 Hz, 1H), 5.10-5.08 (m, 1H), 4.48-4.37 (m, 2H), 3.87-3.82 (m, 2H), 2.65 (q, J = 6.8 Hz, 2H), 2.18 (s, 3H), 2.02 (s, 1.5H), 1.97 (s, 1.5H), 1.07 (t, J = 7.6 Hz, 3H).
[0702] Example 40: (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide
[0703]
[0704] According to the experimental procedure of Ex-20, the reaction was carried out on a scale of 0.20 g to obtain an enantiomeric mixture of Ex-40 [8:12:39:37] (110 mg) as an off-white solid compound. Ex-40 was further separated and purified by chiral HPLC to obtain pure Ex-40 (45 mg, 14.9%) as a white solid [column name: Chiralcel-OX-H (4.6X250) mm, 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100%; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic, t R (Peak-1) 7.13 min. (8%), t R (Peak-2) 7.30min.(12%), t R (Peak-3) 8.03min.(39%), t R (Peak-4) 8.27 min. (37%)]. Ex-40 was isolated and characterized as a mixture of atropisomers. LCMS (ESI) m / z = 397.17 [M+H] +; Chiral HPLC (peak-3): 48.0% (t R 8.04min), (peak-4): 51.5% (t R 8.28min); UPLC (method C): 99.8% (t R 11.19 min); two rotamer peaks were observed in 1H NMR. 1H NMR (400MHz, DMSO-d6): δ8.50(d,J=8.4Hz,0.5H),8.40(d,J=8.0Hz,0.5H),8 .35(s,1H),7.90(s,1H),7.72(d,J=5.2Hz,1H),7.53-7.51(m,1H),7.47(dd,J =7.6Hz,J=0.4Hz,1H),7.41(d,J=7.2Hz,1H),5.16-5.13(m,1H),4.46(m,2H) ,3.94-3.83(m,2H),2.35(s,3H),2.29(s,3H),2.03(s,1.5H),1.98(s,1.5H).
[0705] Example 41: (S)-5-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-1-methyl-1H-imidazole-4-carboxamide
[0706]
[0707] Step-1: Synthesis of (S,Z)-N-(1-(2-fluorophenyl)-1,7-dihydropyrano[3,4-c]pyrazole-4(5H)-ylidene)-2-methylpropane-2-sulfenamide (INT-41.1): According to the experimental procedure of INT-14.3, the reaction was carried out on a scale of 3.0 g to obtain INT-41.1 (1.1 g, 25%) as a yellow solid. LCMS (ESI) m / z=336.08 [M+H] + .
[0708] Step-2: Synthesis of (S)-N-((S)-1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-2-methylpropane-2-sulfenamide (INT-41.2): According to the experimental procedure of INT-14.4, the reaction was carried out on a scale of 1.1 g to obtain INT-20.4 (0.8 g, 72%) as a yellow solid. LCMS (ESI) m / z=338.0 [M+H] + .
[0709] Step-3: Synthesis of (S)-1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-4-amine hydrochloride (INT-41.3): According to the experimental procedure of INT-14.5, the reaction was carried out on a scale of 0.8 g to obtain INT-20.5 (0.5 g, 78%) as an off-white solid. LCMS (ESI) m / z=234.06 [M+H] + .
[0710] Step-4: Synthesis of (S)-5-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-1-methyl-1H-imidazole-4-carboxamide (Ex-41): According to the experimental procedure of Ex-14, the reaction was carried out on a scale of 0.10 g to obtain an enantiomeric mixture of Ex-41 [80:20] (90 mg) as an off-white solid compound. Ex-41 was further separated and purified by chiral HPLC to obtain pure Ex-41 (41 mg, 25.9%) as a white solid [column name: Chiralpak IE (250*4.6) mm, 5 um; mobile phase: CO 2 : MEOH containing 0.1% IP amine (60:40); flow rate: 4.0 mL / min; column temperature: 40°C; t R (Peak-1) 5.90min.(80%), t R (Peak-2) 9.18 min. (20%)]. LCMS (ESI) m / z = 370.20 [M+H] + ; Chiral HPLC (peak-1): 99.6% (t R 5.90min); UPLC (method H): 97.1% (t R 8.22min); 1H NMR (400MHz, DMSO-d6): δ7.72(s,1H),7.61-7.46(m,5H),7.37(td,J=7.6Hz,J=1.2Hz,1H),5.07-5.04(m,1H),4.65(dd,J =14.8Hz, J=12.4Hz, 2H), 3.86 (td, J=8.0Hz, J=4.0Hz, 2H), 3.59 (s, 3H), 2.97 (q, J=7.6Hz, 2H), 1.12 (t, J=7.6Hz, 3H); 19F NMR(DMSO-d6)δ-123.88.
[0711] Example 42: (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
[0712]
[0713] According to the experimental procedure of Ex-17, the reaction was carried out on a scale of 0.30 g to obtain an enantiomeric mixture of Ex-42 [76:24] (140 mg) as an off-white solid compound. Ex-42 was further separated and purified by chiral HPLC to obtain pure Ex-42 (67 mg, 13.6%) as a white solid [column name: Chiralcel AS-H (250*4.6) mm, 5 um; mobile phase: CO 2 : MeOH containing 0.1% IP amine (60:40); flow rate: 3.0 mL / min; column temperature: 40°C; t R (Peak-1) 1.83min.(76%), t R (Peak-2) 2.14 min. (24%)]. LCMS (ESI) m / z = 382.20 [M+H] + ; Chiral HPLC (peak-1): 99.8% (t R 1.81min); UPLC (method H): (peak-1) 99.8% (t R 11.45min); 1HNMR (400MHz, DMSO-d6): δ12.75(s,1H),7.72(s,1H),7.67(br ,s,1H),7.57(t,J=7.6Hz,1H),7.56-7.46(m,2H),7.37(t,J=7.6Hz,1H),5.1 1-5.07(m,1H),4.65(dd,J=14.8Hz,J=8.0Hz,2H),3.85(td,J=11.6Hz,J=4.0 Hz,2H),2.68(d,J=6.4Hz,2H),2.58(t,J=5.2Hz,2H),1.72-1.67(m,4H); 19F NMR(DMSO-d6)δ-123.87.
[0714] Example 43: (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide
[0715]
[0716] According to the experimental procedure of Ex-18, the reaction was carried out on a scale of 0.30 g to obtain an enantiomeric mixture of Ex-43 [78:22] (25 mg) as an off-white solid compound. Ex-43 was further separated and purified by chiral HPLC to obtain pure Ex-43 (7 mg, 1.4%) as a white solid [column name: Chiralcel AS-H (250*4.6) mm, 5 um; mobile phase: CO 2 : MeOH containing 0.1% IP amine (60:40); flow rate: 3.0 mL / min; column temperature: 40°C; t R (Peak-1) 2.26min.(78%), t R (Peak-2)2.64min.(22%)]. LCMS(ESI)m / z=383.25[M+H] + ; Chiral HPLC (peak-1): 99.9% (t R 2.26min); UPLC (method H): (peak-1) 99.6% (t R 11.41min); 1HNMR (400MHz, DMSO-d6): δ8.81 (d, J=7.6Hz, 1H), 7.73 (s, 1H), 7.57-7 .46(m,3H),7.37(t,J=7.2Hz,1H),5.13-5.09(m,1H),4.68-4.61(m,2H),3.90(dd,J =11.6Hz, J=4.4Hz, 1H), 3.82 (dd, J=11.6Hz, J=4.8Hz, 1H), 2.72 (t, J=5.6Hz, 2H), 2. 57-2.55(m,2H),1.81-1.78(m,2H),1.71-1.68(m,2H); 19FNMR(DMSO-d6)δ-123.87.
[0717] Example 44: (S)-4-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-methyl-1H-pyrazole-3-carboxamide
[0718]
[0719] According to the experimental procedure of Ex-19, the reaction was carried out on a scale of 0.30 g to obtain an enantiomeric mixture of Ex-44 [82:18] (190 mg) as an off-white solid compound. Ex-44 was further separated and purified by chiral HPLC to obtain pure Ex-44 (36 mg, 7.5%) as a white solid [column name: Chiralpak IE (250*4.6) mm, 5 um; mobile phase: CO2 : MEOH containing 0.1% IP amine (60:40); flow rate: 3.0 mL / min; column temperature: 40°C; t R (Peak-1) 4.00 min. (82%), t R (Peak-2) 4.85 min. (18%)]. LCMS (ESI) m / z = 370.3 [M+H] + ; Chiral HPLC (peak-3): 99.9% (t R 4.00min); UPLC (method H): (peak-1) 99.8% (t R 10.23min); 1HNMR (400MHz, DMSO-d6): δ12.76(br,s,1H),7.72(s,1H),7.69(d,J=8 .0Hz,1H),7.58(td,J=8.0Hz,J=1.6Hz,1H),7.55-7.46(m,2H),7.37(td,J=7.6Hz, J=1.2Hz,1H),5.10-5.08(m,1H),4.65(dd,J=14.8Hz,J=8.4Hz,2H),3.85(td,J=12 .8Hz, J=4.4Hz, 2H), 2.66 (q, J=7.2Hz, 2H), 2.17 (s, 3H), 1.06 (t, J=7.6Hz, 3H); 19F NMR (DMSO-d6) δ-123.87.
[0720] Example 45: (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide
[0721]
[0722] According to the experimental procedure of Ex-20, the reaction was carried out on a scale of 0.10 g to obtain an enantiomeric mixture of Ex-45 [26:74] (80 mg) as an off-white solid compound. Ex-45 was further separated and purified by chiral HPLC to obtain pure Ex-45 (40 mg, 25.5%) as a white solid [column name: Chiralpak IA (250*4.6) mm, 5 um; mobile phase: CO 2 : MeOH containing 0.1% IP amine (60:40); flow rate: 3.0 mL / min; column temperature: 40°C; t R (Peak-1) 2.61min.(26%), t R (Peak-2) 3.19 min. (74%)]. LCMS (ESI) m / z = 367.25 [M+H] +; Chiral HPLC (peak-2): 98.6% (t R 3.10min); UPLC (method H): 98.9% (t R 10.02min); 1H NMR (400MHz, DMSO-d6): δ8.45(d,J=8.4Hz,1H),8.33(s,1H),7.90(s,1H),7.75(s,1H),7.59(t,J=8.0Hz,1H),7.55-7.47(m,2H),7.37( 19F NMR(DMSO-d6)δ-123.87.
[0723] In addition, the following compounds were prepared similarly to the above method:
[0724] Example 46: (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide
[0725]
[0726] LCMS (ESI) m / z = 416.2 [M+H] +; Chiral HPLC (peak-1): 99.5% (t R 2.48
[0727] min); UPLC (method H): 99.6% (t R =10.43min); 1H NMR (400MHz, DMSO-d6): δ12.78 (s, 1H), 7.74 (d, J = 3.2Hz, 1H), 7.69-7.50 (m, 4H), 5.10-5.08 (m, 1H), 4.52 (d, J = 15.2Hz, J = 14.8Hz, 2H), 3.84 (s, 2H), 2.67 (d, J = 1.6Hz, 2H), 2.57 (t, J = 3.2Hz, 2H), 1.71-1.66 (m, 4H); Two rotamer peaks were observed in 19F NMR. 19F NMR (DMSO-d6) δ -118.17, -118.46.
[0728] Example 47: (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide
[0729]
[0730] LCMS (ESI) m / z=416.15 [M+H]+; Chiral HPLC (peak-1): 99.9% (t R 8.30min); UPLC (method H): 99.8% (t R =8.76min); two rotamer peaks were observed in 1H and 19F NMR. 1H NMR (400MHz, DMSO-d6): δ8.01 (d, J = 8.4 Hz, 0.5H), 7.94 (d, J = 8.0 Hz, 0.5H), 7.74 (d, J = 3.2 Hz, 1H), 7.68-7.58 (m, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.53 (t, J = 8.8 Hz, 1H), 6.75 (s, 1H), 5.10-5.06 (m, 1H), 4. 57(dd,J=14.8Hz,J=3.6Hz,1H),4.48(d,J=14.8Hz,1H),4.42-4.34(m,2H),3.85(d,J=4.0Hz,2H), 2.76(t,J=6.4Hz,2H),1.92-1.86(m,2H),1.76-1.71(m,2H); 19FNMR(DMSO-d6)δ-118.18,-118.49.
[0731] Example 48: (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide
[0732]
[0733] LCMS (ESI) m / z=401.25 [M+H]+; Chiral HPLC (peak-1): 99.9% (t R 7.26min); UPLC (method H): 99.9% (t R=10.27 min); two rotamer peaks were observed in 1H and 19F NMR. 1H NMR (400MHz, DMSO-d6): δ8.48(d,J=8.0Hz,0.5H),8.43(d,J=8.0Hz,0.5H),8.3 4(s,1H),7.90(s,1H),7.77(d,J=2.4Hz,1H),7.68-7.63(m,1H),7.59(d,J=8.4 Hz,1H),7.53(t,J=8.4Hz,1H),5.14-5.12(m,1H),4.60(dd,J=14.8Hz,J=5.6Hz ,1H),4.50(d,J=15.2Hz,1H),3.95-3.85(m,2H),2.35(s,3H),2.29(s,3H); 19F NMR(DMSO-d6)δ-118.15,-118.49.
[0734] Example 49: (S)-N-(1-(3-(methylsulfonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0735]
[0736] LCMS (ESI) m / z=442.22 [M+H]+; Chiral HPLC (peak-1): 99.8% (t R 5.63min); UPLC (method A): 99.4% (t R =11.22min); 1HNMR (400MHz, DMSO-d6): 8.06-8.05 (m, 1H), 7.90 (td, J = 3.6Hz, J=1.6Hz,1H),7.84-7.77(m,2H),7.76(s,1H),7.54(s,1H),7.48(d,J=8.8Hz, 1H),5.09-5.05(m,1H),5.01(s,2H),3.99(t,J=5.6Hz,2H),3.86(d,J=4.0Hz, 2H), 3.32 (s, 3H), 2.99 (t, J = 6.8Hz, 2H), 1.88-1.83 (m, 2H), 1.79-1.75 (m, 2H).
[0737] Example 50: (S)-N-(1-(2-chloro-3-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0738]
[0739] LCMS (ESI) m / z=466.23 [M+H]+; Chiral HPLC (method AR) (peak-1): 99.7% (t R 2.14min); UPLC (method A): 98.8% (t R =8.80min);1H NMR (400MHz, DMSO-d6): 8.05(d,J=7.2Hz,1H),7.91(d,J=7.2Hz,1H),7.74(t,J=6.8Hz,2H),7.56(s,1H),7.44(d,J=8.4Hz,1H),5.09-5.05(m,1H ), 4.58 (dd, J = 15.6Hz, J = 14.8Hz, 2H), 3.99 (t, J = 6.0Hz, 2H), 3.83 (t, J = 3.6Hz, 2H), 2.99 (t, J = 6.4Hz, 2H), 1.88-1.85 (m, 2H), 1.79-1.75 (m, 2H).
[0740] Example 51: (S)-N-(1-(2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0741]
[0742] LCMS (ESI) m / z=398.16 [M+H]+; Chiral HPLC (peak-1): 99.9% (t R 19.3min); UPLC (method D): 99.6% (t R =11.06min); 1HNMR (400MHz, DMSO-d6):7.72-7.69(m,2H),7.59-7.50(m,4H),7.43(d,J=8.4Hz,1H),5.07-5.05(m,1H),4.57(dd,J =15.6Hz, J=14.8Hz, 2H), 4.00 (t, J = 5.6Hz, 2H), 3.85 (t, J = 3.6Hz, 2H), 3.00 (t, J = 6.4Hz, 2H), 1.87-1.85 (m, 2H), 1.80-1.76 (m, 2H).
[0743] Example 52: (S)-N-(1-(o-tolyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0744]
[0745] LCMS (ESI) m / z=378.21 [M+H]+; Chiral HPLC (peak-2): 99.9% (t R 21.04min); UPLC (method A): 99.4% (t R =10.43min); 1HNMR (400MHz, DMSO-d6): 7.63 (s, 1H), 7.56 (s, 1H), 7.44 (d, J=8.4Hz,1H),7.42-7.40(m,2H),7.35-7.30(m,2H),5.07-5.03(m,1H),4.5 3(dd,J=14.8Hz,J=4.8Hz,2H),4.00(t,J=5.6Hz,2H),3.82(d,J=3.6Hz,2H) ,3.00(t,J=6.4Hz,2H),2.08(s,3H),1.89-1.83(m,2H),1.79-1.73(m,2H).
[0746] Example 53: (S)-N-(1-(2-chloro-5-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0747]
[0748] LCMS (ESI) m / z=412.19 [M+H]+; Chiral HPLC (peak-2): 99.6% (t R 14.27min); UPLC (method F): 99.8% (t R =7.30min); 1HNMR (400MHz, DMSO-d6): 7.68 (s, 1H), 7.57 (t, J = 4.4Hz, 2H), 7.44-7.38 (m, 3H), 5.08-5.06 (m, 1H), 4.58 (dd, J = 14.8Hz, J = 10.8 Hz, 2H), 4.01 (t, J = 5.2Hz, 2H), 3.83 (td, J = 11.6Hz, J = 3.2Hz, 2H), 3.01 (t, J = 5.6Hz, 2H), 2.37 (s, 3H), 1.88-1.86 (m, 2H), 1.79-1.78 (m, 2H).
[0749] Example 54: (S)-N-(1-(2-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0750]
[0751] LCMS (ESI) m / z=394.22 [M+H]+; Chiral HPLC (peak-1): 99.9% (t R 5.40min); UPLC (method C): 99.8% (t R =8.67min); 1HNMR (400MHz, DMSO-d6): 7.61 (s, 1H), 7.55 (s, 1H), 7.45 (t, J = 8 .8Hz,1H),7.36(t,J=6.4Hz,2H),7.21(d,J=8.0Hz,1H),7.05(t,J=7.2Hz,1H ),5.06-5.02(m,1H),4.52(dd,J=14.8Hz,J=6.8Hz,2H),3.99(t,J=5.6Hz,2H ), 3.83 (s, 5H), 2.99 (t, J = 6.4Hz, 2H), 1.88-1.83 (m, 2H), 1.79-1.75 (m, 2H).
[0752] Example 55: (S)-N-(1-(2-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0753]
[0754] LCMS (ESI) m / z=432.20 [M+H]+; Chiral HPLC (peak-2): 99.9% (t R 7.72min); UPLC (method C): 99.3% (t R=9.30min); 1H NMR(400MHz, DMSO-d6):7.96(d,J=7.6Hz,1H),7.85(t,J=7.2Hz,1H),7.77(t,J=7.6H z,1H),7.66(s,1H),7.64(d,J=10.4Hz,1H),7.56(s,1H),7.41(d,J=8.4Hz,1H),5.06- 5.04(m,1H),4.55(dd,J=15.6Hz,J=14.8Hz,2H),4.00(t,J=6.0Hz,2H),3.82(dd,J=1 1.6Hz, J=3.6Hz, 2H), 3.00 (t, J=6.4Hz, 2H), 1.92-1.85 (m, 2H), 1.80-1.76 (m, 2H); 19F NMR(DMSO-d6)-58.62.
[0755] Example 56: (S)-N-(1-(3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0756]
[0757] LCMS (ESI) m / z=394.22 [M+H]+; Chiral HPLC (peak-1): 99.7% (t R 5.52min); UPLC (method F): 99.1% (t R =6.03min); 1HNMR (400MHz, DMSO-d6): 7.66 (s, 1H), 7.54 (s, 1H), 7.45-7.39 (m, 2H), 7.07-7.04 (m, 2H), 6.94 (dd, J=8.0Hz, J=2.0Hz, 1H), 5.06-5 .04(m,1H),4.93(s,2H),3.99(t,J=5.6Hz,2H),3.84(d,J=3.6Hz,2H),3 .81(s,3H),2.99(t,J=6.4Hz,2H),1.86-1.85(m,2H),1.78-1.75(m,2H).
[0758] Example 57: (S)-N-(1-(3-(trifluoromethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0759]
[0760] LCMS (ESI) m / z=448.20 [M+H]+; Chiral HPLC (peak-1): 99.7% (t R 7.41min); UPLC (method F): 95.6% (t R =7.35min); 1HNMR (400MHz, DMSO-d6): 7.73 (s, 1H), 7.66 (t, J = 8.4Hz, 1H), 7.56-7.51 (m, 3H), 7.47 (d, J = 8.8Hz, 1H), 7.38 (d, J = 8.0Hz, 1H), 5.08-5.04(m,1H),4.98(s,2H),3.99(t,J=5.6Hz,2H),3.84(d,J=3.6Hz,2H),2.99(t,J=6.4Hz,2H),1.88-1.83(m,2H),1.79-1.74(m,2H).
[0761] Example 58: (S)-N-(1-(2-fluoro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0762]
[0763] LCMS (ESI) m / z=396.21 [M+H]+; Chiral HPLC (peak-2): 99.9% (t R 18.15min); UPLC (method D): 99.4% (t R =11.30min); 1HNMR (400MHz, DMSO-d6): 7.69 (s, 1H), 7.56 (s, 1H), 7.56-7.45 (m, 2H), 7.31-7.26 (m, 2H), 5.08-5.04 (m, 1H), 4.57 (dd, J = 16. 0Hz, J=14.8Hz, 2H), 4.00 (t, J=5.6Hz, 2H), 3.82 (d, J=3.6Hz, 2H), 3.00 (t, J=6.8Hz, 2H), 2.06 (s, 3H), 1.87-1.85 (m, 2H), 1.80-1.74 (m, 2H).
[0764] Example 59: (S)-N-(1-(2,6-difluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0765]
[0766] LCMS (ESI) m / z=400.25 [M+H]+; Chiral HPLC (peak-2): 99.9% (t R 6.72min); UPLC (method A): 99.8% (t R =8.83min); 1HNMR (400MHz, DMSO-d6): 7.75 (s, 1H), 7.67-7.63 (m, 1H), 7.55 ( s,1H),7.48(d,J=8.4Hz,1H),7.40(t,J=8.8Hz,2H),5.08-5.04(m,1H),4.63 (d,J=14.8Hz,1H),4.53(d,J=14.8Hz,1H),4.00(t,J=5.6Hz,2H),3.83(d,J= 4.0Hz,2H),3.00(t,J=6.4Hz,2H),1.89-1.83(m,2H),1.79-1.73(m,2H); 19F NMR (DMSO-d6) -120.09.
[0767] Example 60: (S)-N-(1-(2-chloro-6-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0768]
[0769] LCMS (ESI) m / z=428.19 [M+H]+; Chiral HPLC (peak-2): 99.7% (t R 2.63min); UPLC (method A): 98.8% (t R =9.57min); 1HNMR (400MHz, DMSO-d6): 7.64 (s, 1H), 7.56 (d, J = 4.0Hz, 1H), 7.53 (t, J = 7.6Hz, 1H), 7.38-7.33 (m, 1H), 7.26-7.22 (m, 2H), 5. 04-5.02(m,1H),4.48-4.33(m,2H),4.00(t,J=5.2Hz,2H),3.83-3.78(m,5H),3.00(t,J=6.4Hz,2H),1.89-1.84(m,2H),1.80-1.76(m,2H).
[0770] Example 61: (S)-N-(1-(2-methoxy-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0771]
[0772] LCMS (ESI) m / z=408.4 [M+H]+; Chiral HPLC (peak-1): 99.9% (t R 10.77min); UPLC (method H): 99.9% (t R =8.33min); 1HNMR (400MHz, DMSO-d6): 7.60 (d, J = 2.4Hz, 1H), 7.56 (d, J = 6.0Hz, 1H), 7.4 2-7.35(m,2H),7.04(t,J=7.2Hz,1H),6.95(d,J=7.6Hz,1H),5.06-5.02(m,1H),4.46-4. 30(m,2H),4.00(t,J=5.2Hz,2H),3.82-3.79(m,2H),3.76(s,1.5H),3.73(s,1.5H),3.0 0(t,J=6.4Hz,2H),1.97(s,1.5H),1.91(s,1.5H),1.86-1.85(m,2H),1.80-1.74(m,2H).
[0773] Example 62: (S)-N-(1-(2-chloro-3-hydroxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0774]
[0775] Step-1: Synthesis of 1-(benzyloxy)-2-chloro-3-nitrobenzene (INT-62.1): To a stirred solution of 2-chloro-3-nitrophenol (10.0 g, 57.6 mmol) in DMF (100 mL) was added K 2 CO 3 (23.9 g, 3 eq., 173 mmol) and benzyl bromide (8.21 mL, 69.1 mmol) was added dropwise. The reaction was stirred at 80 °C for 12 h. After completion, the reaction mixture was diluted with ice water and stirred for 1 h. The reaction mass was filtered through a sinter funnel, washed with pentane and dried in vacuo to give crude compound INT-62.1 (13.5 g, 89%) as a brown solid. LCMS (ESI) m / z=262.14 (MH)+ .
[0776] Step-2: Synthesis of 3-(benzyloxy)-2-chloroaniline (INT 62.2): INT-62.1 (9.0 g, 34.1 mmol) was dissolved in EtOH (50 mL) and H 2 NH 4 Cl (9.13 g, 171 mmol) and Fe powder (9.53 g, 171 mmol). The reaction mixture was heated at 70 ° C for 4 h. After completion, the reaction mass was filtered through a celite bed and washed with DCM. The filtrate was washed with cold water, brine, and the organic layer was dried over sodium sulfate, filtered and concentrated to give pure INT-62.2 (7.0 g, 88%) as a slightly black viscous oil. LCMS (ESI) m / z=234.0 [M+H] + .
[0777] Step-3: Synthesis of (3-(benzyloxy)-2-chlorophenyl)hydrazine hydrochloride (INT-62.3): According to the experimental procedure of INT-14.1, the reaction was carried out on a scale of 8.0 g to obtain INT-62.3 (8.0 g, 94%) as a white solid. LCMS (ESI) m / z=249.12 [M+H] + .
[0778] Step-4: Synthesis of 1-(3-(benzyloxy)-2-chlorophenyl)-1,7-dihydropyrano[3,4-c]pyrazol-4(5H)-one (INT-62.4): According to the experimental procedure of INT-14.2, the reaction was carried out on a 2.0 g scale to obtain INT-62.4 (0.65 g, 23%) as a yellow solid. LCMS (ESI) m / z=355.18 [M+H] + .
[0779] Step-5: Synthesis of (S,Z)-N-(1-(3-(benzyloxy)-2-chlorophenyl)-1,7-dihydropyrano[3,4-c]pyrazole-4(5H)-ylidene)-2-methylpropane-2-sulfinamide (INT-62.5): According to the experimental procedure of INT-14.3, the reaction was carried out on a scale of 2.0 g to obtain INT-62.5 (0.9 g, 35%) as a yellow solid. LCMS (ESI) m / z=458.28 [M+H] + .
[0780] Step-6: Synthesis of (S)-N-((S)-1-(3-(benzyloxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-2-methylpropane-2-sulfenamide (INT-62.6): According to the experimental procedure of INT-14.4, the reaction was carried out on a scale of 0.80 g to obtain INT-62.6 (0.78 g, 97%) as a yellow solid. LCMS (ESI) m / z=459.40 [M+H] + .
[0781] Step-7: Synthesis of (S)-1-(3-(benzyloxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazole-4-amine hydrochloride (INT-62.7): According to the experimental procedure of INT-14.5, the reaction was carried out on a scale of 0.78 g to obtain INT-62.7 (0.60 g, 99%) as an off-white solid. LCMS (ESI) m / z=356.80 [M+H] + .
[0782] Step-8: Synthesis of (S)-N-(1-(3-(benzyloxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (INT-62.8): According to the experimental procedure of Ex-14, the reaction was carried out with 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic acid on a scale of 0.40 g to obtain an enantiomeric mixture INT-62.8 (0.40 g, 71%) as an off-white solid compound. LCMS (ESI) m / z=504.13[M+H] + .
[0783] Step-9: Synthesis of (S)-N-(1-(2-chloro-3-hydroxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-62): To a stirred solution of INT-62.8 (0.18 g, 0.36 mmol) in EtOH (18 mL) was added 10% Pd / C (0.095 g, 50% w / w) at room temperature and 1-2 drops of concentrated HCl were added at room temperature. The reaction mass was treated with N 2 Irrigate and press H 2 The atmosphere was refilled. The reaction was stirred at room temperature for 16 h. After completion, H 2, the reaction mass was diluted with DCM and filtered through a celite bed. The celite bed was washed with DCM and the collected organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude product. The crude material was purified by silica gel column chromatography using a gradient of 1-5% DCM in MeOH to obtain an enantiomeric mixture of EX-62 [26:74] (85 mg) as an off-white solid compound. Ex-62 was further separated and purified by chiral HPLC to obtain pure Ex-62 (12 mg, 8.1%) as a white solid [column name: LUX AMYLOSE-1 (4.6*250) mm, 5u; mobile phase: CO 2 / IPA containing 0.2% TEA = (60:40) (v / v); flow rate: 3 mL / min; flow mode: isocratic; column temperature: 35°C; ABPR pressure: 1500 psi, t R (Peak-1) 2.85min.(26%), t R (Peak-2) 3.3 min. (74%)]. LCMS (ESI) m / z = 414.33 [M+H] + ; Chiral HPLC (peak-2): 99.8% (t R 3.33min); UPLC (method A): 99.9% (t R 9.38min); 1HNMR (400MHz, DMSO-d6): 10.71(br,s,1H),7.64(s,1H),7.55(s,1H),7.40(d,J =8.4Hz,1H),7.28(t,J=8.4Hz,1H),7.11(dd,J=8.4Hz,J=0.4Hz,1H),6.95(dd,J=8.0Hz,J=0 .3Hz,1H),5.06-5.02(m,1H),4.52(dd,J=14.4Hz,J=11.2Hz,2H),3.99(t,J=5.6Hz,2H),3.8 2(td,J=11.6Hz,J=3.6Hz,2H),2.99(t,J=6.4Hz,2H),1.88-1.83(m,2H),1.79-1.75(m,2H).
[0784] Example 63: (S)-N-(1-(2-chloro-3-(2-(dimethylamino)ethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0785]
[0786] Step-1: Synthesis of (S)-N-(1-(2-chloro-3-hydroxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-62): To a stirred solution of INT-62.8 (1.2 g, 2.38 mmol) in DCM (24 mL) was added dropwise BBr in DCM (4 mL) at 0 °C. 3 (0.23 mL, 2.38 mmol). The reaction was stirred at 0 °C for 30 min. After completion, the reaction mass was quenched with MeOH at 0 °C and stirred at room temperature for 30 min. The reaction mixture was further concentrated in vacuo to give the crude material. The crude material was purified by silica gel column chromatography using a gradient of 5-10% MeOH in DCM to give Ex-62 (0.5 g, 51%) as a brown solid. LCMS (ESI) m / z=414.28 [M+H] + .
[0787] Step-2: Synthesis of (S)-N-(1-(2-chloro-3-(2-(dimethylamino)ethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-63): To a stirred solution of Ex-62 (0.20 g, 0.48 mmol) and 2-chloro-N,N-dimethylethan-1-amine hydrochloride (0.13 g, 1.21 mmol) in anhydrous DMF (2 mL) was added K 2 CO 3 (0.27 g, 1.93 mmol). The vial was closed with a cap and the solution was stirred at 65 °C for 16 h. After completion, the reaction mass was vacuum distilled and purified by silica gel column chromatography using a gradient of 5-20% MeOH in DCM using 1% trimethylamine in DCM to obtain an enantiomeric mixture of EX-63 [25:75] (160 mg) as an off-white solid compound. Ex-463 was further separated and purified by chiral HPLC to obtain pure Ex-63 (53 mg, 22.6%) as a white solid [column name: Chiralpak-IG (4.6X250) 5um; mobile phase: MeOH / ACN containing 0.1% AH = 50:50 (v / v); flow rate: 1.0 ml / min, temperature: 25 °C; flow mode: isocratic; t R (Peak-1) 7.7 min. (25%), t R (Peak-2)10.2min.(75%)]. LCMS(ESI)m / z=485.29[M+H] +; Chiral HPLC (peak-2): 99.9% (t R 10.27min); UPLC (method I): 95.0% (t R 9.40min); 1H NMR (400MHz, DMSO-d6): 7.67 (s, 1H), 7.56 (s, 1H), 7.47-7.39 (m, 2H), 7.35 (dd, J=8.4Hz, J=0 .8Hz,1H),7.12(dd,J=7.6Hz,J=1.2Hz,1H),5.07-5.03(m,1H),4.53(dd,J=14.8Hz,J=10.8H z,2H),4.22(t,J=6.0Hz,2H),3.99(t,J=5.6Hz,2H),3.83(td,J=11.6Hz,J=4.4Hz,2H),3.00 (t,J=6.4Hz,2H),2.71(t,J=5.6Hz,2H),2.26(s,6H),1.91-1.83(m,2H),1.80-1.76(m,2H).
[0788] Example 64: (S)-N-(1-(2-chloro-3-(2-(dimethylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0789]
[0790] Step-1: Synthesis of (S)-N-(1-(2-chloro-3-(2-(dimethylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-64): To a stirred solution of Ex-62 (0.25 g, 0.60 mmol) and 2-chloro-N,N-dimethylacetamide (0.15 mL, 1.51 mmol) in anhydrous DMF (2 mL) was added NaH 60% w / w (0.06 g, 1.51 mmol) in a screw cap vial at 0°C. The vial was closed with a cap and the solution was stirred at room temperature for 16 h. After completion, the reaction mass was quenched in MeOH and distilled under vacuum to obtain the crude product. The crude product was purified by silica gel column chromatography using a gradient of 2-5% MeOH in DCM to give an enantiomeric mixture of EX-64 [23:69] (53 mg) as an off-white solid compound. Ex-64 was further separated and purified by chiral HPLC to give pure Ex-64 (21 mg, 6.97%) as a white solid [column name: Chiralpak-IG (4.6X250) 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide: ACN = 50:50 (v / v); flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 7.76min.(23%), t R (Peak-2)9.48min.(69%)]. LCMS(ESI)m / z=499.29[M+H] + ; Chiral HPLC (peak-2): 99.4% (t R 9.50min); UPLC (method J): 99.5% (t R 8.21min); 1H NMR(400MHz,DMSO-d6):7.67(s,1H),7.56(s,1H),7.43-7.37(m,2H),7.16(d ,J=8.4Hz,1H),7.11(dd,J=7.6Hz,J=1.2Hz,1H),5.07-5.03(m,3H),4.53(dd, J=14.8Hz,J=10.8Hz,2H),3.99(t,J=5.6Hz,2H),3.83(td,J=11.6Hz,J=3.6H z,2H),3.01-2.98(m,5H),2.86(s,3H),1.96-1.83(m,2H),1.80-1.76(m,2H).
[0791] Example 65: (S)-N-(1-(2-chloro-3-(2-(methylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0792]
[0793] Step-1: Synthesis of ((S)-N-(1-(2-chloro-3-(2-(methylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-65): To a stirred solution of Ex-62 (0.2 g, 0.48 mmol) in anhydrous DMF (2.0 mL) was added Cs 2 CO 3 (0.47 g, 1.45 mmol), KI (0.02 g, 0.12 mmol) and 2-chloro-N-methylacetamide (0.10 g, 0.97 mmol). The reaction was stirred at 100 ° C for 6 h. After completion, the reaction mixture was concentrated in vacuo and purified by silica gel column chromatography using 2-6% MeOH in DCM to obtain a crude product. The crude product was purified by silica gel column chromatography using a gradient of 2-5% MeOH in DCM to obtain an enantiomeric mixture of EX-65 [25:75] (120 mg) as an off-white solid compound. Ex-65 was further separated and purified by chiral HPLC to obtain pure Ex-65 (55 mg, 23.4%) as a white solid [column name: Chiralpak AD-H (250*4.6) mm, 5 um; mobile phase: CO 2 : MeOH containing 0.1% IP amine (60:40); flow rate: 3.0 mL / min; column temperature: 40°C; t R (Peak-1) 4.24min.(25%), t R (Peak-2)8.01min.(75%)]. LCMS(ESI)m / z=485.25[M+H] + ; Chiral HPLC (peak-2): 99.3% (t R 8.02min); UPLC (method H): 95.7% (t R7.56min); 1H NMR(400MHz, DMSO-d6):7.97(q,J=3.6Hz,1H),7.67(s,1H),7.56(s,1H),7.44(t, J=8.0Hz,2H),7.17(t,J=9.6Hz,2H),5.07-5.04(m,1H),4.68(s,2H),4.54(dd,J=1 4.4Hz, J=11.6Hz, 2H), 3.99 (t, J=5.6Hz, 2H), 3.83 (td, J=12.0Hz, J=4.0Hz, 2H), 2 .98(t,J=6.4Hz,2H),2.66(d,J=8.4Hz,3H),1.88-1.83(m,2H),1.78-1.76(m,2H).
[0794] Example 66: (S)-N-(1-(3-(2-acetylaminoethoxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0795]
[0796] Step-1: Synthesis of (S)-tert-butyl (2-(2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)phenoxy)ethyl)carbamate (INT-66.1): To a stirred solution of Ex-62 (0.4 g, 0.97 mmol) in anhydrous DMF (4 mL) was added Cs 2 CO 3 (0.95 g, 2.9 mmol), KI (4 mg, 0.024 mmol) and tert-butyl (2-chloroethyl) carbamate (0.35 g, 1.93 mmol). The reaction was stirred at 80 ° C for 16 h. After completion, the reaction mixture was concentrated in vacuo and purified by silica gel column chromatography using 2-6% MeOH in DCM to give pure INT-18.10 (0.35 g, 65%) as a yellow viscous substance. LCMS (ESI) m / z=557.21 [M+H] + .
[0797] Step-2: Synthesis of (S)-N-(1-(3-(2-aminoethoxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide hydrochloride (INT-66.2): To a stirred solution of INT-66.1 (0.350 g, 0.63 mmol) in anhydrous DCM (7 mL) was added 4M HCl in dioxane (3.5 mL) at room temperature. The reaction was stirred at room temperature for 2 h. After completion, the reaction mixture was concentrated in vacuo to give INT-66.2 (0.300 g, 97%) as a yellow solid. LCMS (ESI) m / z=457.14[M+H] + .
[0798] Step-3: Synthesis of (S)-N-(1-(3-(2-acetylaminoethoxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-66): INT-66.2 (0.30 g, 0.66 mmol) was added to MeOH (3 mL) and H2O at room temperature. 2 To a stirred solution in 4% paraformaldehyde (2% paraformaldehyde) (3 mL) was added TEA (0.17 g, 1.64 mmol) and acetic anhydride (0.10 g, 0.99 mmol) (dissolved in 2.0 ml MeOH) was added dropwise. The reaction mass was stirred at room temperature for 2 h. After completion, the reaction mixture was concentrated in vacuo and purified by silica gel column chromatography using 2-6% MeOH in DCM to obtain an enantiomeric mixture of EX-66 [30:70] (220 mg) as an off-white solid compound. Ex-66 was further separated and purified by chiral HPLC to obtain pure Ex-66 (100 mg, 30.5%) as a white solid [column name: Chiralpak-IG (4.6X250) 5um; mobile phase: MeOH / ACN containing 0.1% AH = 70:30 (v:v); flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 6.57 min. (30%), t R (Peak-2)7.71min.(70%)]. LCMS(ESI)m / z=499.20[M+H] + ; Chiral HPLC (peak-2): 99.9% (t R 7.73min); UPLC (method J): 99.6% (t R8.22min); 1H NMR(400MHz,DMSO-d6):8.11(t,J=4.8Hz,1H),7.66(s,1H),7.56(s,1H),7.45-7.40(m,2H), 7.34(d,J=7.6Hz,1H),7.12(d,J=7.2Hz,1H),5.07-5.03(m,1H),4.53(dd,J=14.8Hz,J=10.8 Hz,2H),4.15(t,J=5.6Hz,2H),3.99(t,J=5.6Hz,2H),3.83(td,J=12.0Hz,J=4.0Hz,2H),3.4 4(q,J=5.6Hz,2H),2.99(t,J=6.4Hz,2H),1.86-1.83(m,2H),1.83(s,3H),1.79-1.76(m,2H).
[0799] Example 67: (S)-N-(1-(2-chloro-3-(2-methoxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0800]
[0801] Step-1: Synthesis of (S)-N-(1-(2-chloro-3-(2-methoxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-67): According to the experimental procedure of Ex-64, the reaction was carried out on a scale of 0.25 g to obtain an enantiomeric mixture of Ex-67 [20:80] (150 mg) as an off-white solid compound. Ex-67 was further separated and purified by chiral HPLC to obtain pure Ex-67 (60 mg, 21.0%) as a white solid [column name: Chiralpak-IG (4.6X250), 5um; mobile phase: MeOH / ACN containing 0.1% ammonium hydroxide = 50:50; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 7.12 min. (20%), t R (Peak-2) 9.18 min. (80%)]. LCMS (ESI) m / z = 472.25 [M+H] + ; Chiral HPLC (peak-2): 99.8% (t R 9.22min); UPLC (method J): 99.7% (t R9.27min); 1H NMR (400MHz, DMSO-d6): 7.66 (s, 1H), 7.56 (s, 1H), 7.45-7.40 (m, 2H), 7.33 (d, J = 8.4Hz, 1H) ,7.11(dd,J=4.0Hz,J=0.8Hz,1H),5.07-5.03(m,1H),4.53(dd,J=14.8Hz,J=10.8Hz,2H),4. 27(t,J=4.4Hz,2H),3.99(t,J=5.6Hz,2H),3.83(td,J=11.6Hz,J=0.4Hz,2H),3.72(t,J=4.4 Hz, 2H), 3.33 (d, J = 8.0 Hz, 3H), 2.99 (t, J = 6.4 Hz, 2H), 1.88-1.83 (m, 2H), 1.79-1.74 (m, 2H).
[0802] Example 68: (S)-N-(1-(2-chloro-3-(2-hydroxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0803]
[0804] Step-1: Synthesis of (S)-N-(1-(2-chloro-3-(2-hydroxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-68): According to the experimental procedure of Ex-64, the reaction was carried out on a scale of 0.25 g to obtain an enantiomeric mixture of Ex-68 [26:74] (180 mg) as an off-white solid compound. Ex-68 was further separated and purified by chiral HPLC to obtain pure Ex-68 (48 mg, 17.3%) as a white solid [column name: Chiralpak-IG (4.6X250) mm, 5um; mobile phase: MeOH / ACN containing 0.1% ammonium hydroxide = 50:50; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 5.48min. (26%), t R (Peak-2)6.54min.(74%)]. LCMS(ESI)m / z=458.23[M+H] + ; Chiral HPLC (peak-2): 99.9% (t R 6.54min); UPLC (method K): 97.9% (t R8.99min); 1H NMR(400MHz,DMSO-d6):7.66(s,1H),7.56(s,1H),7.45-7.40(m,2H),7.32(d,J=8.4Hz,1 H),7.11(dd,J=4.0Hz,J=0.8Hz,1H),5.07-5.03(m,1H),4.93(t,J=5.2Hz,1H),4.53(dd, J=14.8Hz,J=10.8Hz,2H),4.15(t,J=4.8Hz,2H),3.99(t,J=5.6Hz,2H),3.83(t,J=3.2Hz ,2H),3.77(q,J=5.2Hz,2H),2.99(t,J=6.8Hz,2H),1.87-1.83(m,2H),1.79-1.76(m,2H).
[0805] Example 69: (S)-2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoic acid isopropyl ester
[0806]
[0807] Step-1: Synthesis of methyl 2-chloro-3-nitrobenzoate (INT-69.1): To a solution of 2-chloro-3-nitrobenzoic acid (10.0 g, 49.6 mmol) in MeOH (100 mL) was added concentrated H 2 SO 4 (1.35mL, 24.8mmol). The reaction mass was heated at 80 ° C for 16h. After completion, the reaction mass was evaporated under reduced pressure and the crude product was diluted with ice water. The organic layer was extracted with EtOAc, the collected organic layer was washed with brine solution, dried with sodium sulfate, evaporated, and purified by silica gel column chromatography using 10-30% EtOAc in hexane to give INT-69.1 (10.2g, 95%) as a white solid. LCMS was inconsistent, but confirmed by 1H NMR. 1H NMR (400MHz, DMSO-d6): 8.22 (dd, J = 8.0Hz, J = 5.6Hz, 1H), 8.06 (dd, J = 8.0Hz, J = 1.6Hz, 1H), 7.66 (t, J = 7.6Hz, 1H), 3.91 (s, 3H).
[0808] Step-2: Synthesis of methyl 3-amino-2-chlorobenzoate (INT 69.2): To a stirred solution of INT-69.1 (5.0 g, 23.2 mmol) in EtOH (50 mL) and water (15 mL) was added Fe powder (6.48 g, 116.0 mmol) and ammonium chloride (6.2 g, 116.0 mmol) at room temperature. The resulting reaction mixture was stirred at 70 ° C for 4 h. After completion, the precipitate was filtered out and the filtrate was concentrated in vacuo to obtain the crude product. The crude product was dissolved in DCM and water and the organic layer was separated. The organic layer was dried over sodium sulfate and vacuum distilled to give INT-69.2 (3.5 g, 81%) as a colorless oil. LCMS was inconsistent, but confirmed by 1H NMR. 1H NMR (400MHz, DMSO-d6): 7.09 (t, J = 8.0 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 7.2 Hz, 1H), 5.62 (s, 2H), 3.81 (s, 3H).
[0809] Step-3: Synthesis of methyl 2-chloro-3-hydrazinobenzoate hydrochloride (INT-69.3): According to the experimental procedure of INT-14.1, the reaction was carried out on a 4.0 g scale to obtain INT-69.3 (4.0 g, 90%) as a white solid. LCMS (ESI) m / z = 201.22 [M+H] + .
[0810] Step-4: Synthesis of methyl 2-chloro-3-(4-oxo-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoate (INT-69.4): According to the experimental procedure of INT-14.2, the reaction was carried out on a scale of 5.0 g to obtain INT-69.4 (0.72 g, 11%) as a yellow solid. LCMS (ESI) m / z=307.08 [M+H] + .
[0811] Step-5: Synthesis of (S,Z)-3-(4-((tert-butylsulfinyl)imino)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)-2-chlorobenzoic acid isopropyl ester (INT-69.5): According to the experimental procedure of INT-14.3, the reaction was carried out on a scale of 1.5 g to obtain INT-69.5 (1.2 g, 56%) as a yellow solid. LCMS (ESI) m / z=438.07[M+H] + .
[0812] Step-6: Synthesis of isopropyl 3-(S)-(4-((S)-tert-butylsulfinyl)amino)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)-2-chlorobenzoate (INT-69.6): According to the experimental procedure of INT-14.4, the reaction was carried out on a scale of 1.2 g to obtain INT-69.6 (1.2 g, 99%) as a yellow solid. LCMS (ESI) m / z=440.11 [M+H] + .
[0813] Step-7: Synthesis of (S)-3-(4-amino-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)-2-chlorobenzoic acid isopropyl ester hydrochloride (INT-69.7): According to the experimental procedure of INT-14.5, the reaction was carried out on a scale of 1.2 g to obtain INT-69.7 (0.90 g, 98%) as an off-white solid. LCMS (ESI) m / z=337.05 [M+H] + .
[0814] Step-8: Synthesis of (S)-2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoic acid isopropyl ester (Ex-69): According to the experimental procedure of Ex-14, the mixture was reacted with 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxylic acid on a scale of 0.40 g to obtain an enantiomeric mixture of EX-69 [18:22] (70 mg) as an off-white solid compound. Ex-69 was further separated and purified by chiral HPLC to obtain pure Ex-69 (24 mg, 4.1%) as a white solid [column name: Chiralpak-IG (4.6X250) 5um; mobile phase: IPA / ACN containing 0.1% TEA = 70:30 (v / v); flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 5.6min.(18%), t R (Peak-2)7.2min.(82%)]. LCMS(ESI)m / z=484.25[M+H] + ; Chiral HPLC (peak-2): 99.9% (t R 7.25min); UPLC (method D): 99.9% (t R8.95min); 1H NMR (400MHz, DMSO-d6): 7.88 (dd, J=11.6Hz, J=1.6Hz, 1H), 7.75 (dd, J=8.0Hz, J=1.6Hz, 1H), 7. 70(s,1H),7.61(t,J=8.0Hz,1H),7.55(s,1H),7.43(d,J=7.6Hz,1H),5.21-5.15(m,1H),5.07- 5.04(m,1H),4.57(dd,J=14.8Hz,J=14.4Hz,2H),3.99(t,J=5.6Hz,2H),3.83(td,J=11.6Hz,J= 3.6Hz, 2H), 2.99 (t, J = 6.4Hz, 2H), 1.88-1.83 (m, 2H), 1.78-1.76 (m, 2H), 1.33 (d, J = 6.4Hz, 6H).
[0815] Example 70: (S)-N-(1-(2-chloro-3-(dimethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0816]
[0817] Step-1: Synthesis of (S)-2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoic acid (INT-70.1): To a stirred solution of EX-69 (1.2 g, 2.48 mmol) [Note: enantiomerically enriched mixture of EX-69 was used for hydrolysis] in MeOH (6 mL) and THF (6 mL) was added LiOH.H. 2 O (0.42 g, 9.92 mmol) (solution in DM water (1.2 mL)). The reaction was stirred at room temperature for 6 h. After completion, the reaction mass was evaporated under reduced pressure and the aqueous layer was washed with EtOAc. The pH of the aqueous layer was adjusted to 1-2 with 1N HCl solution at room temperature and the reaction mass was completely distilled to obtain INT-70.1 (1.0 g, 91%) as a white solid. LCMS (ESI) m / z=442.07 [M+H].
[0818] Step-2: Synthesis of (S)-N-(1-(2-chloro-3-(dimethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-70): To a stirred solution of INT-70.1 (0.2 g, 0.45 mmol) and 2M THF solution of dimethylamine (0.08 g, 1.81 mmol) in anhydrous DMF (2 mL) at 0°C were added HATU (0.26 mg, 0.68 mmol) and DIPEA (0.24 mL, 1.36 mmol). The reaction was then stirred at room temperature for 16 h. After completion, the reaction mass was poured into ice water and extracted with EtOAc. The collected organic layer was washed with brine, dried over sodium sulphate and evaporated in vacuo to obtain the crude compound. The crude product was purified by silica gel column chromatography using a gradient of 2-10% MeOH in DCM to give an enantiomeric mixture of Ex-70 [22:78] (170 mg) as an off-white solid compound. Ex-70 was further separated and purified by chiral HPLC to give pure Ex-70 (90 mg, 42.4%) as a white solid [column name: Chiralcel-OX-H (4.6X250), 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100%; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 11.8min.(22%), t R (Peak-2)13.5min.(78%)]. LCMS(ESI)m / z=469.23[M+H] + ; Chiral HPLC (peak-2): 98.9% (t R 13.50min); UPLC (method C): 99.8% (t R 9.30min); 1H NMR (400MHz, DMSO-d6): 7.69 (s, 1H), 7.62-7.58 (m, 2H), 7.56 (s, 1H), 7.52 (dd, J= 7.2Hz,J=2.0Hz,1H),7.43(d,J=8.4Hz,1H),5.07-5.04(m,1H),4.57(dd,J=14.8H z,J=13.6Hz,2H),3.99(t,J=5.6Hz,2H),3.83(td,J=11.6Hz,J=3.6Hz,2H),3.02( s,3H),2.99(t,J=6.4Hz,2H),2.81(s,3H),1.86-1.79(m,2H),1.78-1.76(m,2H).
[0819] Example 71: (S)-N-(1-(2-chloro-3-(pyrrolidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0820]
[0821] Step-1: Synthesis of (S)-N-(1-(2-chloro-3-(pyrrolidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-71): According to the experimental procedure of Ex-70, it was reacted with pyrrolidine (0.1 g, 4.0 eq.) on a scale of 0.15 g to obtain an enantiomeric mixture of EX-71 [22:78] (60 mg) as an off-white solid compound. Ex-71 was further separated and purified by chiral HPLC to obtain pure Ex-71 (10 mg, 8.3%) as a white solid [column name: Chiralcel-OX-H (4.6X250), 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100%; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 15.6min.(22%), t R (Peak-2) 18.3 min. (78%)]. LCMS (ESI) m / z = 495.25 [M+H] + ; Chiral HPLC (peak-2): 99.8% (t R 18.42min); UPLC (method L): 96.4% (t R 8.50min); 1H NMR(400MHz,DMSO-d6):7.69(s,1H),7.62-7.59(m,1H),7.57-7.54(m,3H),7.4 2(d,J=8.4Hz,1H),5.07-5.04(m,1H),4.57(dd,J=14.8Hz,J=11.6Hz,2H),3.99 (t,J=5.6Hz,2H),3.83(td,J=8.0Hz,J=0.4Hz,2H),3.49(t,J=6.4Hz,2H),3.12 (t,J=6.4Hz,2H),2.99(t,J=6.4Hz,2H),1.90-1.83(m,6H),1.79-1.76(m,2H).
[0822] Example 72: (S)-N-(1-(2-chloro-3-(piperidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0823]
[0824] Step-1: Synthesis of ((S)-N-(1-(2-chloro-3-(piperidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-72): Following the experimental procedure of Ex-70, the mixture was reacted with piperidine (0.12 g, 4.0 eq.) on a scale of 0.15 g to give a mixture of enantiomers of EX-72 [22 :78] (100 mg), which is an off-white solid compound. Ex-72 was further separated and purified by chiral HPLC to obtain pure Ex-72 (26 mg, 15.0%), which is a white solid [column name: Chiralcel-OX-H (4.6X250), 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100%; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 15.9 min. (22%), t R (Peak-2)18.9min.(78%)]. LCMS(ESI)m / z=509.28[M+H] + ; Chiral HPLC (peak-2): 99.5% (t R 19.24min); UPLC (method C): 99.5% (t R9.05min); 1H NMR (400MHz, DMSO-d6): 7.70 (s, 1H), 7.61-7.56 (m, 3H), 7.51 (dd, J = 7.2Hz, J = 2.0Hz, 1H), 7.43 (d, J = 8 .4Hz,1H),5.07-5.04(m,1H),4.62(d,J=14.8Hz,1H),4.54(dd,J=14.4Hz,J=4.0Hz,1H),3.99(t,J=5. 6Hz,2H),3.84(td,J=15.2Hz,J=3.6Hz,2H),3.71-3.67(m,1H),3.59-3.55(m,1H),3.13(t,J=5.6Hz,2 H), 2.99 (t, J = 6.4Hz, 2H), 1.88-1.84 (m, 2H), 1.79-1.76 (m, 2H), 1.60-1.58 (m, 4H), 1.47-1.46 (m, 2H).
[0825] Example 73: (S)-N-(1-(2-chloro-3-(morpholine-4-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0826]
[0827] Step-1: Synthesis of (S)-N-(1-(2-chloro-3-(morpholine-4-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-73): According to the experimental procedure of Ex-70, it was reacted with morpholine (0.12 g, 4.0 eq.) on a scale of 0.15 g to obtain an enantiomeric mixture of Ex-73 [22:78] (140 mg) as an off-white solid compound. Ex-73 was further separated and purified by chiral HPLC to obtain pure Ex-73 (37 mg, 21.3%) as a white solid [column name: Chiralcel-OX-H (4.6X250), 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100%; flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 17.3min.(22%), t R (Peak-2) 20.3 min. (78%)]. LCMS (ESI) m / z = 511.26 [M+H] + ; Chiral HPLC (peak-2): 99.5% (t R20.53min); UPLC (method C): 99.6% (t R 9.65min); 1H NMR (400MHz, DMSO-d6): 7.70 (s, 1H), 7.63-7.56 (m, 4H), 7.42 (dd, J=4.8Hz, J=3 .6Hz,1H),5.07-5.05(m,1H),4.58(dd,J=14.8Hz,J=14.4Hz,2H),3.99(t,J=5.6 Hz,2H),3.84(td,J=16.0Hz,J=3.6Hz,2H),3.71-3.60(m,4H),3.55(t,J=4.0Hz ,2H),3.17(s,2H),2.99(t,J=6.4Hz,2H),1.88-1.83(m,2H),1.79-1.74(m,2H).
[0828] Example 74: (S)-N-(1-(2-chloro-3-(diethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide
[0829]
[0830] Step-1: Synthesis of (S)-N-(1-(2-chloro-3-(diethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (Ex-74): According to the experimental procedure of Ex-70, it was reacted with diethylamine (0.10 g, 4.0 eq.) on a scale of 0.15 g to obtain an enantiomeric mixture of Ex-74 [20:75] (90 mg) as an off-white solid compound. Ex-74 was further separated and purified by chiral HPLC to obtain pure Ex-74 (12 mg, 7.11%) as a white solid [column name: Chiralcel-OX-H (4.6X250), 5um; mobile phase: MeOH containing 0.1% ammonium hydroxide = 100% flow rate: 1.0 ml / min, temperature: 25°C; flow mode: isocratic; t R (Peak-1) 12.5min.(20%), t R (Peak-2)14.2min.(75%)]. LCMS(ESI)m / z=497.27[M+H] + ; Chiral HPLC (peak-2): 98.1% (t R 14.23min); UPLC (method K): 99.9% (tR 9.48min); 1H NMR (400MHz, DMSO-d6): 7.70 (s, 1H), 7.61-7.56 (m, 3H), 7.52 (dd, J = 7.2Hz, J = 2.4Hz, 1H), 7.43 (d, J = 8.4Hz, 1H),5.07-5.04(m,1H),4.62(d,J=15.2Hz,1H),4.54(dd,J=14.4Hz,J=5.6Hz,1H),3.99(t,J=5.6Hz,2H),3. 84(td,J=11.6Hz,J=3.6Hz,2H),3.66-3.57(m,1H),3.39-3.35(m,1H),3.19-3.11(m,1H),3.08-3.03(m,1H) ,2.99(t,J=6.4Hz,2H),1.88-1.84(m,2H),1.79-1.75(m,2H),1.61(t,J=7.2Hz,3H),1.02(t,J=7.2Hz,3H).
[0831] Biological Examples
[0832] Biological Example 1: Inhibition of human dihydroorotate dehydrogenase (DHODH)
[0833] The inhibition of human dihydroorotate dehydrogenase (DHODH) by the example compounds described herein was determined using one of two assays as described below:
[0834] Assay A
[0835] DHODH enzyme assays were performed with 6 nM recombinant human DHODH (purified essentially as described by Walse et al., Biochemistry, 47, 8929-8936 (2008)). The reaction mixture consisted of 1 mM DL-dihydroorotic acid (#D7003, Sigma-Aldrich), 100 μM 3,4-dimethoxy-5-methyl-p-benzoquinone (#D9150, Sigma-Aldrich), and 100 μM 2,6-dichlorophenolindoxyl sodium salt (DCIP) (#D1878, Sigma-Aldrich) in enzyme buffer (50 mM Tris-HCl pH 8.0, 0.1% Triton X-100, 150 mM KCl). A stock solution of 20 mM DCIP was prepared in enzyme buffer immediately before use and filtered through Whatman paper. Reactions were performed in a total volume of 100 μL, consisting of 1 μL compound, 49 μL enzyme, and 50 μL reaction mixture. After incubation for 70 min at 32 °C, the absorbance loss of the chromophore DCIP was measured at 595 nm.
[0836]
[0837] Biological Example 2: Inhibition of MOLM13
[0838] Assay B
[0839] At the 0th day, MOLM-13 cells (a kind of acute myeloid leukemia cell line) are laid in the RPMI containing 10%FBS and 1%Pen / Strep in 384 well plates with 1,000 cells per well.At the 1st day, start to use compound (concentration range 10E-5 and 6E-12M) treatment cells in the presence or absence of 100 μM uridine.After 72 hours, cell is incubated with or without test compound, by Cell Titer-Glo luminescent cell viability determination (Luminescent CellViability Assay) (Promega, Madison, WI, USA) assesses the viable cell number in every well.Use DMSO to compare as 100% cell viability and use the hole of acellular (only culture medium) to calculate IC50 as 0% cell viability.Every situation has been tested twice, and the effectiveness of test compound is determined by two independent experiments.
[0840] Using the assay described in Biological Example 2, the following IC 50 value.
[0841]
[0842] Figure 2Data obtained for Ex-6, Ex-9, Ex-11 and Ex-13 on MOLM13 cell viability in the presence and absence of uridine are shown.
[0843] Biological Example 3: Antiviral Activity
[0844] Materials and methods
[0845] cell
[0846] The lung cancer epithelial cell line A549 was obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA) and cultured in MEM medium (Gibco BRL, Gaithersburg, MD, USA) containing 10% fetal calf serum (FCS; Gibco BRL), 2 mM L-glutamine (Gibco BRL), and 0.075% sodium bicarbonate (Gibco BRL).
[0847] Virus
[0848] The ZIKV MR766 prototype strain and the DENV-2 laboratory-adapted New Guinea C strain were obtained from ATCC and grown as stocks in the C6 / 36 mosquito cell line (ATCC). Virus stock titers were determined using plaque assays in BHK-21 cells (ATCC).
[0849] Antiviral assay
[0850] Anti-ZIKV and anti-DENV-2 activity in A549 cells was determined using a tetrazolium-based colorimetric cytopathic effect (CPE) reduction assay. This assay has been described in detail previously (Virology. 2021; doi.org / 10.1016 / j.virol.2021.07.003). A549 cells (1.5 x 10 4Cells were plated in 96-well flat-bottom plates (TPP, Trasadingen, Switzerland) and incubated overnight to allow cells to grow to confluence. Drug dilutions were prepared in culture medium, in which the FCS concentration was reduced to 2%, and diluted three times in the plate (in duplicate). Finally, 100 μL of virus was added, with an MOI of 1 for ZIKV and an MOI of 5 for DENV-2, in a final volume of 200 μL. Cytopathic effects caused by the virus were checked regularly by microscopy. After 3 days of ZIKV infection and 4 days of DENV-2 infection, when strong cytopathic effects were observed in positive controls (i.e., untreated infected cells), cell viability was assessed spectrophotometrically by in situ reduction of the tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS / PES) using the CellTiter 96AQueous One Solution Cell Proliferation Assay (Promega, Fitchburg, WI, USA). After three hours of MTS incubation, the virus was inactivated using 0.5% Triton X-100 (Thermo Fisher Scientific, Waltham, MA, USA), and the absorbance was recorded at 490 nm using a 96-well plate reader and compared with four cell control replicates (cells without virus and drug) and four virus control wells (cells with virus but without drug). Each assay was performed twice. The median inhibitory concentration (IC) was calculated from each dose-response curve by performing nonlinear regression. 50 ), or a concentration that inhibited virus-induced cell death by 50%. The absorbance was recorded using a VersaMax ELISA™ microplate reader (Molecular Devices) and the Softmax The cytotoxic concentrations (CC 50 ).
[0851] Results and discussion
[0852] The antiviral activity of Ex-9 compound against ZIKV and DENV-2 was evaluated. In parallel, the cytotoxicity of the compound against A549 cells was also determined. The results are shown in the table below, where the compound exhibited antiviral activity against ZIKV and DENV-2.
[0853]
[0854] IC 50= concentration required to inhibit 50% of ZIKV / DENV-induced CPE in A549 cells.
[0855] CC 50 = concentration required to reduce the viability of mock-infected A549 cells by 50%.
[0856] Head-to-head Example 1: O-analogs (Examples 3-69) are more stable than C-analogs (Compounds A-X)
[0857] Human liver microsome metabolic stability: The microsomal metabolic stability assay utilized pooled human liver microsomes (mixed gender, BD Gentest) supplemented with cofactors NADPH and UDPGA (Solarbio S&T Co., LTD). Two independent experiments were performed as follows:
[0858] a) With cofactors (NADPH & UDPGA): 25 μL 10 mM NADPH and 25 μL 20 mM UDPGA were added to 197.5 μL reaction solution (phosphate buffer (final concentration in the assay was 100 mM), MgCl 2 (final concentration in the assay was (5 mM)), alamethacin (final concentration in the assay was 0.025 mg / mL), and microsomes (final concentration in the assay was 0.5 mg / mL).
[0859] b) Without cofactors (NADPH & UDPGA): 50 μL H 2 O was added to 197.5 μL of the reaction solution.
[0860] The mixture was preheated at 37°C for 10 minutes. The reaction was started by adding 2.5 μL of 100 μM control compound or test compound solution. Diclofenac was used as a positive control in this study. The final concentration of the control compound and the test compound was 1 μM. 25 μL aliquots were taken from the reaction solution at 0.5, 5, 15, 30 and 60 minutes. The reaction was stopped by adding 5 volumes of cold acetonitrile containing an internal standard. The samples were centrifuged at 3,220 g for 40 minutes. An aliquot of 100 μL of the supernatant was mixed with 100 μL of ultrapure H 2 O mixed, and then used for LC-MS / MS analysis. Determine the peak area according to the extracted ion chromatogram. Calculate the percentage of the remaining parent according to the area ratio of the test compound. Determine the slope value by linear regression of the remaining parent percentage relative to the natural logarithm of the incubation time curve.
[0861] Human Hepatocyte Metabolic Stability: Human hepatocytes (X008000, BioIVT) were freshly thawed prior to incubation with test compounds. Hepatocytes were transferred to a 50 mL conical tube and centrifuged at 100 g for 10 min. Thawing medium was removed and replaced with pre-warmed (37°C) incubation medium (William's E medium supplemented with GlutaMAX) to a hepatocyte density of ~1.5 × 10 6 Cell viability was determined using AO / PI staining, and hepatocytes were diluted to 0.5 × 10 cells / mL using incubation medium. 6 The working density of live cells / mL was 198 μL of hepatocytes was added to each well of a 96-well plate and placed in an incubator to warm the hepatocytes for 10 minutes. 2 μL of test compound or positive control was placed in the corresponding well of a 96-well plate (the final concentration of the test compound was 1 μM) to start the reaction. The plate was returned to the incubator and the well contents of 25 μL aliquots were taken out at 0, 15, 30, 60, 90 and 120 minutes. The aliquots were mixed with 6 volumes (150 μL) of acetonitrile containing internal standards (100 nM alprazolam, 200 nM caffeine and 100 nM tolbutamide) to terminate the reaction. The plate was centrifuged at 3,200 g for 20 minutes. An aliquot of 150 μL of supernatant was used for LC / MS / MS analysis. All incubations were performed in duplicate.
[0862] Peak areas were determined from the extracted ion chromatograms to determine the in vitro half-life (t 1 / 2 ). In vitro half-life (in vitro t 1 / 2 ) is obtained by slope value (in vitro t 1 / 2 =-0.693 / k). All calculations were performed using Microsoft Excel. Table 3 below summarizes the results and demonstrates that the compounds of the present invention have improved stability when compared head to head with the corresponding C-analogs.
[0863]
[0864]
[0865]
[0866]
[0867] Head-to-Head Example 2: O-analogue Ex-9 has no inhibitory effect on human CYP compared to compound C
[0868] CYP Inhibition: Co-incubation of compounds with selective substrates for P450 enzymes was performed using pooled human liver microsomes (Cat. No. H0610, Xenotech) to determine their potential to cause drug-drug interactions. The assay was performed in duplicate. The formation of acetaminophen, 7'-hydroxycoumarin, hydrobupropion, N-desethylamodiaquine, 4'-hydroxydiclofenac, 4'-hydroxymephenytoin, 1'-hydroxybufuralol, 6'-hydroxychlorzoxazone, which are markers for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, was quantified. CYP3A4 inhibition was measured using 2 substrates, measuring the formation of 6β-hydroxytestosterone (3A4-T) and 1'-hydroxymidazolam (3A4-M). Incubations were performed in 96 deep well plates, with each well containing: 179 μL of stock solution (0.2 mg / mL microsomes plus CYP substrate (see below for final substrate concentrations and incubation times for different CYP assays) in 100 mM phosphate buffer, and 1 μL of compound working solution or vehicle. The final concentration of compound in the assay was 30 μM when a single dose was used, or 0.1, 0.3, 1, 3, 10 and 30 μM for dose response.
[0869]
[0870] The incubation plate was placed in a water bath and preheated at 37°C for 5 minutes, and the reaction was started by adding 20 μL of 10 mM NADPH solution and incubated at 37°C for the above time. The reaction was stopped by adding 1.5 volumes (300 μL) of cold ACN containing 3% formic acid and 200 nM tolbutamide, 200 nM alprazolam, and 200 nM labalol. The plate was centrifuged at 3,220 g for 50 minutes, and 200 μL of the supernatant was transferred to the analytical plate for LC / MS / MS analysis. The corresponding metabolite formation in each probe substrate was compared with the metabolite formation observed in the solvent control incubation.
[0871]
[0872] abbreviation
[0873] The abbreviations as used herein are known to those skilled in the art. Specifically, the following abbreviations may be used herein.
[0874] Aq. Water-based
[0875] ACN Acetonitrile
[0876] AcOH Acetic acid
[0877] DCM Dichloromethane
[0878] DEA Diethylamine
[0879] DIPEA N,N-Diisopropylethylamine
[0880] DMF Dimethylformamide
[0881] DMF-DMA Dimethylformamide dimethyl acetal
[0882] DMSO Dimethyl sulfoxide
[0883] EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
[0884] EtOH
[0885] HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium hexafluorophosphate 3-oxide
[0886] HBTU N,N,N',N'-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate HCl
[0887] HOBt Hydroxybenzotriazole
[0888] HPLC High Performance Liquid Chromatography
[0889] HRMS High Resolution Mass Spectrometry
[0890] MeOH Methanol
[0891] NaBH 3 CN Sodium cyanide borohydride
[0892] NaNO 2 Sodium Nitrite
[0893] NH 4 Cl Ammonium chloride
[0894] NMR Nuclear Magnetic Resonance
[0895] SnCl 2 Tin(II) chloride
[0896] T 3 P Propanephosphonic anhydride
[0897] TBTU O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
[0898] TFA Trifluoroacetic acid
[0899] THF Tetrahydrofuran
[0900] Ti(OiPr) 4 Titanium(IV) Tetraisopropoxide
[0901] TLC Thin layer chromatography
[0902] UPLC Ultra-Performance Liquid Chromatography
Claims
1. A compound of formula I or a pharmaceutically acceptable salt thereof, wherein : A 1 represents aryl or heteroaryl and is optionally substituted; A 2 represents aryl or heteroaryl and is optionally substituted; L 1 Represents -C(O)-, -C(O)N(R 2 )-、-C(O)O-、-S(O) j -or-S(O) k N(R 3 )-; R 1 represents H or C optionally substituted by one or more halogens 1-3 alkyl; R 2 and R 3 Each independently represents H or C optionally substituted by one or more halogens 1-3 alkyl; Each j independently represents 0, 1, or 2; and Each k independently represents 1 or 2.
2. The compound according to claim 1, in: A 1 represents optionally one or more independently selected from G 1 The aryl group is optionally substituted by one or more independently selected from G 2 A heteroaryl group substituted with a group; A 2 represents optionally one or more independently selected from G 3 The aryl group is optionally substituted by one or more independently selected from G 4 A heteroaryl group substituted with a group; Each G 1 independently represent halogen, R a1 、-CN、-A a1 -C(Q a1 )R b1 , -A b1 -C(Q b1 )N(R c1 )R d1 , -A c1 -C(Q c1 )OR e1 , -A d1 -S(O) p R f1 , -A e1 -S(O) q N(R g1 )R h1 , -A f1 -S(O) p OR i1 、-N 3 、-N(R j1 )R k1 、-N(H)CN、-NO 2 、-ONO 2 、-OR l1 or -SR m1 ; Each Q a1 To Q c1 Independently represents =O, =S, =NR n1 OR = N (OR o1 ); Each A a1 To A f1 independently represent a single bond, -N(R p1 )-or-O-; Each G 2 independently represent halogen, R a2 、-CN、-A a2 -C(Q a2 )R b2 -A b2 -C(Q b2 )N(R c2 )R d2 , -A c2 -C(Q c2 )OR e2 , -A d2 -S(O) p R f2 , -A e2 -S(O) q N(R g2 )R h2 , -A f2 -S(O) p OR i2 、-N 3 、-N(R j2 )R k2 、-N(H)CN、-NO 2 、-ONO 2 、-OR l2 or -SR m2 ; Each Q a2 To Q c2 Independently represents =O, =S, =NR n2 OR = N (OR o2 ); Each A a2 To A f2 independently represent a single bond, -N(R p2 )-or-O-; Each G 3 independently represent halogen, R a3 、-CN、-A a3 -C(Q a3 )R b3 , -A b3 -C(Q b3 )N(R c3 )R d3 , -A c3 -C(Q c3 )OR e3 , -A d3 -S(O) p R f3 , -A e3 -S(O) q N(R g3 )R h3 , -A f3 -S(O) p OR i3 、-N 3 、-N(R j3 )R k3 、-N(H)CN、-NO 2 、-ONO 2 、-OR l3 or -SR m3 ; Each Q a3 To Q c3 Independently represents =O, =S, =NR n3 OR = N (OR o3 ); Each A a3 To A f3 independently represent a single bond, -N(R p3 )-or-O-; Each G 4 independently represent halogen, R a4 、-CN、-A a4 -C(Q a4 )R b4 , -A b4 -C(Q b4 )N(R c4 )R d4 , -A c4 -C(Q c4 )OR e4 , -A d4 -S(O) p R f4 , -A e4 -S(O) q N(R g4 )R h4 , -A f4 -S(O) p OR i4 、-N 3 、-N(R j4 )R k4 、-N(H)CN、-NO 2 、-ONO 2 、-OR l4 or -SR m4 ; Each Q a4 To Q c4 Independently represents =O, =S, =NR n4 OR = N (OR o4 ); Each A a4 To A f4 independently represent a single bond, -N(R p4 )-or-O-; Each R a1 and R f1 Independently represents optionally one or more independently selected from G 5a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 5b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 5c The aryl group is optionally substituted by one or more independently selected from G 5d A heteroaryl group substituted with a group; Each R p1 independently represents H or C optionally substituted by one or more halogens 1-6 alkyl; Each R b1 , R c1 , R d1 , R e1 , R g1 , R h1 , R i1 , R j1 , R k1 , R l1 , R m1 , R n1 and R o1 independently represents H, optionally one or more independently selected from G 5a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 5b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 5c The aryl group is optionally substituted by one or more independently selected from G 5d A heteroaryl group substituted with a group of Optionally R c1 and R d1 , R g1 and R h1 and / or R j1 and R k1 Any of the following are joined together with the nitrogen atom to which they are attached to form a 3- to 6-membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected halogens, C 1-3 Alkyl and =O group substitution; Each R a2 and R f2 Independently represents optionally one or more independently selected from G 6a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 6b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 6c The aryl group is optionally substituted by one or more independently selected from G 6d A heteroaryl group substituted with a group; Each R p2 independently represents H or C optionally substituted by one or more F 1-6 alkyl; Each R b2 , R c2 , R d2 , R e2 , R g2 , R h2 , R i2 , R j2 , R k2 , R l2 , R m2 , R n2 and R o2 independently represents H, optionally one or more independently selected from G 6a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 6b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 6c The aryl group is optionally substituted by one or more independently selected from G 6d A heteroaryl group substituted with a group of Optionally R c2 and R d2 , R g2 and R h2 and / or R j2 and R k2 Any of the following are joined together with the nitrogen atom to which they are attached to form a 3- to 6-membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected halogens, C 1-3 Alkyl and =O group substitution; Each R a3 and R f3 Independently represents optionally one or more independently selected from G 7a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 7b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 7c The aryl group is optionally substituted by one or more independently selected from G 7d A heteroaryl group substituted with a group; Each R p3 independently represents H or C optionally substituted by one or more F 1-6 alkyl; Each R b3 , R c3 , R d3 , R e3 , R g3 , R h3 , R i3 , R j3 , R k3 , R l3 , R m3 , R n3 and R o3 independently represents H, optionally one or more independently selected from G 7a The group substituted C 1-6 Alkyl, optionally with one or more independently selected from G 7b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 7c The aryl group is optionally substituted by one or more independently selected from G 7d A heteroaryl group substituted with a group of Optionally R c3 and R d3 , R g3 and R h3 and / or R j3 and R k3 Any of the following are joined together with the nitrogen atom to which they are attached to form a 3- to 6-membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected halogens, C 1-3 Alkyl and =O group substitution; Each R a4 and R f4 Independently represents optionally one or more independently selected from G 8a The group substituted C 1-6 Alkyl or optionally one or more independently selected from G 8b The heterocycloalkyl substituted with a group, optionally substituted with one or more independently selected from G 8c The aryl group is optionally substituted by one or more independently selected from G 8d A heteroaryl group substituted with a group; Each R p4 independently represents H or C optionally substituted by one or more F 1-6 alkyl; Each R b4 , R c4 , R d4 , R e4 , R g4 , R h4 , R i4 , R j4 , R k4 , R l4 , R m4 , R n4 and R o4 independently represents H, optionally one or more independently selected from G 8a The group substituted C 1-6 Alkyl or optionally one or more independently selected from G 8b A heterocycloalkyl group substituted with: Optionally R c4 and R d4 , R g4 and R h4 and / or R j4 and R k4 Any of the following are joined together with the nitrogen atom to which they are attached to form a 3- to 6-membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more independently selected halogens, C 1-3 Alkyl and =O group substitution; Each G 5a , G 5b , G 6a , G 6b , G 7a , G 7b , G 8a and G 8b independently represent halogen, -CN, -N(R b5 )R c5 、-OR d5 、-SR e5 or =O; Each G 5c , G 5d , G 6c , G 6d , G 7c , G 7d , G 8c and G 8d independently represent halogen, R a5 、-CN、-N(R b5 )R c5 、-OR d5 、-SR e5 or =O; Each R a5 independently represents C optionally substituted by one or more F 1-6 alkyl; Each R b5 , R c5 , R d5 and R e5 independently represents H or C optionally substituted by one or more F 1-6 Alkyl or =O; and or R b5 and R c5 are joined together with the nitrogen atom to which they are attached to form a 3 to 6 membered ring, the ring optionally containing another heteroatom and the ring optionally being substituted with one or more C selected from F, optionally substituted with one or more F 1-3 Alkyl and =O group substitution; And each p and q independently represents 1 or 2.
3. The compound according to claim 2, in: A 1 represents optionally one or more independently selected from G 1 The phenyl group substituted by or optionally by one or more independently selected from G 2 A heteroaryl group substituted with a group; A 2 represents optionally one or more independently selected from G 3 The phenyl group substituted by or optionally by one or more independently selected from G 4 A 5- or 6-membered heteroaryl group substituted with a group; L 1 stands for -C(O)N(R 2 )-、-C(O)O-、-S(O) 2 N(R 3 )-, C(O)- or -S(O) 2 -; preferably wherein L 1 represents -C(O)-; R 1 represents H or C optionally substituted by one or more F 1-3 Alkyl, preferably wherein R 1 Represents H; R 2 and R 3 Each independently represents H or C optionally substituted by one or more F 1-3 alkyl; Each G 1 Independently represents -CN, -A a1 -C(Q a1 )R b1 , -A b1 -C(Q b1 )N(R c1 )R d1 , -A c1 -C(Q c1 )OR e1 , -A d1 -S(O) p R f1 , -A e1 -S(O) q N(R g1 )R h1 , -A f1 -S(O) p OR i1 、-N 3 、-N(R j1 )R k1 、-N(H)CN、-NO 2 、-ONO 2 , halogen, R a1 、-OR l1 or -SR m1 (e.g. halogen, R a1 、-C(O)OR e1 、-OR l1 and-SR m1 ); each Q a1 To Q c1 Independently represents =O, =S, =NR n1 OR = N (OR o1 )(e.g. =O); and / or each A a1 To A f1 independently represent a single bond, -N(R p1 )-or-O-; Each G 2 Independently represents -CN, -A a2 -C(Q a2 )R b2 -A b2 -C(Q b2 )N(R c2 )R d2 , -A c2 -C(Q c2 )OR e2 , -A d2 -S(O) p R f2 , -A e2 -S(O) q N(R g2 )R h2 , -A f2 -S(O) p OR i2 、-N 3 、-N(R j2 )R k2 、-N(H)CN、-NO 2 、-ONO 2 , halogen, R a2 、-OR l2 or -SR m2 (e.g. halogen, R a2 、-C(O)OR e2 、-OR l2 or -SR m2 ); each Q a2 To Q c2 Independently represents =O, =S, =NR n2 OR = N (OR o2 )(e.g. =O); and / or each A a2 To A f2 independently represent a single bond, -N(R p2 )-or-O-; Each G 3 Independently represents -CN, -A a3 -C(Q a3 )R b3 , -A b3 -C(Q b3 )N(R c3 )R d3 , -A c3 -C(Q c3 )OR e3 , -A d3 -S(O) p R f3 , -A e3 -S(O) q N(R g3 )R h3 , -A f3 -S(O) p OR i3 、-N 3 、-N(R j3 )R k3 、-N(H)CN、-NO 2 、-ONO 2 , halogen, R a3 、-OR l3 or -SR m3 ; Each Q a3 To Q c3 Independently represents =O, =S, =NR n3 OR = N (OR o3 ); and / or each A a3 To A f3 independently represent a single bond, -N(R p3 )-or-O-; and / or Each G 4 Independently represents -CN, -A a4 -C(Q a4 )R b4 , -A b4 -C(Q b4 )N(R c4 )R d4 , -A c4 -C(Q c4 )OR e4 , -A d4 -S(O) p R f4 , -A e4 -S(O) q N(R g4 )R h4 , -A f4 -S(O) p OR i4 、-N 3 、-N(R j4 )R k4 、-N(H)CN、-NO 2 、-ONO 2 , halogen, R a4 、-OR l4 or -SR m4 ; Each Q a4 To Q c4 Independently represents =O, =S, =NR n4 OR = N (OR o4 ); and / or each A a4 To A f4 independently represent a single bond, -N(R p4 )-or-O-.
4. The compound according to claim 2 or 3, in: A 1 represents optionally one or two independently selected from halogen, R a2 、-C(O)OR e2 、-OR l2 and-SR m2 A monocyclic or bicyclic heteroaryl group substituted with a group; A 1 represents C optionally substituted by one or two independently selected halogens, optionally substituted by one or more fluorines 1-3 Alkyl, -C(O)OH, -C(O)OC 1-3 Alkyl, -OH, -OC 1-3 Alkyl, -SH and -SC 1-3 a monocyclic or bicyclic heteroaryl substituted with an alkyl group; Representative A 1 The monocyclic or bicyclic heteroaryl is a 5- or 6-membered monocyclic or 9-membered bicyclic heteroaryl; and / or Representative A 1 The monocyclic or bicyclic heteroaryl is selected from tetrahydro-2,1-benzisoxazolyl, benzoxazolyl, pyrazinyl, indazolyl, quinolinyl, 5H,6H,7H,8H-imidazo[1,5-a]pyridin-3-yl, 5H,6H,7H,8H-imidazo[1,5-a]pyridin-1-yl, imidazo[1,5-a]pyridin-3-yl, pyridyl, thiazolyl, isoxazolyl and tetrahydro-1,2-benzisoxazolyl, preferably 5H,6H,7H,8H-imidazo[1,5-a]pyridin-3-yl or 5H,6H,7H,8H-imidazo[1,5-a]pyridin-1-yl.
5. The compound according to any one of claims 2 to 4, in: A 2 represents optionally one or more independently selected from halogen, -A a3 -C(Q a3 )R b3 , -A c3 -C(Q c3 )OR e3 , R a3 AND-OR l3 phenyl substituted with a group; and / or A 2 represents optionally substituted by one or more independently selected from halogen, -C(O)-morpholinyl, -C(O)OC 1-3 Alkyl and C 1-4 Phenyl substituted with an alkyl group.
6. A compound according to any one of claims 2 to 5, in: A 1 is a 9-membered bicyclic heteroaryl (e.g., 5H, 6H, 7H, 8H-imidazo [1, 5-a] pyridin-3-yl, 5H, 6H, 7H, 8H-imidazo [1, 5-a] pyridin-1-yl, 4H, 5H, 6H, 7H-1, 2-benzisoxazol-3-yl, 4H, 5H, 6H, 7H-2, 1-benzisoxazol-3-yl or 4H, 5H, 6H, 7H-indazol-3-yl); a 6-membered heteroaryl (e.g., pyridinyl) or a 5-membered heteroaryl (e.g., pyrazolyl or imidazolyl), wherein the 5-membered heteroaryl or 6-membered heteroaryl is optionally one or more independently selected from G 2 The group is substituted; A 2 is optionally one or more independently selected from G 3 Phenyl substituted with a group; R 1 is H; and / or L 1 It is -C(O)-.
7. The compound according to claim 6, in: Each G 2 Independently represents R a2 (For example, C 1-2 alkyl); and / or Each G 3 independently represent halogen, R a3 , -A b3 -C(Q b3 )N(R c3 )R d3 , -A c3 -C(Q c3 )OR e3 , -A d3 -S(O) p R f3 、-OR l3 ; Optionally among them: Halogen is fluorine or chlorine, R a3 Yes CH 3 or CF 3 , A b3 , A c3 and A d3 It is a single bond, Q b3 and Q c3 is = O, p is 2, R c3 and R d3 Yes CH 3 or are joined together with the nitrogen atom to which they are attached to form a 5- or 6-membered ring, which optionally contains another heteroatom (e.g. oxygen), R e3 It is C 1-3 Alkyl, R f3 Yes CH 3 , R l3 Yes CH 3 CF 3 、N(CH 3 ) 2 Substituted C 2 Alkyl, OH, OCH 3 or N(C=O)CH 3 , and / or C(=O)N(CH 3 ) 2 Substituted C 1 alkyl.
8. The compound according to any one of claims 1 to 7, wherein the compound is a compound of formula Ia or a pharmaceutically acceptable salt thereof, wherein A 1 , A 2 , L 1 and R 1 As defined in any one of claims 1 to 7.
9. The compound according to any one of claims 1 to 7, wherein the compound is: N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (R)-N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (S)-N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide (R)-N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide (S)-N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide (R)-N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide (S)-N-(1-(2-Fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide N-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide N-((4S)-1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide N-((4R)-1-(2-Chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide N-1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide N-((4S)-1-(2-Chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide N-((4R)-1-(2-Chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (S)-N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide (R)-N-(1-(2,6-dichlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide; (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide; (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide; (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide; (S)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (R)-N-(1-(2-chloro-3-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide; (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide; (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (S)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide; (R)-N-(1-(2-chloro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide; (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide; (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide; (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide; (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide; (S)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (R)-N-(1-(2-chloro-6-fluoro-3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide; (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-ethyl-1-methyl-1H-imidazole-4-carboxamide; (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide; (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4-ethyl-5-methyl-1H-pyrazole-3-carboxamide; (S)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (R)-N-(1-(2-chloro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (S)-5-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-1-methyl-1H-imidazole-4-carboxamide; (R)-5-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-1-methyl-1H-imidazole-4-carboxamide; (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide; (S)-4-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-methyl-1H-pyrazole-3-carboxamide; (R)-4-ethyl-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5-methyl-1H-pyrazole-3-carboxamide; (S)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (R)-N-(1-(2-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (R)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide; (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (R)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-3-carboxamide; (S)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (R)-N-(1-(2-chloro-6-fluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-4,5-dimethylpicolinamide; (S)-N-(1-(3-(methylsulfonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(3-(methylsulfonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(o-tolyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(o-tolyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-5-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-5-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-(trifluoromethyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(3-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(3-(trifluoromethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(3-(trifluoromethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-fluoro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-fluoro-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2,6-difluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2,6-difluorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-6-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-6-methoxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-methoxy-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-methoxy-6-methylphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-hydroxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-hydroxyphenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(2-(dimethylamino)ethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(2-(dimethylamino)ethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(2-(dimethylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(2-(dimethylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(2-(methylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(2-(methylamino)-2-oxoethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(3-(2-acetylaminoethoxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(3-(2-acetylaminoethoxy)-2-chlorophenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(2-methoxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(2-methoxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(2-hydroxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(2-hydroxyethoxy)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoic acid isopropyl ester; (R)-2-chloro-3-(4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamido)-4,7-dihydropyrano[3,4-c]pyrazol-1(5H)-yl)benzoic acid isopropyl ester; (S)-N-(1-(2-chloro-3-(dimethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(dimethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(pyrrolidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(pyrrolidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(piperidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(piperidine-1-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(morpholine-4-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(morpholine-4-carbonyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (S)-N-(1-(2-chloro-3-(diethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; (R)-N-(1-(2-chloro-3-(diethylcarbamoyl)phenyl)-1,4,5,7-tetrahydropyrano[3,4-c]pyrazol-4-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine-1-carboxamide; or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 9 and optionally one or more pharmaceutically acceptable adjuvants, diluents and / or carriers.
11. A compound as defined in any one of claims 1 to 9 or a pharmaceutical composition as defined in claim 10 for use as a medicament.
12. A compound as defined in any one of claims 1 to 9 or a pharmaceutical composition as defined in claim 10 for use in the treatment of cancer and / or the treatment or prevention of viral infections.
13. A combination product, include: (A) a compound as defined in any one of claims 1 to 9; and (B) one or more additional therapeutic agents for treating cancer or for treating or preventing viral infection, Components (A) and (B) are each formulated as a mixture optionally with one or more pharmaceutically acceptable adjuvants, diluents or carriers.
14. A kit comprising: (a) a compound as defined in any one of claims 1 to 9 or a pharmaceutical composition as defined in claim 10; and (b) one or more additional therapeutic agents for treating cancer or for treating or preventing viral infection, optionally in admixture with one or more pharmaceutically acceptable adjuvants, diluents or carriers, The components (a) and (b) are each provided in a form suitable for administration in combination with the other component.
15. A process for preparing a compound as defined in any one of claims 1 to 9, said process include: (i) making the compound of formula II Where R 1 and A 2 As defined in any one of claims 1 to 9, with a compound of formula III LG 1 -L 1 -A 1 (III) Among them A 1 and L 1 As defined in any one of claims 1 to 9 and LG 1 represents a suitable leaving group, reacted in the presence of a suitable solvent and optionally in the presence of a suitable base and / or a suitable catalyst; (ii) When L 1 stands for -C(O)N(R 2 )-, where R 2 When H represents, the compound of formula II and the compound of formula IV A 1 -N=C=O (IV) Among them A 1 As defined in any one of claims 1 to 9, in the presence of a suitable solvent and optionally in the presence of a suitable base and / or a suitable catalyst; or (iii) making the compound of formula (V) Where R 1 and A 1 and L 1 As defined in any one of claims 1 to 9, and a compound of formula VI LG 2 -AND 2 (YOU) Among them A 2 As defined in any one of claims 1 to 9 and LG 2 represents a suitable leaving group, in the presence of a suitable solvent and optionally in the presence of a suitable base and / or a suitable catalyst.
